

Autoimmune Dilated Cardiomyopathy in PD-1 Receptor

Science

291, 319-322

DOI: [10.1126/science.291.5502.319](https://doi.org/10.1126/science.291.5502.319)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Plasma Fibrinogen Levels and the Clinical Course of Acute Myocardial Infarction. <i>Angiology</i> , 1983, 34, 693-698.	1.8	22
2	Cardiac Myosin and the TH1/TH2 Paradigm in Autoimmune Myocarditis. <i>American Journal of Pathology</i> , 2001, 159, 5-12.	3.8	54
3	The expanding world of co-stimulation: the two-signal model revisited. <i>Trends in Immunology</i> , 2001, 22, 217-223.	6.8	180
4	PD-1: an inhibitory immunoreceptor involved in peripheral tolerance. <i>Trends in Immunology</i> , 2001, 22, 265-268.	6.8	428
5	Altered apoptosis pathways in mantle cell lymphoma detected by oligonucleotide microarray. <i>Blood</i> , 2001, 98, 787-794.	1.4	169
6	Maintenance and loss of self-tolerance in B cells. <i>Seminars in Immunopathology</i> , 2001, 23, 351-366.	4.0	3
7	Laser capture microdissection-based expression profiling identifies PD1-ligand as a target of the nude locus gene product. <i>European Journal of Immunology</i> , 2001, 31, 2497-2503.	2.9	41
8	PD-L2 is a second ligand for PD-1 and inhibits T cell activation. <i>Nature Immunology</i> , 2001, 2, 261-268.	14.5	2,504
9	Knockout mice: a paradigm shift in modern immunology. <i>Nature Reviews Immunology</i> , 2001, 1, 11-19.	22.7	53
10	Docking Protein Gab2 Is Phosphorylated by ZAP-70 and Negatively Regulates T Cell Receptor Signaling by Recruitment of Inhibitory Molecules. <i>Journal of Biological Chemistry</i> , 2001, 276, 45175-45183.	3.4	80
11	KNOCKOUT MICE: A PARADIGM SHIFT IN MODERN IMMUNOLOGY. <i>Nature Reviews Immunology</i> , 2001, 1, 11-19.	22.7	57
12	PD-1 immunoreceptor inhibits B cell receptor-mediated signaling by recruiting src homology 2-domain-containing tyrosine phosphatase 2 to phosphotyrosine. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2001, 98, 13866-13871.	7.1	732
13	Targeting T cell costimulation in autoimmune disease. <i>Expert Opinion on Therapeutic Targets</i> , 2002, 6, 275-289.	3.4	46
14	Expression of Programmed Death 1 Ligands by Murine T Cells and APC. <i>Journal of Immunology</i> , 2002, 169, 5538-5545.	0.8	831
15	B7-H1 Is Expressed by Human Endothelial Cells and Suppresses T Cell Cytokine Synthesis. <i>Journal of Immunology</i> , 2002, 169, 3581-3588.	0.8	300
16	Adapter Molecule Grb2-Associated Binder 1 Is Specifically Expressed in Marginal Zone B Cells and Negatively Regulates Thymus-Independent Antigen-2 Responses. <i>Journal of Immunology</i> , 2002, 168, 5110-5116.	0.8	27
17	Inducible Costimulator Costimulates Cytotoxic Activity and IFN- γ Production in Activated Murine NK Cells. <i>Journal of Immunology</i> , 2002, 169, 3676-3685.	0.8	72
18	Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002, 99, 12293-12297.	7.1	2,563

#	ARTICLE	IF	CITATIONS
19	Programmed Death-1 Targeting Can Promote Allograft Survival. <i>Journal of Immunology</i> , 2002, 169, 6546-6553.	0.8	219
20	Who are the enemies? Inflammation and autoimmune mechanisms. <i>European Heart Journal Supplements</i> , 2002, 4, G27-G32.	0.1	7
21	Time course of gene expression in rat experimental autoimmune myocarditis. <i>Clinical Science</i> , 2002, 103, 623-632.	4.3	37
22	The B7 Family of Ligands and Its Receptors: New Pathways for Costimulation and Inhibition of Immune Responses. <i>Annual Review of Immunology</i> , 2002, 20, 29-53.	21.8	792
23	T-Cell costimulatory pathways relevant to transplant rejection and tolerance. <i>Transplantation Reviews</i> , 2002, 16, 205-219.	2.9	4
24	Is peripartum cardiomyopathy an organ-specific autoimmune disease?. <i>Autoimmunity Reviews</i> , 2002, 1, 73-77.	5.8	43
25	B7 Family Molecules: Novel Immunomodulators at the Maternal-Fetal Interface. <i>Placenta</i> , 2002, 23, S95-S101.	1.5	101
26	T-cell activation: a multidimensional signaling network. <i>Current Opinion in Cell Biology</i> , 2002, 14, 575-580.	5.4	69
27	CTLA-4 regulates cell cycle progression during a primary immune response. <i>European Journal of Immunology</i> , 2002, 32, 366-373.	2.9	115
28	PD-1:PD-L inhibitory pathway affects both CD4+ and CD8+ T cells and is overcome by IL-2. <i>European Journal of Immunology</i> , 2002, 32, 634.	2.9	612
29	CD154-CD40 interactions mediate differentiation to plasma cells in healthy individuals and persons with systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2002, 46, 1417-1429.	6.7	50
30	Negative co-receptors on lymphocytes. <i>Current Opinion in Immunology</i> , 2002, 14, 391-396.	5.5	152
31	The right place at the right time: novel B7 family members regulate effector T cell responses. <i>Current Opinion in Immunology</i> , 2002, 14, 384-390.	5.5	107
32	New regulatory co-receptors: inducible co-stimulator and PD-1. <i>Current Opinion in Immunology</i> , 2002, 14, 779-782.	5.5	221
33	Making and breaking tolerance. <i>Current Opinion in Immunology</i> , 2002, 14, 744-759.	5.5	92
34	Microanatomical localization of PD-1 in human tonsils. <i>Immunology Letters</i> , 2002, 83, 215-220.	2.5	69
35	Structural mechanisms of costimulation. <i>Nature Immunology</i> , 2002, 3, 427-434.	14.5	123
36	Protect the killer: CTLs need defenses against the tumor. <i>Nature Medicine</i> , 2002, 8, 787-789.	30.7	22

#	ARTICLE	IF	CITATIONS
37	Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion. <i>Nature Medicine</i> , 2002, 8, 793-800.	30.7	4,217
38	The enemy within: keeping self-reactive T cells at bay in the periphery. <i>Nature Reviews Immunology</i> , 2002, 2, 11-19.	22.7	503
39	The B7-CD28 superfamily. <i>Nature Reviews Immunology</i> , 2002, 2, 116-126.	22.7	1,513
40	Differential expression of PD-L1 and PD-L2, ligands for an inhibitory receptor PD-1, in the cells of lymphohematopoietic tissues. <i>Immunology Letters</i> , 2002, 84, 57-62.	2.5	249
41	Immunology of B7-H1 and Its Roles in Human Diseases. <i>International Journal of Hematology</i> , 2003, 78, 321-328.	1.6	34
42	Modulation of costimulation to enhance tumor immunity. <i>Cancer Immunology, Immunotherapy</i> , 2003, 52, 663-669.	4.2	18
43	The Art of War: Innate and adaptive immune responses. <i>Cellular and Molecular Life Sciences</i> , 2003, 60, 2604-2621.	5.4	115
44	B7-H1 pathway and its role in the evasion of tumor immunity. <i>Journal of Molecular Medicine</i> , 2003, 81, 281-287.	3.9	249
45	Negative T cell costimulation and islet tolerance. <i>Diabetes/Metabolism Research and Reviews</i> , 2003, 19, 179-185.	4.0	19
46	Preferential contribution of B7-H1 to programmed death-1-mediated regulation of hapten-specific allergic inflammatory responses. <i>European Journal of Immunology</i> , 2003, 33, 2773-2782.	2.9	119
47	Endothelial expression of PD-L1 and PD-L2 down-regulates CD8 ⁺ T cell activation and cytotoxicity. <i>European Journal of Immunology</i> , 2003, 33, 3117-3126.	2.9	413
48	Increased salivary gland tissue expression of Fas, Fas ligand, cytotoxic T lymphocyte-associated antigen 4, and programmed cell death 1 in primary Sjögren's syndrome. <i>Arthritis and Rheumatism</i> , 2003, 48, 174-185.	6.7	95
49	Negative feedback of T cell activation through inhibitory adapters and costimulatory receptors. <i>Immunological Reviews</i> , 2003, 192, 143-160.	6.0	64
50	Association of a putative regulatory polymorphism in the PD-1 gene with susceptibility to type 1 diabetes. <i>Tissue Antigens</i> , 2003, 62, 492-497.	1.0	207
51	B cell inhibitory receptors and autoimmunity. <i>Immunology</i> , 2003, 108, 263-273.	4.4	93
52	T-cell costimulatory pathways in allograft rejection and tolerance. <i>Immunological Reviews</i> , 2003, 196, 85-108.	6.0	202
53	Mouse B7-H3 induces antitumor immunity. <i>Gene Therapy</i> , 2003, 10, 1728-1734.	4.5	112
54	Gene Expression Profile of Serial Samples of Transformed B-Cell Lymphomas. <i>Laboratory Investigation</i> , 2003, 83, 271-285.	3.7	110

#	ARTICLE	IF	CITATIONS
55	BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1. <i>Nature Immunology</i> , 2003, 4, 670-679.	14.5	768
56	The B7 family member B7-H3 preferentially down-regulates T helper type 1-mediated immune responses. <i>Nature Immunology</i> , 2003, 4, 899-906.	14.5	479
57	Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. <i>Nature Medicine</i> , 2003, 9, 562-567.	30.7	1,157
58	Autoantibodies against cardiac troponin I are responsible for dilated cardiomyopathy in PD-1-deficient mice. <i>Nature Medicine</i> , 2003, 9, 1477-1483.	30.7	606
59	New insights into the pathogenesis of dilated cardiomyopathy: possible underlying autoimmune mechanisms and therapy. <i>Autoimmunity Reviews</i> , 2003, 3, 277-277.	5.8	0
60	B7 Family Molecules Are Favorably Positioned at the Human Maternal-Fetal Interface ¹ . <i>Biology of Reproduction</i> , 2003, 68, 1496-1504.	2.7	189
61	BTLA: a new inhibitory receptor with a B7-like ligand. <i>Trends in Immunology</i> , 2003, 24, 524-527.	6.8	83
62	The genetics of human systemic lupus erythematosus. <i>Trends in Immunology</i> , 2003, 24, 595-602.	6.8	165
63	The Programmed Death-1 (PD-1) Pathway Regulates Autoimmune Diabetes in Nonobese Diabetic (NOD) Mice. <i>Journal of Experimental Medicine</i> , 2003, 198, 63-69.	8.5	697
64	Differential binding properties of B7-H1 and B7-DC to programmed death-1. <i>Biochemical and Biophysical Research Communications</i> , 2003, 307, 672-677.	2.1	181
65	B7S1, a Novel B7 Family Member that Negatively Regulates T Cell Activation. <i>Immunity</i> , 2003, 18, 863-873.	14.3	386
66	Regulation of immune and autoimmune responses by ICOS. <i>Journal of Autoimmunity</i> , 2003, 21, 255-260.	6.5	86
67	Current Perspective on the Pathogenesis of Graves' Disease and Ophthalmopathy. <i>Endocrine Reviews</i> , 2003, 24, 802-835.	20.1	415
68	Blockade of B7-H1 Suppresses the Development of Chronic Intestinal Inflammation. <i>Journal of Immunology</i> , 2003, 171, 4156-4163.	0.8	163
69	Vav1 Dephosphorylation by the Tyrosine Phosphatase SHP-1 as a Mechanism for Inhibition of Cellular Cytotoxicity. <i>Molecular and Cellular Biology</i> , 2003, 23, 6291-6299.	2.3	239
70	Molecular Modeling and Functional Mapping of B7-H1 and B7-DC Uncouple Costimulatory Function from PD-1 Interaction. <i>Journal of Experimental Medicine</i> , 2003, 197, 1083-1091.	8.5	259
71	PD-L1 and PD-L2 are differentially regulated by Th1 and Th2 cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003, 100, 5336-5341.	7.1	536
72	Blockade of Programmed Death-1 Engagement Accelerates Graft-Versus-Host Disease Lethality by an IFN- γ -Dependent Mechanism. <i>Journal of Immunology</i> , 2003, 171, 1272-1277.	0.8	305

#	ARTICLE	IF	CITATIONS
73	Critical Role of the Programmed Death-1 (PD-1) Pathway in Regulation of Experimental Autoimmune Encephalomyelitis. <i>Journal of Experimental Medicine</i> , 2003, 198, 71-78.	8.5	461
74	PD-1 Inhibits Antiviral Immunity at the Effector Phase in the Liver. <i>Journal of Experimental Medicine</i> , 2003, 198, 39-50.	8.5	353
75	T Cell Rewiring in Differentiation and Disease. <i>Journal of Immunology</i> , 2003, 171, 3325-3331.	0.8	57
76	Autoimmune cardiomyopathy and heart block develop spontaneously in HLA-DQ8 transgenic IAA ⁺ knockout NOD mice. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003, 100, 13447-13452.	7.1	64
77	Blockade of Programmed Death-1 Ligands on Dendritic Cells Enhances T Cell Activation and Cytokine Production. <i>Journal of Immunology</i> , 2003, 170, 1257-1266.	0.8	842
78	Thyroid-Specific Expression of IFN- β Limits Experimental Autoimmune Thyroiditis by Suppressing Lymphocyte Activation in Cervical Lymph Nodes. <i>Journal of Immunology</i> , 2003, 170, 5523-5529.	0.8	30
79	Absence of Programmed Death Receptor 1 Alters Thymic Development and Enhances Generation of CD4/CD8 Double-Negative TCR-Transgenic T Cells. <i>Journal of Immunology</i> , 2003, 171, 4574-4581.	0.8	99
80	Program Death-1 Engagement Upon TCR Activation Has Distinct Effects on Costimulation and Cytokine-Driven Proliferation: Attenuation of ICOS, IL-4, and IL-21, But Not CD28, IL-7, and IL-15 Responses. <i>Journal of Immunology</i> , 2003, 170, 711-718.	0.8	248
81	BOOSTING T CELL COSTIMULATION IN CANCER: THE POSSIBILITIES SEEM ENDLESS. <i>International Reviews of Immunology</i> , 2003, 22, 173-194.	3.3	10
82	Stimulating PD-1 ⁻ signals concurrent with blocking CD154 co-stimulation induces long-term islet allograft survival. <i>Transplantation</i> , 2003, 76, 994-999.	1.0	140
83	B7-H1 is up-regulated in HIV infection and is a novel surrogate marker of disease progression. <i>Blood</i> , 2003, 101, 2514-2520.	1.4	157
84	Immunological tolerance and its breakdown in Chagas heart disease role of parasitokines. <i>Frontiers in Bioscience - Landmark</i> , 2003, 8, e218-227.	3.0	6
85	Molecular and Cellular Mechanisms Associated with Autoimmune Diseases. <i>International Journal of Environmental Research and Public Health</i> , 2004, 1, 39-73.	2.6	8
86	PD-1 blockade inhibits hematogenous spread of poorly immunogenic tumor cells by enhanced recruitment of effector T cells. <i>International Immunology</i> , 2004, 17, 133-144.	4.0	413
87	The genetic basis of systemic lupus erythematosus-knowledge of today and thoughts for tomorrow. <i>Human Molecular Genetics</i> , 2004, 13, 143R-148.	2.9	49
88	Murine B7-H3 Is a Negative Regulator of T Cells. <i>Journal of Immunology</i> , 2004, 173, 2500-2506.	0.8	299
89	A Spontaneous Model for Autoimmune Myocarditis Using the Human MHC Molecule HLA-DQ8. <i>Journal of Immunology</i> , 2004, 172, 2651-2658.	0.8	45
90	Gene-Targeted Mice Lacking the Trex1 (DNase III) 5' DNA Exonuclease Develop Inflammatory Myocarditis. <i>Molecular and Cellular Biology</i> , 2004, 24, 6719-6727.	2.3	316

#	ARTICLE	IF	CITATIONS
91	Acquisition of anergic and suppressive activities in transforming growth factor- β -costimulated CD4+CD25- T cells. <i>International Immunology</i> , 2004, 16, 1203-1213.	4.0	102
92	Refolding and Characterization of Recombinant Human GST-PD-1 Fusion Protein Expressed in <i>Escherichia coli</i> . <i>Acta Biochimica Et Biophysica Sinica</i> , 2004, 36, 141-146.	2.0	9
93	B7-DC Regulates Asthmatic Response by an IFN- γ -Dependent Mechanism. <i>Journal of Immunology</i> , 2004, 172, 2530-2541.	0.8	136
94	Altering immune tolerance therapeutically: the power of negative thinking. <i>Journal of Leukocyte Biology</i> , 2004, 75, 586-599.	3.3	18
95	Blockade of the Interaction Between PD-1 and PD-L1 Accelerates Graft Arterial Disease in Cardiac Allografts. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2004, 24, 2057-2062.	2.4	88
96	Blocking Programmed Death-1 Ligand-PD-1 Interactions by Local Gene Therapy Results in Enhancement of Antitumor Effect of Secondary Lymphoid Tissue Chemokine. <i>Journal of Immunology</i> , 2004, 173, 4919-4928.	0.8	111
97	SHP-1 and SHP-2 Associate with Immunoreceptor Tyrosine-Based Switch Motif of Programmed Death 1 upon Primary Human T Cell Stimulation, but Only Receptor Ligation Prevents T Cell Activation. <i>Journal of Immunology</i> , 2004, 173, 945-954.	0.8	989
98	Transgenic Expression of CTLA-4 Controls Lymphoproliferation in IL-2-Deficient Mice. <i>Journal of Immunology</i> , 2004, 173, 5415-5424.	0.8	21
99	Regulation of Postsurgical Fibrosis by the Programmed Death-1 Inhibitory Pathway. <i>Journal of Immunology</i> , 2004, 172, 5774-5781.	0.8	24
100	PD-L1/B7H-1 Inhibits the Effector Phase of Tumor Rejection by T Cell Receptor (TCR) Transgenic CD8+ T Cells. <i>Cancer Research</i> , 2004, 64, 1140-1145.	0.9	679
101	PD-L1-deficient mice show that PD-L1 on T cells, antigen-presenting cells, and host tissues negatively regulates T cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004, 101, 10691-10696.	7.1	556
102	Immunopathological Basis of Virus-induced Myocarditis. <i>Clinical and Developmental Immunology</i> , 2004, 11, 1-5.	3.3	26
103	Suppression of expression and function of negative immune regulator PD-1 by certain pattern recognition and cytokine receptor signals associated with immune system danger. <i>International Immunology</i> , 2004, 16, 1181-1188.	4.0	27
104	Cloning and Identification of Two Novel Splice Variants of Human PD-L2. <i>Acta Biochimica Et Biophysica Sinica</i> , 2004, 36, 284-289.	2.0	31
105	Co-inhibitory molecules of the B7- β /CD28 family in the control of T-cell immunity. <i>Nature Reviews Immunology</i> , 2004, 4, 336-347.	22.7	1,110
106	Interferon- γ enhances monocyte and dendritic cell expression of B7-H1 (PD-L1), a strong inhibitor of autologous T-cell activation: relevance for the immune modulatory effect in multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2004, 155, 172-182.	2.3	249
107	New B7 Family Members with Positive and Negative Costimulatory Function. <i>American Journal of Transplantation</i> , 2004, 4, 8-14.	4.7	33
108	New insights into the pathogenesis of dilated cardiomyopathy: possible underlying autoimmune mechanisms and therapy. <i>Autoimmunity Reviews</i> , 2004, 3, 277-284.	5.8	43

#	ARTICLE	IF	CITATIONS
109	PD-1 ligands, negative regulators for activation of naïve, memory, and recently activated human CD4+ T cells. <i>Cellular Immunology</i> , 2004, 230, 89-98.	3.0	64
110	Current advances in the human lupus genetics. <i>Current Rheumatology Reports</i> , 2004, 6, 391-398.	4.7	35
111	On the pathogenesis of autoimmune thyroid disease: a unifying hypothesis. <i>Clinical Endocrinology</i> , 2004, 60, 397-409.	2.4	70
112	Association of a programmed death 1 gene polymorphism with the development of rheumatoid arthritis, but not systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2004, 50, 770-775.	6.7	148
113	Paradoxical role of programmed death-1 ligand-2 in Th2 immune responses <i>in vitro</i> and in a mouse asthma model <i>in vivo</i> . <i>European Journal of Immunology</i> , 2004, 34, 3326-3336.	2.9	47
114	Frontline: Characterization of B7 molecules belonging to the B7 family expressed on immune cells. <i>European Journal of Immunology</i> , 2004, 34, 2089-2099.	2.9	90
115	The expression of B7-H1 on keratinocytes in chronic inflammatory mucocutaneous disease and its regulatory role. <i>Immunology Letters</i> , 2004, 94, 215-222.	2.5	67
116	Emerging paradigms of T-cell co-stimulation. <i>Current Opinion in Immunology</i> , 2004, 16, 321-327.	5.5	132
117	The regulation of lymphocyte activation by inhibitory receptors. <i>Current Opinion in Immunology</i> , 2004, 16, 328-336.	5.5	90
118	New insights into disease pathogenesis from mouse lupus genetics. <i>Current Opinion in Immunology</i> , 2004, 16, 787-793.	5.5	43
119	Costimulatory molecules and T-cell-B-cell interactions. <i>Rheumatic Disease Clinics of North America</i> , 2004, 30, 175-191.	1.9	26
120	The expression and function of costimulatory molecules B7H and B7-H1 on colonic epithelial cells. <i>Gastroenterology</i> , 2004, 126, 1347-1357.	1.3	141
121	Models of coxsackievirus-B3-induced myocarditis: recent advances. <i>Drug Discovery Today: Disease Models</i> , 2004, 1, 381-386.	1.2	9
122	Models of autoimmune heart disease. <i>Drug Discovery Today: Disease Models</i> , 2004, 1, 411-416.	1.2	0
123	A putative regulatory polymorphism in PD-1 is associated with nephropathy in a population-based cohort of systemic lupus erythematosus patients. <i>Lupus</i> , 2004, 13, 510-516.	1.6	46
124	The deficiency of immunoregulatory receptor PD-1 causes mild osteopetrosis. <i>Bone</i> , 2004, 35, 1059-1068.	2.9	28
125	PD-1 inhibits T-cell receptor induced phosphorylation of the ZAP70/CD3 ζ signalosome and downstream signaling to PKC δ . <i>FEBS Letters</i> , 2004, 574, 37-41.	2.8	643
126	Role of LAG-3 in Regulatory T Cells. <i>Immunity</i> , 2004, 21, 503-513.	14.3	1,040

#	ARTICLE	IF	CITATIONS
127	Structural and Functional Analysis of the Costimulatory Receptor Programmed Death-1. <i>Immunity</i> , 2004, 20, 337-347.	14.3	331
128	The Roles of the New Negative T Cell Costimulatory Pathways in Regulating Autoimmunity. <i>Immunity</i> , 2004, 20, 529-538.	14.3	202
129	Update on human systemic lupus erythematosus genetics. <i>Current Opinion in Rheumatology</i> , 2004, 16, 513-521.	4.3	139
130	B cells in human and murine systemic lupus erythematosus. <i>Current Opinion in Rheumatology</i> , 2004, 16, 505-512.	4.3	47
131	Programmed death-1“programmed death-L1 interaction is essential for induction of regulatory cells by intratracheal delivery of alloantigen. <i>Transplantation</i> , 2004, 77, 6-12.	1.0	34
132	Environmental Factors and Risk of Idiopathic Dilated Cardiomyopathy-A Multi-Hospital Case-Control Study in Japan-. <i>Circulation Journal</i> , 2004, 68, 1011-1017.	1.6	6
133	B7-homolog 1 expression by human glioma: a new mechanism of immune evasion. <i>NeuroReport</i> , 2005, 16, 1081-1085.	1.2	93
134	The CD28 family: a T-cell rheostat for therapeutic control of T-cell activation. <i>Blood</i> , 2005, 105, 13-21.	1.4	276
135	Erratum for vol. 104, p. 3422. <i>Blood</i> , 2005, 105, 21-21.	1.4	0
136	Innate Immunity in Experimental Autoimmune Myocarditis. , 2005, , 1-15.		3
137	THE B7 FAMILY REVISITED. <i>Annual Review of Immunology</i> , 2005, 23, 515-548.	21.8	2,104
138	Co-stimulatory pathways in lymphocyte regulation: the immunoglobulin superfamily. <i>British Journal of Haematology</i> , 2005, 130, 809-824.	2.5	46
139	Co-stimulatory molecules as potential targets for therapeutic intervention in allergic airway disease. <i>Clinical and Experimental Allergy</i> , 2005, 35, 1521-1534.	2.9	18
140	Resting dendritic cells induce peripheral CD8+ T cell tolerance through PD-1 and CTLA-4. <i>Nature Immunology</i> , 2005, 6, 280-286.	14.5	478
141	PDCD1: a tissue-specific susceptibility locus for inherited inflammatory disorders. <i>Genes and Immunity</i> , 2005, 6, 430-437.	4.1	42
142	The B7/CD28 costimulatory family in autoimmunity. <i>Immunological Reviews</i> , 2005, 204, 128-143.	6.0	129
143	Alternative splice variants of the human PD-1 gene. <i>Cellular Immunology</i> , 2005, 235, 109-116.	3.0	171
144	Regulation of murine chronic colitis by CD4+CD25- programmed death-1+ T“„cells. <i>European Journal of Immunology</i> , 2005, 35, 1773-1785.	2.9	46

#	ARTICLE	IF	CITATIONS
145	Kinetics of costimulatory molecule expression by T cells and dendritic cells during the induction of tolerance versus immunity in vivo. <i>European Journal of Immunology</i> , 2005, 35, 1086-1096.	2.9	65
146	Antagonism between MyD88- and TRIF-dependent signals in B7RP-1 up-regulation. <i>European Journal of Immunology</i> , 2005, 35, 1918-1927.	2.9	18
147	Antibody-mediated signaling through PD-1 costimulates T cells and enhances CD28-dependent proliferation. <i>European Journal of Immunology</i> , 2005, 35, 3545-3560.	2.9	28
148	Biliary epithelial cells regulate autoreactive T cells: Implications for biliary-specific diseases. <i>Hepatology</i> , 2005, 41, 151-159.	7.3	55
150	A new haplotype of PDCD1 is associated with rheumatoid arthritis in Hong Kong Chinese. <i>Arthritis and Rheumatism</i> , 2005, 52, 1058-1062.	6.7	131
151	BAFF overexpression and accelerated glomerular disease in mice with an incomplete genetic predisposition to systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2005, 52, 2080-2091.	6.7	110
152	Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy. <i>Cancer Immunology, Immunotherapy</i> , 2005, 54, 307-314.	4.2	509
153	Dendritic cell-mediated T cell polarization. <i>Seminars in Immunopathology</i> , 2005, 26, 289-307.	4.0	296
154	The balance of immune responses: costimulation versus coinhibition. <i>Journal of Molecular Medicine</i> , 2005, 83, 193-202.	3.9	69
155	Fc Receptors and Their Role in Immune Regulation and Autoimmunity. <i>Journal of Clinical Immunology</i> , 2005, 25, 1-18.	3.8	197
157	Immune Modulations. , 2005, , 475-490.		0
158	Dendritic Cells and Autoimmunity. <i>Transfusion Medicine and Hemotherapy</i> , 2005, 32, 363-368.	1.6	4
159	Role of B7-H1 and B7-H4 molecules in down-regulating effector phase of T-cell immunity: novel cancer escaping mechanisms. <i>Frontiers in Bioscience - Landmark</i> , 2005, 10, 2856.	3.0	55
160	Signaling by ITIM-Bearing Receptors. <i>Current Immunology Reviews</i> , 2005, 1, 201-212.	1.2	11
161	Expression of immunological molecules by cardiomyocytes and inflammatory and interstitial cells in rat autoimmune myocarditis. <i>Cardiovascular Research</i> , 2005, 68, 278-288.	3.8	37
162	Role of the Programmed Death-1 Pathway in Regulation of Alloimmune Responses In Vivo. <i>Journal of Immunology</i> , 2005, 174, 3408-3415.	0.8	164
164	Lymphocytes Are Not Required for the Rapid Onset of Coronary Heart Disease in Scavenger Receptor Class B Type I/Apolipoprotein E Double Knockout Mice. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2005, 25, 803-808.	2.4	19
165	The therapeutic potential of immune therapy in idiopathic dilated cardiomyopathy. <i>Future Cardiology</i> , 2005, 1, 675-682.	1.2	1

#	ARTICLE	IF	CITATIONS
166	Molecules involved in Tâ€“B co-stimulation and B cell homeostasis: possible targets for an immunological intervention in autoimmunity. <i>Expert Opinion on Biological Therapy</i> , 2005, 5, S61-S71.	3.1	17
167	PD-1/PD-L pathway and autoimmunity. <i>Autoimmunity</i> , 2005, 38, 353-357.	2.6	85
168	Blockade of B7-H1 on Macrophages Suppresses CD4+ T Cell Proliferation by Augmenting IFN-Î³-Induced Nitric Oxide Production. <i>Journal of Immunology</i> , 2005, 175, 1586-1592.	0.8	129
169	Prevention of Experimental Autoimmune Encephalomyelitis by Transfer of Embryonic Stem Cell-Derived Dendritic Cells Expressing Myelin Oligodendrocyte Glycoprotein Peptide along with TRAIL or Programmed Death-1 Ligand. <i>Journal of Immunology</i> , 2005, 174, 1888-1897.	0.8	122
170	Analysis of the Role of Negative T Cell Costimulatory Pathways in CD4 and CD8 T Cell-Mediated Alloimmune Responses In Vivo. <i>Journal of Immunology</i> , 2005, 174, 6648-6656.	0.8	139
171	Microglial Expression of the B7 Family Member B7 Homolog 1 Confers Strong Immune Inhibition: Implications for Immune Responses and Autoimmunity in the CNS. <i>Journal of Neuroscience</i> , 2005, 25, 2537-2546.	3.6	150
172	Establishment of NOD-Pdcd1 ^{-/-} mice as an efficient animal model of type I diabetes. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005, 102, 11823-11828.	7.1	380
173	The New Immunosuppression: Intervention at the Dendritic Cell-T-Cell Interface. <i>Current Drug Targets Immune, Endocrine and Metabolic Disorders</i> , 2005, 5, 397-411.	1.8	8
174	Programmed Death-1 (PD-1):PD-Ligand 1 Interactions Inhibit TCR-Mediated Positive Selection of Thymocytes. <i>Journal of Immunology</i> , 2005, 175, 7372-7379.	0.8	122
175	Differential Effects of B and T Lymphocyte Attenuator and Programmed Death-1 on Acceptance of Partially versus Fully MHC-Mismatched Cardiac Allografts. <i>Journal of Immunology</i> , 2005, 175, 5774-5782.	0.8	113
176	The complement inhibitory protein DAF (CD55) suppresses T cell immunity in vivo. <i>Journal of Experimental Medicine</i> , 2005, 201, 567-577.	8.5	212
177	Hydronephrosis associated with antiurothelial and antinuclear autoantibodies in BALB/c-Fcgr2b ^{+/+} /Pdcd1 ^{+/+} mice. <i>Journal of Experimental Medicine</i> , 2005, 202, 1643-1648.	8.5	47
178	THE NOD MOUSE: A Model of Immune Dysregulation. <i>Annual Review of Immunology</i> , 2005, 23, 447-485.	21.8	949
179	Cardiac Autoantibodies in Viral Myocarditis. <i>Heart Failure Clinics</i> , 2005, 1, 333-343.	2.1	14
180	Immunomodulatory and Immunoabsorptive Treatments. <i>Heart Failure Clinics</i> , 2005, 1, 457-465.	2.1	2
181	Thymic Commitment of Regulatory T Cells Is a Pathway of TCR-Dependent Selection That Isolates Repertoires Undergoing Positive or Negative Selection. , 2005, 293, 43-71.		71
182	The genetics of shared autoimmunity. <i>Autoimmunity</i> , 2005, 38, 205-208.	2.6	11
183	Agents targeting inflammation in heart failure. <i>Expert Opinion on Investigational Drugs</i> , 2005, 14, 557-566.	4.1	35

#	ARTICLE	IF	CITATIONS
184	The inhibitory leukocyte-associated Ig-like receptor-1 (LAIR-1) is expressed at high levels by human naive T cells and inhibits TCR mediated activation. <i>Molecular Immunology</i> , 2005, 42, 1521-1530.	2.2	69
185	Pathogenic roles of cardiac autoantibodies in dilated cardiomyopathy. <i>Trends in Molecular Medicine</i> , 2005, 11, 322-326.	6.7	40
186	Expression of B7-H1 and B7-DC on the airway epithelium is enhanced by double-stranded RNA. <i>Biochemical and Biophysical Research Communications</i> , 2005, 330, 263-270.	2.1	40
187	PD-L1 is expressed by human renal tubular epithelial cells and suppresses T cell cytokine synthesis. <i>Clinical Immunology</i> , 2005, 115, 184-191.	3.2	86
188	Therapeutic opportunities in the B7/CD28 family of ligands and receptors. <i>Current Opinion in Pharmacology</i> , 2005, 5, 424-430.	3.5	32
189	The Immunomodulatory Proteins B7-DC, B7-H2, and B7-H3 Are Differentially Expressed across Gestation in the Human Placenta. <i>American Journal of Pathology</i> , 2005, 167, 465-473.	3.8	77
190	Role of immunoglobulin G3 subclass in dilated cardiomyopathy: Results from protein A immunoadsorption. <i>American Heart Journal</i> , 2005, 150, 729-736.	2.7	73
191	Autoimmune Ovarian Disease in Day 3-Thymectomized Mice: The Neonatal Time Window, Antigen Specificity of Disease Suppression, and Genetic Control. , 2005, 293, 209-247.		19
193	Association of the programmed cell death 1 (PDCD1) gene polymorphism with ankylosing spondylitis in the Korean population. <i>Arthritis Research and Therapy</i> , 2006, 8, R163.	3.5	70
194	Checkpoint Blockade in Cancer Immunotherapy. <i>Advances in Immunology</i> , 2006, 90, 297-339.	2.2	498
195	Immunology of Pregnancy. , 2006, , .		11
196	Gene Expression Profiles of Cumulus Cell Oocyte Complexes during Ovulation Reveal Cumulus Cells Express Neuronal and Immune-Related Genes: Does this Expand Their Role in the Ovulation Process?. <i>Molecular Endocrinology</i> , 2006, 20, 1300-1321.	3.7	231
197	Cancer vaccines and tumor dormancy: a long-term struggle between host antitumor immunity and persistent cancer cells?. <i>Expert Review of Vaccines</i> , 2006, 5, 773-781.	4.4	10
198	PROTECTING THE PUMP: Controlling Myocardial Inflammatory Responses. <i>Annual Review of Physiology</i> , 2006, 68, 67-95.	13.1	60
199	Aberrant Regulation of Synovial T Cell Activation by Soluble Costimulatory Molecules in Rheumatoid Arthritis. <i>Journal of Immunology</i> , 2006, 177, 8844-8850.	0.8	194
200	Tissue expression of PD-L1 mediates peripheral T cell tolerance. <i>Journal of Experimental Medicine</i> , 2006, 203, 883-895.	8.5	1,042
201	Mechanisms of Immune Evasion by Tumors. <i>Advances in Immunology</i> , 2006, 90, 51-81.	2.2	580
202	Immunoadsorption in dilated cardiomyopathy: 6-month results from a randomized study. <i>American Heart Journal</i> , 2006, 152, 712.e1-712.e6.	2.7	96

#	ARTICLE	IF	CITATIONS
203	Delivering PD-1 inhibitory signal concomitant with blocking ICOS co-stimulation suppresses lupus-like syndrome in autoimmune BXSB mice. <i>Clinical Immunology</i> , 2006, 118, 258-267.	3.2	55
204	Reviving exhausted T lymphocytes during chronic virus infection by B7-H1 blockade. <i>Trends in Molecular Medicine</i> , 2006, 12, 244-246.	6.7	30
205	Non-specific immunoadsorption in patients with dilated cardiomyopathy: Mechanisms and clinical effects. <i>International Journal of Cardiology</i> , 2006, 112, 30-33.	1.7	32
206	SHP2 forecast for the immune system: fog gradually clearing. <i>Trends in Immunology</i> , 2006, 27, 154-160.	6.8	50
207	The PD-1/PD-L pathway in immunological tolerance. <i>Trends in Immunology</i> , 2006, 27, 195-201.	6.8	632
208	Autoimmunity in systemic lupus erythematosus: Integrating genes and biology. <i>Seminars in Immunology</i> , 2006, 18, 230-243.	5.6	37
209	Specific removal of β_1 -adrenoceptor autoantibodies by immunoadsorption in rabbits with autoimmune cardiomyopathy improved cardiac structure and function. <i>Journal of Molecular and Cellular Cardiology</i> , 2006, 41, 78-85.	1.9	20
211	CD4+PD-1+T Cells Acting as Regulatory Cells during the Induction of Anterior Chamber-Associated Immune Deviation. , 2006, 47, 4444.		40
212	Microarray Analysis of Mercury-Induced Changes in Gene Expression in Human Liver Carcinoma (HepG2) Cells: Importance in Immune Responses. <i>International Journal of Environmental Research and Public Health</i> , 2006, 3, 141-173.	2.6	35
213	Coinhibitory T-Cell Signaling in Islet Allograft Rejection and Tolerance. <i>Cell Transplantation</i> , 2006, 15, 105-119.	2.5	65
214	Gene Transfer of Programmed Death Ligand-1.Ig Prolongs Cardiac Allograft Survival. <i>Transplantation</i> , 2006, 82, 1733-1737.	1.0	42
215	Phenotypic and genetic analyses of T-cell-mediated immunoregulation in patients with Type 1 diabetes. <i>Diabetic Medicine</i> , 2006, 23, 1145-1150.	2.3	49
216	Effects of Immunoadsorption on the nt-BNP and nt-ANP Plasma Levels of Patients Suffering From Dilated Cardiomyopathy. <i>Therapeutic Apheresis and Dialysis</i> , 2006, 10, 42-48.	0.9	36
217	Effects of antibodies obtained from patients with dilated cardiomyopathy on the function of isolated rat hearts. <i>European Journal of Clinical Investigation</i> , 2006, 36, 85-90.	3.4	8
218	Taking the brake off T cells in chronic viral infection. <i>Nature Medicine</i> , 2006, 12, 276-277.	30.7	13
219	Genetics of autoimmune diseases – disorders of immune homeostasis. <i>Nature Reviews Genetics</i> , 2006, 7, 917-928.	16.3	176
220	A protective role for programmed death 1 in progression of murine adriamycin nephropathy. <i>Kidney International</i> , 2006, 70, 1244-1250.	5.2	13
221	Programmed Death-1 Gene Polymorphisms in Patients With Systemic Lupus Erythematosus in Taiwan. <i>Journal of Clinical Immunology</i> , 2006, 26, 506-511.	3.8	49

#	ARTICLE	IF	CITATIONS
222	The genetics of systemic lupus erythematosus: understanding how SNPs confer disease susceptibility. <i>Seminars in Immunopathology</i> , 2006, 28, 109-117.	4.0	12
223	Unraveling the genetics of systemic lupus erythematosus. <i>Seminars in Immunopathology</i> , 2006, 28, 119-130.	4.0	127
224	Physiologic regulation of central and peripheral T cell tolerance: lessons for therapeutic applications. <i>Journal of Molecular Medicine</i> , 2006, 84, 887-899.	3.9	24
225	Association of a BTLA gene polymorphism with the risk of rheumatoid arthritis. <i>Journal of Biomedical Science</i> , 2006, 13, 853-860.	7.0	37
226	Aspirin-Treated Human DCs Up-Regulate ILT-3 and Induce Hyporesponsiveness and Regulatory Activity in Responder T Cells. <i>American Journal of Transplantation</i> , 2006, 6, 2046-2059.	4.7	61
227	The role of leukemia-derived B7-H1 (PD-L1) in tumor-T-cell interactions in humans. <i>Experimental Hematology</i> , 2006, 34, 888-894.	0.4	47
228	PD-L1 and PD-L2 have distinct roles in regulating host immunity to cutaneous leishmaniasis. <i>European Journal of Immunology</i> , 2006, 36, 58-64.	2.9	78
229	Contribution of the PD-1 ligands/PD-1 signaling pathway to dendritic cell-mediated CD4+ T cell activation. <i>European Journal of Immunology</i> , 2006, 36, 2472-2482.	2.9	164
230	Blockade of PD-L1 (B7-H1) augments human tumor-specific T cell responses in vitro. <i>International Journal of Cancer</i> , 2006, 119, 317-327.	5.1	276
231	What does the immunogenetic basis of rheumatoid arthritis teach us about the immunobiology of the disease?. <i>Expert Review of Clinical Immunology</i> , 2006, 2, 717-725.	3.0	0
232	High-level expression of B7-1 molecules by dendritic cells suppresses the function of activated T cells and desensitizes allergen-primed animals. <i>Journal of Leukocyte Biology</i> , 2006, 79, 686-695.	3.3	35
233	Immunological Tolerance Using Synthetic Peptides - Basic Mechanisms and Clinical Application. <i>Current Molecular Medicine</i> , 2006, 6, 631-643.	1.3	18
234	Trophoblast CD274 (B7-H1) Is Differentially Expressed Across Gestation: Influence of Oxygen Concentration. <i>Biology of Reproduction</i> , 2006, 74, 352-358.	2.7	60
235	Generation and Characterization of B7-H4/B7S1/B7x-Deficient Mice. <i>Molecular and Cellular Biology</i> , 2006, 26, 6403-6411.	2.3	72
236	Cardiac Troponin I but Not Cardiac Troponin T Induces Severe Autoimmune Inflammation in the Myocardium. <i>Circulation</i> , 2006, 114, 1693-1702.	1.6	210
237	A Regulatory CD4+ T Cell Subset in the BB Rat Model of Autoimmune Diabetes Expresses Neither CD25 Nor Foxp3. <i>Journal of Immunology</i> , 2006, 177, 7820-7832.	0.8	37
238	B7-H1-Induced Apoptosis as a Mechanism of Immune Privilege of Corneal Allografts. <i>Journal of Immunology</i> , 2006, 177, 5928-5935.	0.8	190
239	Expression of B7-H1 in Inflammatory Renal Tubular Epithelial Cells. <i>Nephron Experimental Nephrology</i> , 2006, 102, e81-e92.	2.2	39

#	ARTICLE	IF	CITATIONS
240	T Cell Costimulation in the Development of Cardiac Allograft Vasculopathy. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2006, 26, 1447-1456.	2.4	18
241	Regulation of T cell activation and tolerance by PDL2. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 11695-11700.	7.1	151
242	The Biochemical Mechanisms of T-Cell Anergy. <i>Current Immunology Reviews</i> , 2006, 2, 73-99.	1.2	0
243	Cutting Edge: Programed Death (PD) Ligand-1/PD-1 Interaction Is Required for CD8+ T Cell Tolerance to Tissue Antigens. <i>Journal of Immunology</i> , 2006, 177, 8291-8295.	0.8	123
245	Cutting Edge: B and T Lymphocyte Attenuator and Programmed Death Receptor-1 Inhibitory Receptors Are Required for Termination of Acute Allergic Airway Inflammation. <i>Journal of Immunology</i> , 2006, 176, 3909-3913.	0.8	84
246	B and T Lymphocyte Attenuator-Mediated Signal Transduction Provides a Potent Inhibitory Signal to Primary Human CD4 T Cells That Can Be Initiated by Multiple Phosphotyrosine Motifs. <i>Journal of Immunology</i> , 2006, 176, 6603-6614.	0.8	76
247	CD4 T Cells Play Major Effector Role and CD8 T Cells Initiating Role in Spontaneous Autoimmune Myocarditis of HLA-DQ8 Transgenic IAb Knockout Nonobese Diabetic Mice. <i>Journal of Immunology</i> , 2006, 176, 7715-7725.	0.8	41
248	Insulin-induced remission in new-onset NOD mice is maintained by the PD-1/PD-L1 pathway. <i>Journal of Experimental Medicine</i> , 2006, 203, 2737-2747.	8.5	280
249	Programmed death-1 (PD-1) defines a transient and dysfunctional oligoclonal T cell population in acute homeostatic proliferation. <i>Journal of Experimental Medicine</i> , 2007, 204, 2321-2333.	8.5	57
250	Role of PD-1 and its ligand, B7-H1, in early fate decisions of CD8 T cells. <i>Blood</i> , 2007, 110, 186-192.	1.4	169
251	Expression of PD-1, PD-L1, and PD-L2 in the Liver in Autoimmune Liver Diseases. <i>American Journal of Gastroenterology</i> , 2007, 102, 302-312.	0.4	69
252	Specific and high-affinity binding of tetramerized PD-L1 extracellular domain to PD-1-expressing cells: possible application to enhance T cell function. <i>International Immunology</i> , 2007, 19, 881-890.	4.0	11
253	T-cell co-stimulatory molecules: their role in allergic immune reactions. <i>European Respiratory Journal</i> , 2007, 29, 1246-1255.	6.7	39
254	Endothelial Programmed Death-1 Ligand 1 (PD-L1) Regulates CD8 ⁺ T-Cell-Mediated Injury in the Heart. <i>Circulation</i> , 2007, 116, 2062-2071.	1.6	221
255	Programmed death-1 concentration at the immunological synapse is determined by ligand affinity and availability. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 17765-17770.	7.1	97
256	Roles of programmed death-1 (PD-1)/PD-1 ligands pathway in the development of murine acute myocarditis caused by coxsackievirus B3. <i>Cardiovascular Research</i> , 2007, 75, 158-167.	3.8	51
257	MYOCARDIAL AUTOANTIBODIES AND THEIR CLINICAL SIGNIFICANCE. , 2007, , 355-365.		1
258	Interaction between B7-H1 and PD-1 determines initiation and reversal of T-cell anergy. <i>Blood</i> , 2007, 110, 180-185.	1.4	209

#	ARTICLE	IF	CITATIONS
259	PD-1/PD-L1 Pathway Is Involved in Suppressing Alloreactivity of Heart Infiltrating T Cells During Murine GVHD Across Minor Histocompatibility Antigen Barriers. <i>Transplantation</i> , 2007, 84, 214-222.	1.0	18
260	New Approaches to the Prevention of Organ Allograft Rejection and Tolerance Induction. <i>Transplantation</i> , 2007, 84, S38-S41.	1.0	6
261	Immunoadsorption in dilated cardiomyopathy. <i>Transfusion and Apheresis Science</i> , 2007, 37, 187-190.	1.0	3
262	Molecular basis for checkpoints in the CD8 T cell response: Tolerance versus activation. <i>Seminars in Immunology</i> , 2007, 19, 153-161.	5.6	38
263	Molecular mapping of autoimmune B cell responses in experimental myocarditis. <i>Journal of Autoimmunity</i> , 2007, 28, 224-233.	6.5	25
264	PD-1 and PD-1 ligands: from discovery to clinical application. <i>International Immunology</i> , 2007, 19, 813-824.	4.0	1,064
265	Impairment of organ-specific T cell negative selection by diabetes susceptibility genes: genomic analysis by mRNA profiling. <i>Genome Biology</i> , 2007, 8, R12.	9.6	37
266	Understanding Gene Expression Patterns in Immune-Mediated Disorders. <i>Journal of Immunotoxicology</i> , 2007, 4, 201-207.	1.7	7
267	The B7 Family and Cancer Therapy: Costimulation and Coinhibition. <i>Clinical Cancer Research</i> , 2007, 13, 5271-5279.	7.0	308
268	NMR Studies of Interactions between C-Terminal Tail of Kir2.1 Channel and PDZ1,2 Domains of PSD95. <i>Biochemistry</i> , 2007, 46, 5315-5322.	2.5	20
270	FcγR3 Receptors IIa on Cardiomyocytes and Their Potential Functional Relevance in Dilated Cardiomyopathy. <i>Journal of the American College of Cardiology</i> , 2007, 49, 1684-1692.	2.8	66
271	Dendritic Cells and Coregulatory Signals: Immune Checkpoint Blockade to Stimulate Immunotherapy. , 2007, , 257-275.		0
272	FcγRIIB as a modulator of autoimmune disease susceptibility. <i>Autoimmunity</i> , 2007, 40, 409-417.	2.6	50
274	Peripheral Tolerance of T Cells in the Mouse. , 2007, , 223-242.		1
275	Inhibitory Receptors and Autoimmunity in the Mouse. , 2007, , 261-273.		0
276	Programmed cell death 1 gene (PDCD1) polymorphism and pemphigus foliaceus (fogo selvagem) disease susceptibility. <i>Genetics and Molecular Biology</i> , 2007, 30, 314-321.	1.3	14
277	Programmed Death Ligand-1 and Galectin-1: Pieces in the Puzzle of Tumor-Immune Escape. , 2007, , 333-346.		0
278	A Proposal Concept of a Polygene Network in Systemic Vasculitis: Lessons from MRL Mouse Models. <i>Allergology International</i> , 2007, 56, 79-86.	3.3	9

#	ARTICLE	IF	CITATIONS
279	PD-1 expression extends beyond dendritic cells/macrophages to B1 cells enriched for V α 11/V β 12 and phosphatidylcholine binding. <i>European Journal of Immunology</i> , 2007, 37, 2405-2410.	2.9	173
280	Programmed cell death-1 (PD-1) and its ligand PD-L1 are required for allograft tolerance. <i>European Journal of Immunology</i> , 2007, 37, 2983-2990.	2.9	68
281	The sound of silence: modulating energy in T lymphocytes. <i>Current Opinion in Immunology</i> , 2007, 19, 658-664.	5.5	32
282	The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection. <i>Nature Immunology</i> , 2007, 8, 239-245.	14.5	1,286
283	Immunostimulatory monoclonal antibodies for cancer therapy. <i>Nature Reviews Cancer</i> , 2007, 7, 95-106.	28.4	564
284	Blockade of the PD-1/PD-1L pathway reverses the protective effect of anti-CD40L therapy in a rat to mouse concordant islet xenotransplantation model. <i>Xenotransplantation</i> , 2007, 14, 243-248.	2.8	14
285	From T-cell activation signals to signaling control of anti-cancer immunity. <i>Immunological Reviews</i> , 2007, 220, 151-168.	6.0	69
286	Striking Dichotomy of PD-L1 and PD-L2 Pathways in Regulating Alloreactive CD4+and CD8+T Cells In Vivo. <i>American Journal of Transplantation</i> , 2007, 7, 2683-2692.	4.7	48
287	Inhibitory costimulation and anti-tumor immunity. <i>Seminars in Cancer Biology</i> , 2007, 17, 288-298.	9.6	27
288	PD-1/PD-L1, but not PD-1/PD-L2, interactions regulate the severity of experimental autoimmune encephalomyelitis. <i>Journal of Neuroimmunology</i> , 2007, 182, 124-134.	2.3	175
289	The PD-1/PD-L pathway is up-regulated during IL-12-induced suppression of EAE mediated by IFN-gamma. <i>Journal of Neuroimmunology</i> , 2007, 185, 75-86.	2.3	63
290	Increases in circulating T lymphocytes expressing HLA-DR and CD40 ligand in patients with dilated cardiomyopathy. <i>Heart and Vessels</i> , 2007, 22, 316-321.	1.2	17
291	Immunoabsorption and subsequent immunoglobulin substitution decreases myocardial gene expression of desmin in dilated cardiomyopathy. <i>Journal of Molecular Medicine</i> , 2007, 85, 1429-1435.	3.9	15
292	Overexpression of B7-H1 (PD-L1) significantly associates with tumor grade and postoperative prognosis in human urothelial cancers. <i>Cancer Immunology, Immunotherapy</i> , 2007, 56, 1173-1182.	4.2	413
293	Contribution of the PD-L1/PD-1 pathway to T-cell exhaustion: an update on implications for chronic infections and tumor evasion. <i>Cancer Immunology, Immunotherapy</i> , 2007, 56, 739-745.	4.2	412
294	Potent Systemic Antitumor Immunity Induced by Vaccination with Chemotactic-Prostate Tumor Associated Antigen Gene-Modified Tumor Cell and Blockade of B7-H1. <i>Journal of Clinical Immunology</i> , 2007, 27, 117-130.	3.8	12
295	Polymorphisms of Genes for Programmed Cell Death 1 Ligands in Patients with Rheumatoid Arthritis. <i>Journal of Clinical Immunology</i> , 2007, 27, 563-567.	3.8	15
296	PD-1 gene haplotype is associated with the development of type 1 diabetes mellitus in Japanese children. <i>Human Genetics</i> , 2007, 121, 223-232.	3.8	63

#	ARTICLE	IF	CITATIONS
297	Autoimmunological features in inflammatory cardiomyopathy. <i>Clinical Research in Cardiology</i> , 2007, 96, 469-480.	3.3	51
299	TLR-mediated induction of negative regulatory ligands on dendritic cells. <i>Journal of Molecular Medicine</i> , 2008, 86, 443-455.	3.9	30
300	B7-1 restricts neuroantigen-specific T cell responses and confines inflammatory CNS damage: Implications for the lesion pathogenesis of multiple sclerosis. <i>European Journal of Immunology</i> , 2008, 38, 1734-1744.	2.9	72
301	PD-1 ligands expressed on myeloid-derived APC in the CNS regulate T cell responses in EAE. <i>European Journal of Immunology</i> , 2008, 38, 2706-2717.	2.9	103
302	Development of autoimmune hepatitis-like disease and production of autoantibodies to nuclear antigens in mice lacking B and T lymphocyte attenuator. <i>Arthritis and Rheumatism</i> , 2008, 58, 2498-2510.	6.7	98
303	PD-1 and Its Ligands in Tolerance and Immunity. <i>Annual Review of Immunology</i> , 2008, 26, 677-704.	21.8	4,462
304	Islet Glia, Neurons, and Î² Cells. <i>Annals of the New York Academy of Sciences</i> , 2008, 1150, 32-42.	3.8	26
305	Cell intrinsic mechanisms of T cell inhibition and application to cancer therapy. <i>Immunological Reviews</i> , 2008, 224, 141-165.	6.0	207
306	Control of peripheral T cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways. <i>Immunological Reviews</i> , 2008, 224, 166-182.	6.0	840
307	How tumours escape mass destruction. <i>Oncogene</i> , 2008, 27, 5894-5903.	5.9	175
308	PD-1/PD-L1, PD-1/PD-L2, and other co-inhibitory signaling pathways in transplantation. <i>Transplant International</i> , 2008, 21, ???-???	1.6	40
309	Novel recombinant congenic mouse strain developing arthritis with enthesopathy. <i>Pathology International</i> , 2008, 58, 407-414.	1.3	6
310	Programmed Death-1: From gene to protein in autoimmune human myasthenia gravis. <i>Journal of Neuroimmunology</i> , 2008, 193, 149-155.	2.3	25
311	Fatal Autoimmune Hepatitis Induced by Concurrent Loss of Naturally Arising Regulatory T Cells and PD-1-Mediated Signaling. <i>Gastroenterology</i> , 2008, 135, 1333-1343.	1.3	109
312	Pathological autoantibodies in cardiomyopathy. <i>Autoimmunity</i> , 2008, 41, 454-461.	2.6	50
313	Potential role of antibodies against cardiac Kv channel-interacting protein 2 in dilated cardiomyopathy. <i>American Heart Journal</i> , 2008, 156, 92-99.e2.	2.7	28
314	The Dialect of Immune System in the CNS: The Nervous Tissue as an Immune Compartment for T Cells and Dendritic Cells. , 2008, , 197-221.		0
315	Role of inflammation in heart failure. <i>International Journal of Cardiology</i> , 2008, 125, S10-S11.	1.7	0

#	ARTICLE	IF	CITATIONS
316	Immunoabsorption as treatment option in dilated cardiomyopathy. <i>Autoimmunity</i> , 2008, 41, 484-489.	2.6	30
317	Clinical implications of anti-heart autoantibodies in myocarditis and dilated cardiomyopathy. <i>Autoimmunity</i> , 2008, 41, 35-45.	2.6	112
318	Programmed Death Ligand 1 Regulates a Critical Checkpoint for Autoimmune Myocarditis and Pneumonitis in MRL Mice. <i>Journal of Immunology</i> , 2008, 181, 2513-2521.	0.8	157
319	NFATc1 Regulates PD-1 Expression upon T Cell Activation. <i>Journal of Immunology</i> , 2008, 181, 4832-4839.	0.8	311
320	IL-10 and PD-L1 operate through distinct pathways to suppress T-cell activity during persistent viral infection. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 20428-20433.	7.1	186
321	Functional Tolerance of CD8+ T Cells Induced by Muscle-Specific Antigen Expression. <i>Journal of Immunology</i> , 2008, 181, 408-417.	0.8	23
322	Crystal structure of the complex between programmed death-1 (PD-1) and its ligand PD-L2. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 10483-10488.	7.1	176
323	PD-1 deficiency reveals various tissue-specific autoimmunity by H-2 ^b and dose-dependent requirement of H-2 ^{g7} for diabetes in NOD mice. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 3533-3538.	7.1	44
324	A Lupus-Suppressor BALB/c Locus Restricts IgG2 Autoantibodies without Altering Intrinsic B Cell-Tolerance Mechanisms. <i>Journal of Immunology</i> , 2008, 180, 3807-3814.	0.8	14
325	Protective Role of Programmed Death 1 Ligand 1 (PD-L1) in Nonobese Diabetic Mice. <i>Diabetes</i> , 2008, 57, 1861-1869.	0.6	73
326	The PD-1/PD-L1 complex resembles the antigen-binding Fv domains of antibodies and T cell receptors. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 3011-3016.	7.1	357
328	Expression and Function of PDCD1 at the Human Maternal-Fetal Interface. <i>Biology of Reproduction</i> , 2008, 79, 562-569.	2.7	79
329	Cutting Edge: Programmed Death-1/Programmed Death Ligand 1 Interaction Regulates the Induction and Maintenance of Invariant NKT Cell Energy. <i>Journal of Immunology</i> , 2008, 181, 6707-6710.	0.8	131
330	Identification of Cardiac Troponin I Sequence Motifs Leading to Heart Failure by Induction of Myocardial Inflammation and Fibrosis. <i>Circulation</i> , 2008, 118, 2063-2072.	1.6	97
332	Anti-heart autoantibodies in familial dilated cardiomyopathy. <i>Autoimmunity</i> , 2008, 41, 462-469.	2.6	33
333	Immunoabsorption in Dilated Cardiomyopathy. , 2008, , 123-131.		0
334	Programmed death-1 as a factor in immune exhaustion and activation in HIV infection. <i>Current Opinion in HIV and AIDS</i> , 2008, 3, 362-367.	3.8	44
335	Genetically determined myocarditis: clinical presentation and immunological characteristics. <i>Current Opinion in Cardiology</i> , 2008, 23, 219-226.	1.8	28

#	ARTICLE	IF	CITATIONS
337	Expression of Programmed Death Ligand-1 (PD-L1) on B Cells Regulates IL-17 Production of Activated CD4+ T Cells. <i>The Journal of the Korean Rheumatism Association</i> , 2008, 15, 131.	0.1	0
338	Human Corneal Endothelial Cells Expressing Programmed Death-Ligand 1 (PD-L1) Suppress PD-1 ⁺ T Helper 1 Cells by a Contact-Dependent Mechanism. , 2009, 50, 263.		65
339	Dysregulation of CD8+ lymphocyte apoptosis, chronic disease, and immune regulation. <i>Frontiers in Bioscience - Landmark</i> , 2009, Volume, 3771.	3.0	55
340	T Cell Activation. <i>Annual Review of Immunology</i> , 2009, 27, 591-619.	21.8	1,679
341	Reviving Function in CD4+ T Cells Adapted to Persistent Systemic Antigen. <i>Journal of Immunology</i> , 2009, 183, 4284-4291.	0.8	23
342	PD-1/PD-L Blockade Prevents Anergy Induction and Enhances the Anti-Tumor Activities of Glycolipid-Activated Invariant NKT Cells. <i>Journal of Immunology</i> , 2009, 182, 2816-2826.	0.8	178
343	Recruitment of Sprouty1 to Immune Synapse Regulates T Cell Receptor Signaling. <i>Journal of Immunology</i> , 2009, 183, 7178-7186.	0.8	16
344	Constitutive Neuronal Expression of the Immune Regulator, Programmed Death 1 (PD-1), Identified During Experimental Autoimmune Uveitis. <i>Ocular Immunology and Inflammation</i> , 2009, 17, 47-55.	1.8	39
345	Human decidual stromal cells suppress cytokine secretion by allogenic CD4+ T cells via PD-1 ligand interactions. <i>Human Reproduction</i> , 2009, 24, 3160-3171.	0.9	63
346	Blockade of B7-H1 or B7-DC induces an anti-tumor effect in a mouse pancreatic cancer model. <i>International Journal of Oncology</i> , 2009, 35, 741-9.	3.3	68
347	Variable Increased Expression of Program Death-1 and Program Death-1 Ligands on Peripheral Mononuclear Cells Is Not Impaired in Patients with Systemic Lupus Erythematosus. <i>Journal of Biomedicine and Biotechnology</i> , 2009, 2009, 1-6.	3.0	19
348	Anti-Programmed Death-1 Synergizes with Granulocyte Macrophage Colony-Stimulating Factor- α Secreting Tumor Cell Immunotherapy Providing Therapeutic Benefit to Mice with Established Tumors. <i>Clinical Cancer Research</i> , 2009, 15, 1623-1634.	7.0	174
349	T-Cell Suppression by Programmed Cell Death 1 Ligand 1 on Retinal Pigment Epithelium during Inflammatory Conditions. , 2009, 50, 2862.		77
350	PD-1-Mediated Suppression of IL-2 Production Induces CD8+ T Cell Anergy In Vivo. <i>Journal of Immunology</i> , 2009, 182, 6682-6689.	0.8	184
351	Differentiation-Induced Post-Transcriptional Control of B7-H1 in Human Trophoblast Cells. <i>Placenta</i> , 2009, 30, 48-55.	1.5	16
352	Maternal PD-1 regulates accumulation of fetal antigen-specific CD8+ T cells in pregnancy. <i>Journal of Reproductive Immunology</i> , 2009, 80, 12-21.	1.9	68
353	Association study between <i>BTLA</i> and <i>TIGIT</i> lymphocyte attenuator gene and type 1 diabetes mellitus or systemic lupus erythematosus in the Japanese population. <i>International Journal of Immunogenetics</i> , 2009, 36, 65-68.	1.8	18
354	Altered availability of PD-1/PD ligands is associated with the failure to control autoimmunity in NOD mice. <i>Cellular Immunology</i> , 2009, 258, 161-171.	3.0	15

#	ARTICLE	IF	CITATIONS
355	Chronically inflamed livers up-regulate expression of inhibitory B7 family members. <i>Hepatology</i> , 2009, 50, 1625-1637.	7.3	128
356	B7-DC-silenced dendritic cells induce stronger anti-HBV immunity in transgenic mice. <i>Archives of Virology</i> , 2009, 154, 1813-1821.	2.1	3
357	Cancer immunotherapy: co-stimulatory agonists and co-inhibitory antagonists. <i>Clinical and Experimental Immunology</i> , 2009, 157, 9-19.	2.6	126
358	Development of troponin autoantibodies in experimental coxsackievirus B3 myocarditis. <i>European Journal of Clinical Investigation</i> , 2009, 39, 457-462.	3.4	17
359	Inhibitory Receptors of the Immune System: Functions and Therapeutic Implications. <i>Cellular and Molecular Immunology</i> , 2009, 6, 407-414.	10.5	9
360	Negative regulators of T cell activation: potential targets for therapeutic intervention in cancer, autoimmune disease, and persistent infections. <i>Immunological Reviews</i> , 2009, 229, 67-87.	6.0	150
361	Yin-Yang of costimulation: crucial controls of immune tolerance and function. <i>Immunological Reviews</i> , 2009, 229, 88-100.	6.0	138
362	Costimulatory and coinhibitory receptors in anti-tumor immunity. <i>Immunological Reviews</i> , 2009, 229, 126-144.	6.0	246
363	Sequence, structure, function, immunity: structural genomics of costimulation. <i>Immunological Reviews</i> , 2009, 229, 356-386.	6.0	83
364	Costimulatory pathways in transplantation: challenges and new developments. <i>Immunological Reviews</i> , 2009, 229, 271-293.	6.0	189
365	B7-H1 up-regulation on dendritic-like leukemia cells suppresses T cell immune function through modulation of IL-10/IL-12 production and generation of Treg cells. <i>Leukemia Research</i> , 2009, 33, 948-957.	0.8	37
366	Inhibitory Signals Mediated by Programmed Death-1 Are Involved With T Cell Function in Chronic Periodontitis. <i>Journal of Periodontology</i> , 2009, 80, 1833-1844.	3.4	18
367	Prostate cancer lesions are surrounded by FOXP3+, PD-1+ and B7-H1+ lymphocyte clusters. <i>European Journal of Cancer</i> , 2009, 45, 1664-1672.	2.8	129
368	Autoimmune myocarditis: Past, present and future. <i>Journal of Autoimmunity</i> , 2009, 33, 282-289.	6.5	75
369	Aspirin and the Induction of Tolerance by Dendritic Cells. <i>Handbook of Experimental Pharmacology</i> , 2009, , 197-213.	1.8	43
371	Immunoabsorption in patients with dilated cardiomyopathy. <i>Atherosclerosis Supplements</i> , 2009, 10, 126-128.	1.2	3
372	Accelerated Course of Experimental Autoimmune Encephalomyelitis in PD-1-Deficient Central Nervous System Myelin Mutants. <i>American Journal of Pathology</i> , 2009, 174, 2290-2299.	3.8	39
373	Vascular dysfunction in idiopathic dilated cardiomyopathy. <i>Nature Reviews Cardiology</i> , 2009, 6, 590-598.	13.7	79

#	ARTICLE	IF	CITATIONS
374	The Mouse Resources at the RIKEN BioResource Center. <i>Experimental Animals</i> , 2009, 58, 85-96.	1.1	42
375	Programmed death 1 signaling on chronic myeloid leukemia-specific T cells results in T-cell exhaustion and disease progression. <i>Blood</i> , 2009, 114, 1528-1536.	1.4	250
376	Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. <i>Blood</i> , 2009, 114, 1537-1544.	1.4	1,481
377	PD-1 on dendritic cells impedes innate immunity against bacterial infection. <i>Blood</i> , 2009, 113, 5811-5818.	1.4	179
378	PD-1/PD-L1 interactions inhibit antitumor immune responses in a murine acute myeloid leukemia model. <i>Blood</i> , 2009, 114, 1545-1552.	1.4	354
379	Cosignaling Molecules Around LIGHT-HVEM-BTLA: From Immune Activation to Therapeutic Targeting. <i>Current Molecular Medicine</i> , 2009, 9, 911-927.	1.3	15
380	Selection of CD8+PD-1+ Lymphocytes in Fresh Human Melanomas Enriches for Tumor-reactive T Cells. <i>Journal of Immunotherapy</i> , 2010, 33, 956-964.	2.4	174
381	Immune Regulatory Antibodies. <i>Cancer Journal (Sudbury, Mass)</i> , 2010, 16, 311-317.	2.0	27
382	Chemotherapy rescues tumor-driven aberrant CD4+ T-cell differentiation and restores an activated polyfunctional helper phenotype. <i>Blood</i> , 2010, 115, 2397-2406.	1.4	72
383	Melanoma Immunotherapy. <i>Mount Sinai Journal of Medicine</i> , 2010, 77, 620-642.	1.9	13
384	Cbl-b in T-cell activation. <i>Seminars in Immunopathology</i> , 2010, 32, 137-148.	6.1	46
385	Lack of evidence for a pathogenic role of proteasome-directed autoimmunity in dilated cardiomyopathy. <i>Basic Research in Cardiology</i> , 2010, 105, 557-567.	5.9	5
386	Structural immunology of costimulatory and coinhibitory molecules. <i>Science China Life Sciences</i> , 2010, 53, 183-189.	4.9	8
387	Immune Checkpoint Proteins: A New Therapeutic Paradigm for Cancer—Preclinical Background: CTLA-4 and PD-1 Blockade. <i>Seminars in Oncology</i> , 2010, 37, 430-439.	2.2	276
388	PD-1, gender, and autoimmunity. <i>Autoimmunity Reviews</i> , 2010, 9, 583-587.	5.8	79
389	Differential expression and alternative splicing of genes in lumbar spinal cord of an amyotrophic lateral sclerosis mouse model. <i>Brain Research</i> , 2010, 1340, 52-69.	2.2	22
390	Cardiac troponins and autoimmunity: Their role in the pathogenesis of myocarditis and of heart failure. <i>Clinical Immunology</i> , 2010, 134, 80-88.	3.2	66
391	IFN- γ receptor signaling ameliorates transplant vasculopathy through attenuation of CD8 ⁺ T cell-mediated injury of vascular endothelial cells. <i>European Journal of Immunology</i> , 2010, 40, 733-743.	2.9	18

#	ARTICLE	IF	CITATIONS
392	B7 ¹ expression on non ^B and non ^T cells promotes distinct effects on T ^H and B ¹ cell responses in autoimmune arthritis. <i>European Journal of Immunology</i> , 2010, 40, 3117-3127.	2.9	65
393	Lower expression levels of the programmed death 1 receptor on CD4 ⁺ CD25 ⁺ T cells and correlation with the PD-1.3A genotype in patients with systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2010, 62, 1702-1711.	6.7	55
394	Diagnostic and prognostic biomarker discovery strategies for autoimmune disorders. <i>Journal of Proteomics</i> , 2010, 73, 1045-1060.	2.4	24
395	Tonic T cell signalling and T cell tolerance as opposite effects of self-recognition on dendritic cells. <i>Current Opinion in Immunology</i> , 2010, 22, 601-608.	5.5	39
396	REVIEW ARTICLE: B7 Family Molecules as Regulators of the Maternal Immune System in Pregnancy. <i>American Journal of Reproductive Immunology</i> , 2010, 63, 506-519.	1.2	55
397	Immunoadsorption in dilated cardiomyopathy: long-term reduction of cardiodepressant antibodies. <i>European Journal of Clinical Investigation</i> , 2010, 40, 685-691.	3.4	48
398	Fc γ 3-Receptor IIa Polymorphism and the Role of Immunoadsorption in Cardiac Dysfunction in Patients With Dilated Cardiomyopathy. <i>Clinical Pharmacology and Therapeutics</i> , 2010, 87, 452-458.	4.7	41
399	Octamer binding protein 2 (Oct2) regulates PD-L2 gene expression in B-1 cells through lineage-specific activity of a unique, intronic promoter. <i>Genes and Immunity</i> , 2010, 11, 55-66.	4.1	16
400	Prostate cancer as a model for tumour immunotherapy. <i>Nature Reviews Immunology</i> , 2010, 10, 580-593.	22.7	314
401	Mechanistic Features of Cell-Surface Adhesion Receptors. , 2010, , 63-69.		0
402	Suppression of Bystander T Helper 1 Cells by Iris Pigment Epithelium-Inducing Regulatory T Cells via Negative Costimulatory Signals. , 2010, 51, 2529.		16
403	PD-1 deficiency results in the development of fatal myocarditis in MRL mice. <i>International Immunology</i> , 2010, 22, 443-452.	4.0	208
404	Blockade of Programmed Death-1 in Young (New Zealand Black \times New Zealand White)F1 Mice Promotes the Activity of Suppressive CD8 ⁺ T Cells That Protect from Lupus-Like Disease. <i>Journal of Immunology</i> , 2010, 185, 6563-6571.	0.8	35
405	Phase I Study of Single-Agent Anti-Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates. <i>Journal of Clinical Oncology</i> , 2010, 28, 3167-3175.	1.6	2,667
406	Autoantibodies against cardiac troponin I in patients with congestive heart failure. <i>European Journal of Heart Failure</i> , 2010, 12, 668-675.	7.1	17
407	Anti-troponin autoantibodies and the cardiovascular system. <i>Heart</i> , 2010, 96, 1518-1524.	2.9	40
408	Autoantibodies against cardiac troponin I: friend or foe?. <i>European Journal of Heart Failure</i> , 2010, 12, 645-648.	7.1	11
409	Targeting lymphocyte co-stimulation: From bench to bedside. <i>Autoimmunity</i> , 2010, 43, 514-525.	2.6	33

#	ARTICLE	IF	CITATIONS
410	Mechanisms of T-cell inhibition: implications for cancer immunotherapy. <i>Expert Review of Vaccines</i> , 2010, 9, 89-105.	4.4	27
411	Cutting Edge: Programmed Death-1 Defines CD8+CD122+ T Cells as Regulatory versus Memory T Cells. <i>Journal of Immunology</i> , 2010, 185, 803-807.	0.8	120
412	Immunobiology of Cancer Therapies Targeting CD137 and B7-H1/PD-1 Cosignal Pathways. <i>Current Topics in Microbiology and Immunology</i> , 2010, 344, 245-267.	1.1	44
413	Anti-Programmed Cell Death 1 Antibody Reduces CD4+PD-1+ T Cells and Relieves the Lupus-Like Nephritis of NZB/W F1 Mice. <i>Journal of Immunology</i> , 2010, 184, 2337-2347.	0.8	73
414	Increased Programmed Death-1 Expression on CD4+ T Cells in Cutaneous T-Cell Lymphoma. <i>Archives of Dermatology</i> , 2010, 146, 1382.	1.4	124
415	Programmed to direct alloimmunity. <i>Kidney International</i> , 2010, 78, 8-9.	5.2	2
416	Co-inhibitory molecules: Controlling the effectors or controlling the controllers?. <i>Self/nonself</i> , 2010, 1, 77-88.	2.0	20
417	Genetic Factors Predisposing to Systemic Lupus Erythematosus and Lupus Nephritis. <i>Seminars in Nephrology</i> , 2010, 30, 164-176.	1.6	81
418	Signaling Amplification at the Immunological Synapse. <i>Current Topics in Microbiology and Immunology</i> , 2010, 340, 109-122.	1.1	20
419	Role of PD-1 in Regulating T-Cell Immunity. <i>Current Topics in Microbiology and Immunology</i> , 2010, 350, 17-37.	1.1	244
420	Detection of protein on BTLA ^{low} cells and in vivo antibody-mediated down-modulation of BTLA on lymphoid and myeloid cells of C57BL/6 and BALB/c BTLA allelic variants. <i>Immunobiology</i> , 2010, 215, 570-578.	1.9	26
421	Structure and function of programmed death (PD) molecules. <i>Veterinary Immunology and Immunopathology</i> , 2010, 134, 33-38.	1.2	21
422	Feline programmed death and its ligand: Characterization and changes with feline immunodeficiency virus infection. <i>Veterinary Immunology and Immunopathology</i> , 2010, 134, 107-114.	1.2	24
423	Delayed administration of anti-PD-1 antibody reverses immune dysfunction and improves survival during sepsis. <i>Journal of Leukocyte Biology</i> , 2010, 88, 233-240.	3.3	266
424	Induction of pathogenic cytotoxic T lymphocyte tolerance by dendritic cells: a novel therapeutic target. <i>Expert Opinion on Therapeutic Targets</i> , 2010, 14, 797-824.	3.4	8
425	Functional Anatomy of T Cell Activation and Synapse Formation. <i>Annual Review of Immunology</i> , 2010, 28, 79-105.	21.8	440
426	Slow Down and Survive: Enigmatic Immunoregulation by BTLA and HVEM. <i>Annual Review of Immunology</i> , 2010, 28, 389-411.	21.8	193
427	Dysregulated Generation of Follicular Helper T Cells in the Spleen Triggers Fatal Autoimmune Hepatitis in Mice. <i>Gastroenterology</i> , 2011, 140, 1322-1333.e5.	1.3	61

#	ARTICLE	IF	CITATIONS
428	Autoantibodies against cardiac troponin I in patients presenting with myocarditis. <i>CVD Prevention and Control</i> , 2011, 6, 41.	0.7	7
429	Recent advances in immunotherapy for the treatment of prostate cancer. <i>Expert Opinion on Biological Therapy</i> , 2011, 11, 997-1009.	3.1	20
430	Mesalamine-induced B7-1 expression on hepatic stellate cells attenuates autoimmune liver injury. <i>Hepatology Research</i> , 2011, 41, 79-86.	3.4	4
433	Immunotherapy for Renal Cell Carcinoma. <i>Hematology/Oncology Clinics of North America</i> , 2011, 25, 793-812.	2.2	23
434	Cancer immunotherapy comes of age. <i>Nature</i> , 2011, 480, 480-489.	27.8	3,115
435	The benefit of animal models for autoimmune hepatitis. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2011, 25, 643-651.	2.4	17
436	Programmed death-1 is required for systemic self-tolerance in newly generated T cells during the establishment of immune homeostasis. <i>Journal of Autoimmunity</i> , 2011, 36, 301-312.	6.5	54
437	The role of co-inhibitory signals in spontaneous tolerance of weakly mismatched transplants. <i>Immunobiology</i> , 2011, 216, 918-924.	1.9	15
438	T cell coinhibition in prostate cancer: new immune evasion pathways and emerging therapeutics. <i>Trends in Molecular Medicine</i> , 2011, 17, 47-55.	6.7	44
439	Costimulatory pathways in transplantation. <i>Seminars in Immunology</i> , 2011, 23, 293-303.	5.6	80
440	Programmed Cell Death 1 Suppresses B-1b Cell Expansion and Long-Lived IgG Production in Response to T Cell-Independent Type 2 Antigens. <i>Journal of Immunology</i> , 2011, 187, 5183-5195.	0.8	51
441	LAG-3, TGF- β 2, and cell-intrinsic PD-1 inhibitory pathways contribute to CD8 but not CD4 T-cell tolerance induced by allogeneic BMT with anti-CD40L. <i>Blood</i> , 2011, 117, 5532-5540.	1.4	38
442	Biomarkers of Heart Failure in Myocarditis and Dilated Cardiomyopathy. , 2011, , .		4
443	PD-1 and Autoimmunity. <i>Critical Reviews in Immunology</i> , 2011, 31, 265-295.	0.5	24
444	Alternatives to heart transplantation integration of biology with surgery. <i>Frontiers in Bioscience - Elite</i> , 2011, E3, 635-647.	1.8	9
445	cDNA Sequence and Fab Crystal Structure of HL4E10, a Hamster IgG Lambda Light Chain Antibody Stimulatory for β 1 T Cells. <i>PLoS ONE</i> , 2011, 6, e19828.	2.5	5
446	Lack of an Association of PD-1 and Its Ligand Genes with Behcet's Disease in a Chinese Han Population. <i>PLoS ONE</i> , 2011, 6, e25345.	2.5	13
447	Role of Immunotherapy for Renal Cell Cancer in 2011. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2011, 9, 1011-1018.	4.9	22

#	ARTICLE	IF	CITATIONS
448	Beyond Cancer Vaccines. <i>Cancer Journal (Sudbury, Mass)</i> , 2011, 17, 372-378.	2.0	26
449	PD-1 Blockade by CT-011, Anti-PD-1 Antibody, Enhances Ex Vivo T-cell Responses to Autologous Dendritic Cell/Myeloma Fusion Vaccine. <i>Journal of Immunotherapy</i> , 2011, 34, 409-418.	2.4	270
450	Shifting the equilibrium in cancer immunoediting: from tumor tolerance to eradication. <i>Immunological Reviews</i> , 2011, 241, 104-118.	6.0	229
451	Intrinsic and extrinsic control of peripheral T cell tolerance by costimulatory molecules of the CD28/B7 family. <i>Immunological Reviews</i> , 2011, 241, 180-205.	6.0	330
452	Timeline: a decade of advances in immunotherapy. <i>Nature Medicine</i> , 2011, 17, 296-296.	30.7	4
453	Angiotensin II-induced dilated cardiomyopathy in Balb/c but not C57BL/6J mice. <i>Experimental Physiology</i> , 2011, 96, 756-764.	2.0	54
454	The role of the PD-1 pathway in autoimmunity and peripheral tolerance. <i>Annals of the New York Academy of Sciences</i> , 2011, 1217, 45-59.	3.8	290
455	L2pB1: A new player in autoimmunity. <i>Molecular Immunology</i> , 2011, 48, 1292-1300.	2.2	12
456	Tumor immune surveillance and ovarian cancer. <i>Cancer and Metastasis Reviews</i> , 2011, 30, 141-151.	5.9	47
457	Editorial on the manuscript entitled "Impact of Troponin I-Autoantibodies in Chronic Dilated and Ischemic Cardiomyopathy" by Andreas O. Doesch and co-workers. <i>Basic Research in Cardiology</i> , 2011, 106, 1-4.	5.9	3
458	The effects of PDL-Ig on collagen-induced arthritis. <i>Rheumatology International</i> , 2011, 31, 513-519.	3.0	54
459	Enhanced programmed death 1 (PD-1) and PD-1 ligand (PD-L1) expression in patients with actinic cheilitis and oral squamous cell carcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2011, 60, 965-74.	4.2	70
460	Searching for costimulatory requirements of $\gamma\delta$ T cells. <i>Cellular and Molecular Life Sciences</i> , 2011, 68, 2345-2355.	5.4	61
461	Characteristics and PD-1 expression of peripheral CD4 ⁺ CD127 ^{lo} CD25 ^{hi} FoxP3 ⁺ Treg cells in chronic HCV infected-patients. <i>Virology Journal</i> , 2011, 8, 279.	3.4	39
462	Phenotype, effector function, and tissue localization of PD-1-expressing human follicular helper T cell subsets. <i>BMC Immunology</i> , 2011, 12, 53.	2.2	42
463	The negative costimulatory molecule PD-1 modulates the balance between immunity and tolerance via miR-21. <i>European Journal of Immunology</i> , 2011, 41, 1754-1763.	2.9	57
464	Expression and function of PD-1 in human $\gamma\delta$ T cells that recognize phosphoantigens. <i>European Journal of Immunology</i> , 2011, 41, 345-355.	2.9	138
465	The majority of infiltrating CD8 T lymphocytes in multiple sclerosis lesions is insensitive to enhanced PD-L1 levels on CNS cells. <i>Glia</i> , 2011, 59, 841-856.	4.9	47

#	ARTICLE	IF	CITATIONS
466	Hepatic B7 homolog 1 expression is essential for controlling cold ischemia/reperfusion injury after mouse liver transplantation. <i>Hepatology</i> , 2011, 54, 216-228.	7.3	37
467	B7-H1 Overexpression Regulates Epithelial-Mesenchymal Transition and Accelerates Carcinogenesis in Skin. <i>Cancer Research</i> , 2011, 71, 1235-1243.	0.9	84
468	Using monoclonal antibodies to stimulate antitumor cellular immunity. <i>Expert Review of Vaccines</i> , 2011, 10, 1093-1106.	4.4	14
469	PD-1 and LAG-3 inhibitory co-receptors act synergistically to prevent autoimmunity in mice. <i>Journal of Experimental Medicine</i> , 2011, 208, 395-407.	8.5	256
470	VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses. <i>Journal of Experimental Medicine</i> , 2011, 208, 577-592.	8.5	539
471	Phenotype, Function, and Gene Expression Profiles of Programmed Death-1hi CD8 T Cells in Healthy Human Adults. <i>Journal of Immunology</i> , 2011, 186, 4200-4212.	0.8	211
472	Prostate Cancer Immunotherapy: Figure 1.. <i>Clinical Cancer Research</i> , 2011, 17, 5233-5238.	7.0	57
473	Lack of B and T lymphocyte attenuator exacerbates autoimmune disorders and induces Fas-independent liver injury in MRL-lpr/lpr mice. <i>International Immunology</i> , 2011, 23, 335-344.	4.0	24
474	Divide and conquer. <i>Chimerism</i> , 2011, 2, 29-32.	0.7	1
475	Programmed Death 1 Regulates Development of Central Memory CD8 T Cells after Acute Viral Infection. <i>Journal of Immunology</i> , 2011, 186, 6280-6286.	0.8	43
476	IFN- γ Directly Promotes Programmed Cell Death-1 Transcription and Limits the Duration of T Cell-Mediated Immunity. <i>Journal of Immunology</i> , 2011, 186, 2772-2779.	0.8	278
477	Regulation of Trypanosoma cruzi-Induced Myocarditis by Programmed Death Cell Receptor 1. <i>Infection and Immunity</i> , 2011, 79, 1873-1881.	2.2	48
478	A Functional Polymorphism in B and T Lymphocyte Attenuator Is Associated with Susceptibility to Rheumatoid Arthritis. <i>Clinical and Developmental Immunology</i> , 2011, 2011, 1-8.	3.3	34
479	The PD-1/PD-L1 (B7-H1) Pathway in Chronic Infection-Induced Cytotoxic T Lymphocyte Exhaustion. <i>Journal of Biomedicine and Biotechnology</i> , 2011, 2011, 1-9.	3.0	118
480	Constitutive Genes and Lupus. , 2011, , 47-61.		4
481	From Tumor Immunosuppression to Eradication: Targeting Homing and Activity of Immune Effector Cells to Tumors. <i>Clinical and Developmental Immunology</i> , 2011, 2011, 1-15.	3.3	123
482	The CTLA-4 and PD-1/PD-L1 Inhibitory Pathways Independently Regulate Host Resistance to Plasmodium-induced Acute Immune Pathology. <i>PLoS Pathogens</i> , 2012, 8, e1002504.	4.7	110
483	Novel Anti-Melanoma Immunotherapies: Disarming Tumor Escape Mechanisms. <i>Clinical and Developmental Immunology</i> , 2012, 2012, 1-9.	3.3	24

#	ARTICLE	IF	CITATIONS
484	Coinhibitory Molecules in Autoimmune Diseases. <i>Clinical and Developmental Immunology</i> , 2012, 2012, 1-7.	3.3	39
485	Programmed death 1 protects from fatal circulatory failure during systemic virus infection of mice. <i>Journal of Experimental Medicine</i> , 2012, 209, 2485-2499.	8.5	167
486	Immunotherapies: The Blockade of Inhibitory Signals. <i>International Journal of Biological Sciences</i> , 2012, 8, 1420-1430.	6.4	24
487	T-cell Inhibitors. <i>Dermatitis</i> , 2012, 23, 195-202.	1.6	6
488	Autoantibodies in Heart Failure and Cardiac Dysfunction. <i>Circulation Research</i> , 2012, 110, 145-158.	4.5	142
489	Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape. <i>Science Translational Medicine</i> , 2012, 4, 127ra37.	12.4	1,837
490	Antibodies Against B7-DC with Differential Binding Properties Exert Opposite Effects. <i>Hybridoma</i> , 2012, 31, 40-47.	0.4	6
491	Immune Inhibitory Molecules LAG-3 and PD-1 Synergistically Regulate T-cell Function to Promote Tumoral Immune Escape. <i>Cancer Research</i> , 2012, 72, 917-927.	0.9	1,311
492	Immunotherapy for Prostate Cancer Enters Its Golden Age. <i>Clinical Medicine Insights: Oncology</i> , 2012, 6, CMO.S7475.	1.3	6
493	Positive and Negative Regulation of Cellular Immune Responses in Physiologic Conditions and Diseases. <i>Clinical and Developmental Immunology</i> , 2012, 2012, 1-11.	3.3	78
494	PD-1 Protects against Inflammation and Myocyte Damage in T Cell-Mediated Myocarditis. <i>Journal of Immunology</i> , 2012, 188, 4876-4884.	0.8	218
495	Approaches Used in Immunotherapy for Prostate Cancer. <i>Current Cancer Therapy Reviews</i> , 2012, 8, 238-244.	0.3	0
496	BALB/c-Fcgr2b ^{-/-} /Pdc1 ^{-/-} mouse expressing anti-urothelial antibody is a novel model of autoimmune cystitis. <i>Scientific Reports</i> , 2012, 2, 317.	3.3	10
497	Polyfunctional CD4+ T cells are essential for eradicating advanced B-cell lymphoma after chemotherapy. <i>Blood</i> , 2012, 120, 2229-2239.	1.4	74
498	Role of the PD-1 Pathway in the Immune Response. <i>American Journal of Transplantation</i> , 2012, 12, 2575-2587.	4.7	348
499	Immunology beats cancer: a blueprint for successful translation. <i>Nature Immunology</i> , 2012, 13, 1129-1132.	14.5	148
500	Lessons learned from experimental myocarditis. <i>Herz</i> , 2012, 37, 817-821.	1.1	6
501	Immunoregulatory molecules are master regulators of inflammation during the immune response. <i>FEBS Letters</i> , 2012, 586, 2897-2905.	2.8	32

#	ARTICLE	IF	CITATIONS
502	Znaczenie receptora programowanej śmierci 1 oraz jego ligandów w układzie immunologicznym oraz nowotworach. Acta Haematologica Polonica, 2012, 43, 132-145.	0.3	11
503	IFN- γ is reciprocally involved in the concurrent development of organ-specific autoimmunity in the liver and stomach. Autoimmunity, 2012, 45, 186-198.	2.6	11
504	Effects of immunoglobulin to prevent coronary allograft vasculopathy in heart transplantation. Expert Opinion on Therapeutic Targets, 2012, 16, 783-789.	3.4	2
505	Immunotherapy earns its spot in the ranks of cancer therapy. Journal of Experimental Medicine, 2012, 209, 201-209.	8.5	118
506	Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2. Journal of Experimental Medicine, 2012, 209, 1201-1217.	8.5	864
507	IgA plasma cells express the negative regulatory co-stimulatory molecule programmed cell death 1 ligand and have a potential tolerogenic role in the intestine. Biochemical and Biophysical Research Communications, 2012, 425, 918-923.	2.1	19
508	Immune Tolerance and Transplantation. Seminars in Oncology, 2012, 39, 629-642.	2.2	68
509	Plasmacytoid Dendritic Cells Are Inefficient in Activation of Human Regulatory T Cells. PLoS ONE, 2012, 7, e44056.	2.5	7
510	Immunotherapy for Castration-Resistant Prostate Cancer. Urologic Clinics of North America, 2012, 39, 465-481.	1.8	11
511	The Role of Intrauterine Immune Privilege in Perinatal Infectious Diseases. , 2012, , 53-91.		1
512	Animal Models for Autoimmune Liver Disease – What Is Relevant for Immune-Mediated Liver Disease. Digestive Diseases, 2012, 30, 2-10.	1.9	9
513	Genetic polymorphisms and surface expression of CTLA-4 and PD-1 on T cells of silica-exposed workers. International Journal of Hygiene and Environmental Health, 2012, 215, 562-569.	4.3	25
514	Evolution of cellular immunotherapy: from allogeneic transplant to dendritic cell vaccination as treatment for multiple myeloma. Immunotherapy, 2012, 4, 1043-1051.	2.0	9
515	Targeting Immune Checkpoints. Cancer Journal (Sudbury, Mass), 2012, 18, 153-159.	2.0	41
516	The blockade of immune checkpoints in cancer immunotherapy. Nature Reviews Cancer, 2012, 12, 252-264.	28.4	10,874
517	The Inhibitory Receptor PD-1 Regulates IgA Selection and Bacterial Composition in the Gut. Science, 2012, 336, 485-489.	12.6	377
518	Germinal Centers. Annual Review of Immunology, 2012, 30, 429-457.	21.8	1,740
519	Role of PD-1 in HIV Pathogenesis and as Target for Therapy. Current HIV/AIDS Reports, 2012, 9, 81-90.	3.1	127

#	ARTICLE	IF	CITATIONS
520	Prostate cancer, tumor immunity and a renewed sense of optimism in immunotherapy. <i>Cancer Immunology, Immunotherapy</i> , 2012, 61, 453-468.	4.2	22
521	Development of Novel Immune Interventions for Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2012, 10, 84-92.	1.9	17
522	Program death-1 regulates peripheral T cell tolerance via an anergy-independent mechanism. <i>Clinical Immunology</i> , 2012, 143, 128-133.	3.2	12
523	Genes, tolerance and systemic autoimmunity. <i>Autoimmunity Reviews</i> , 2012, 11, 664-669.	5.8	31
524	The B7 Homologues and their Receptors in Hematologic Malignancies. <i>European Journal of Haematology</i> , 2012, 88, 465-475.	2.2	17
525	Immunotherapy of cancer in 2012. <i>Ca-A Cancer Journal for Clinicians</i> , 2012, 62, 309-335.	329.8	379
526	Antigen-specific blocking of CD4-specific immunological synapse formation using BPI and current therapies for autoimmune diseases. <i>Medicinal Research Reviews</i> , 2012, 32, 727-764.	10.5	28
527	Dilated cardiomyopathy update: infectious-immune theory revisited. <i>Heart Failure Reviews</i> , 2013, 18, 703-714.	3.9	30
528	An exon polymorphism of programmed cell death 1 gene is associated with both the susceptibility and thoracolumbar kyphosis severity of ankylosing spondylitis in a Chinese Han population. <i>Journal of Orthopaedic Science</i> , 2013, 18, 514-518.	1.1	13
529	B7 family checkpoint regulators in immune regulation and disease. <i>Trends in Immunology</i> , 2013, 34, 556-563.	6.8	263
530	Molecular Pathways: Coexpression of Immune Checkpoint Molecules: Signaling Pathways and Implications for Cancer Immunotherapy. <i>Clinical Cancer Research</i> , 2013, 19, 4917-4924.	7.0	244
531	Programmed cell death 1 inhibits inflammatory helper T-cell development through controlling the innate immune response. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 16073-16078.	7.1	44
533	A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application. <i>Nature Immunology</i> , 2013, 14, 1212-1218.	14.5	783
534	Recent insights into the role of the PD-1/PD-L1 pathway in immunological tolerance and autoimmunity. <i>Autoimmunity Reviews</i> , 2013, 12, 1091-1100.	5.8	213
535	Advances in the development of cancer immunotherapies. <i>Trends in Immunology</i> , 2013, 34, 90-98.	6.8	37
536	Progress and potential of immune checkpoint blockade for treating advanced renal cell carcinoma. <i>Immunotherapy</i> , 2013, 5, 607-619.	2.0	3
537	Harnessing the Power of the Immune System to Target Cancer. <i>Annual Review of Medicine</i> , 2013, 64, 71-90.	12.2	126
538	Immune Co-signaling to Treat Cancer. , 2013, , 211-280.		1

#	ARTICLE	IF	CITATIONS
539	Intrahepatic Expression of Programmed Death-1 and its Ligands in Patients with HBV-Related Acute-on-Chronic Liver Failure. <i>Inflammation</i> , 2013, 36, 110-120.	3.8	31
540	PD-1 Dependent Exhaustion of CD8+ T Cells Drives Chronic Malaria. <i>Cell Reports</i> , 2013, 5, 1204-1213.	6.4	147
541	The heart of the matter: Protection of the myocardium from T cells. <i>Journal of Autoimmunity</i> , 2013, 45, 90-96.	6.5	63
542	Splenectomy Prolongs the Effects of Corticosteroids in Mouse Models of Autoimmune Hepatitis. <i>Gastroenterology</i> , 2013, 145, 209-220.e9.	1.3	33
543	TNF- α is essential in the induction of fatal autoimmune hepatitis in mice through upregulation of hepatic CCL20 expression. <i>Clinical Immunology</i> , 2013, 146, 15-25.	3.2	39
544	Advances in targeting cell surface signalling molecules for immune modulation. <i>Nature Reviews Drug Discovery</i> , 2013, 12, 130-146.	46.4	229
545	The DC-HIL ligand syndecan-4 is a negative regulator of T cell alloreactivity responsible for graft-versus-host disease. <i>Immunology</i> , 2013, 138, 173-182.	4.4	20
546	Immune-mediated and autoimmune myocarditis: clinical presentation, diagnosis and management. <i>Heart Failure Reviews</i> , 2013, 18, 715-732.	3.9	91
547	Anti-programmed death-1 and anti-programmed death-ligand 1 antibodies in cancer therapy. <i>Expert Opinion on Biological Therapy</i> , 2013, 13, 847-861.	3.1	110
548	Immunotherapy for Renal Cell Carcinoma. , 2013, , 279-301.		0
549	Coinhibitory molecules in cancer biology and therapy. <i>Cytokine and Growth Factor Reviews</i> , 2013, 24, 147-161.	7.2	26
550	Interleukin-21 and tumor necrosis factor- α are critical for the development of autoimmune gastritis in mice. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2013, 28, 982-991.	2.8	15
551	At the Bench: Preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapy. <i>Journal of Leukocyte Biology</i> , 2013, 94, 25-39.	3.3	317
552	Immunosuppression in sepsis: a novel understanding of the disorder and a new therapeutic approach. <i>Lancet Infectious Diseases</i> , The, 2013, 13, 260-268.	9.1	1,138
553	Antibody-based therapy in colorectal cancer. <i>Immunotherapy</i> , 2013, 5, 533-545.	2.0	31
554	T-cell costimulation in graft-versus-host disease and graft-versus-leukemia effect. , 2013, , 195-222.		0
555	Cancer immunotherapies, their safety and toxicity. <i>Expert Opinion on Drug Safety</i> , 2013, 12, 631-645.	2.4	123
556	Endoplasmic reticulum stress response and inflammatory cytokines in type 2 diabetic nephropathy: Role of indoleamine 2,3-dioxygenase and programmed death-1. <i>Experimental and Molecular Pathology</i> , 2013, 94, 343-351.	2.1	41

#	ARTICLE	IF	CITATIONS
557	The Role of Interleukin-6 in the Expression of PD-1 and PDL-1 on Central Nervous System Cells following Infection with Theiler's Murine Encephalomyelitis Virus. <i>Journal of Virology</i> , 2013, 87, 11538-11551.	3.4	34
558	PD-1 and CTLA-4 Mediated Inhibitory Signaling for T cell Exhaustion during Chronic Viral Infections. <i>Journal of Clinical & Cellular Immunology</i> , 2013, 01, .	1.5	3
559	Demystifying Immunotherapy in Prostate Cancer. <i>Cancer Journal (Sudbury, Mass)</i> , 2013, 19, 50-58.	2.0	20
560	Antagonist Antibodies to PD-1 and B7-H1 (PD-L1) in the Treatment of Advanced Human Cancer. <i>Clinical Cancer Research</i> , 2013, 19, 1021-1034.	7.0	458
561	Molecular Insights for Optimizing T Cell Receptor Specificity Against Cancer. <i>Frontiers in Immunology</i> , 2013, 4, 154.	4.8	35
562	Suppression of IL-22-Producing T Helper 22 Cells by RPE Cells via PD-L1/PD-1 Interactions. , 2013, 54, 6926.		23
563	Emerging treatments in management of prostate cancer: biomarker validation and endpoints for immunotherapy clinical trial design. <i>ImmunoTargets and Therapy</i> , 2013, 3, 1.	5.8	4
564	Costimulatory Molecules on Immunogenic Versus Tolerogenic Human Dendritic Cells. <i>Frontiers in Immunology</i> , 2013, 4, 82.	4.8	180
565	Increased PD-1 expression on CD4+ and CD8+ T cells is involved in immune evasion in gastric cancer. <i>Journal of Surgical Oncology</i> , 2013, 107, 517-522.	1.7	75
566	PD-1 Regulates T Cell Proliferation in a Tissue and Subset-Specific Manner During Normal Mouse Pregnancy. <i>Immunological Investigations</i> , 2013, 42, 385-408.	2.0	20
567	Structure and Interactions of the Human Programmed Cell Death 1 Receptor. <i>Journal of Biological Chemistry</i> , 2013, 288, 11771-11785.	3.4	256
568	The Role of B-Cells in Heart Failure. <i>Methodist DeBakey Cardiovascular Journal</i> , 2021, 9, 15.	1.0	25
569	Costimulation Blockade. <i>Transplantation</i> , 2013, 95, 527-535.	1.0	74
570	Sinomenine inhibits the expression of PD-L1 in the peripheral blood mononuclear cells of mesangial proliferative nephritis patients. <i>Molecular Medicine Reports</i> , 2013, 7, 1223-1228.	2.4	11
571	Programmed cell death-1 deficiency results in atrial remodeling in C57BL/6 mice. <i>International Journal of Molecular Medicine</i> , 2013, 31, 423-429.	4.0	16
572	The nature of activatory and tolerogenic dendritic cell-derived signal II. <i>Frontiers in Immunology</i> , 2013, 4, 53.	4.8	91
573	Regulation of Neuroinflammation through Programed Death-1/Programed Death Ligand Signaling in Neurological Disorders. <i>Frontiers in Cellular Neuroscience</i> , 2014, 8, 271.	3.7	38
574	Fallen Angels or Risen Apes? A Tale of the Intricate Complexities of Imbalanced Immune Responses in the Pathogenesis and Progression of Immune-Mediated and Viral Cancers. <i>Frontiers in Immunology</i> , 2014, 5, 90.	4.8	4

#	ARTICLE	IF	CITATIONS
575	PD-1 as an emerging therapeutic target in renal cell carcinoma: current evidence. <i>OncoTargets and Therapy</i> , 2014, 7, 1349.	2.0	37
576	PD-1 identifies the patient-specific CD8+ tumor-reactive repertoire infiltrating human tumors. <i>Journal of Clinical Investigation</i> , 2014, 124, 2246-2259.	8.2	892
577	Programmed Death-1 Pathway in Host Tissues Ameliorates Th17/Th1-Mediated Experimental Chronic Graft-versus-Host Disease. <i>Journal of Immunology</i> , 2014, 193, 2565-2573.	0.8	67
578	PD-1 is not required for natural or peripherally induced regulatory T cells: Severe autoimmunity despite normal production of regulatory T cells. <i>European Journal of Immunology</i> , 2014, 44, 3560-3572.	2.9	38
579	Sipuleucel-T and immunotherapy in the treatment of prostate cancer. <i>Expert Opinion on Biological Therapy</i> , 2014, 14, 709-719.	3.1	8
580	Therapeutic cancer vaccines: a long and winding road to success. <i>Expert Review of Vaccines</i> , 2014, 13, 131-144.	4.4	12
581	The role of cytotoxic T cells in IgG4-related dacryoadenitis and sialadenitis, the so-called Mikulicz's disease. <i>Modern Rheumatology</i> , 2014, 24, 953-960.	1.8	10
582	Progression of autoimmune hepatitis is mediated by IL-18-producing dendritic cells and hepatic CXCL9 expression in mice. <i>Hepatology</i> , 2014, 60, 224-236.	7.3	61
583	The panoply of $\gamma\delta$ T cells in the skin. <i>Journal of Dermatological Science</i> , 2014, 76, 3-9.	1.9	55
584	PD-1 blockage delays murine squamous cell carcinoma development. <i>Carcinogenesis</i> , 2014, 35, 424-431.	2.8	42
585	Antibodies Against Potassium Channel Interacting Protein 2 Induce Necrosis in Isolated Rat Cardiomyocytes. <i>Journal of Cellular Biochemistry</i> , 2014, 115, 678-689.	2.6	3
586	Linking susceptibility genes and pathogenesis mechanisms using mouse models of systemic lupus erythematosus. <i>DMM Disease Models and Mechanisms</i> , 2014, 7, 1033-1046.	2.4	70
587	Biochemical Signaling of PD-1 on T Cells and Its Functional Implications. <i>Cancer Journal (Sudbury, Mass)</i> , 2014, 20, 262-264.	2.0	62
588	PD-1 as an Immune Modulatory Receptor. <i>Cancer Journal (Sudbury, Mass)</i> , 2014, 20, 262-264.	2.0	62
589	Disruption of CXCR2-Mediated MDSC Tumor Trafficking Enhances Anti-PD1 Efficacy. <i>Science Translational Medicine</i> , 2014, 6, 237ra67.	12.4	579
590	Armed Therapeutic Viruses – A Disruptive Therapy on the Horizon of Cancer Immunotherapy. <i>Frontiers in Immunology</i> , 2014, 5, 74.	4.8	39
591	Sex differences in monocytes and TLR4 associated immune responses; implications for systemic lupus erythematosus (SLE). <i>Journal of Immunotherapy Applications</i> , 2014, 1, 1.	3.0	32
592	Immune Checkpoint Blockade in Cancer Treatment: A Double-Edged Sword Cross-Targeting the Host as an ‘Innocent Bystander’. <i>Toxins</i> , 2014, 6, 914-933.	3.4	62

#	ARTICLE	IF	CITATIONS
593	Expression of Programmed Death-1 (PD-1) on CD4+ and CD8+ T cells in Rheumatoid Arthritis. Inflammation, 2014, 37, 116-121.	3.8	58
594	Expression regulation of co-inhibitory molecules on human natural killer cells in response to cytokine stimulations. Cytokine, 2014, 65, 33-41.	3.2	50
595	Targeting the programmed cell death 1: programmed cell death ligand 1 pathway reverses T cell exhaustion in patients with sepsis. Critical Care, 2014, 18, R3.	5.8	236
596	Immune and genetic gardening of the intestinal microbiome. FEBS Letters, 2014, 588, 4102-4111.	2.8	47
597	Orchestrating immune check-point blockade for cancer immunotherapy in combinations. Current Opinion in Immunology, 2014, 27, 89-97.	5.5	111
598	Immunological Toleranceâ€”T Cells. , 2014, , 87-102.		1
600	Coinhibitory molecule PD-1 as a potential target for the immunotherapy of multiple myeloma. Leukemia, 2014, 28, 993-1000.	7.2	92
601	Checkpoint blocking antibodies in cancer immunotherapy. FEBS Letters, 2014, 588, 368-376.	2.8	227
602	<sc>PD</sc>â€”1 modulates steadyâ€”state and infectionâ€”induced <sc>IL</sc>â€”10 production in vivo. European Journal of Immunology, 2014, 44, 469-479.	2.9	18
603	Interference with PD-L1/PD-1 co-stimulation during antigen presentation enhances the multifunctionality of antigen-specific T cells. Gene Therapy, 2014, 21, 262-271.	4.5	73
604	The PD-1 pathway as a therapeutic target to overcome immune escape mechanisms in cancer. Expert Opinion on Therapeutic Targets, 2014, 18, 1-14.	3.4	38
605	Current Perspectives on Immunotherapy. Seminars in Oncology, 2014, 41, S14-S29.	2.2	28
606	Mechanism of Action of Immunotherapy. Seminars in Oncology, 2014, 41, S3-S13.	2.2	121
607	The Path to Reactivation of Antitumor Immunity and Checkpoint Immunotherapy. Cancer Immunology Research, 2014, 2, 926-936.	3.4	23
608	Programmed cell death 1 (PD-1) regulates the effector function of CD8 T cells via PD-L1 expressed on target keratinocytes. Journal of Autoimmunity, 2014, 53, 1-9.	6.5	58
609	Disruption of the immune-checkpoint <i>VISTA</i> gene imparts a proinflammatory phenotype with predisposition to the development of autoimmunity. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 14846-14851.	7.1	156
610	Telomere shortening and immune activity in war veterans with posttraumatic stress disorder. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2014, 54, 275-283.	4.8	59
611	Myeloid-derived suppressor cells and their role in CTLA-4 blockade therapy. Cancer Immunology, Immunotherapy, 2014, 63, 977-983.	4.2	31

#	ARTICLE	IF	CITATIONS
612	VSIG4 expression on macrophages facilitates lung cancer development. <i>Laboratory Investigation</i> , 2014, 94, 706-715.	3.7	65
613	Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti-PD-1 Therapy. <i>Clinical Cancer Research</i> , 2014, 20, 5064-5074.	7.0	2,050
614	Role of the Programmed Death-1 (PD-1) pathway in regulation of Theiler's murine encephalomyelitis virus-induced demyelinating disease. <i>Journal of Neuroimmunology</i> , 2014, 274, 78-85.	2.3	12
615	Tumor-Induced Immune Suppression. , 2014, , .		3
616	<i>In Vitro</i> Characterization of the Anti-PD-1 Antibody Nivolumab, BMS-936558, and <i>In Vivo</i> Toxicology in Non-Human Primates. <i>Cancer Immunology Research</i> , 2014, 2, 846-856.	3.4	514
617	Immune Checkpoint Blockade. <i>Hematology/Oncology Clinics of North America</i> , 2014, 28, 585-600.	2.2	70
618	Low programmed cell death-1 (PD-1) expression in peripheral CD4 ⁺ T cells in Japanese patients with autoimmune type 1 diabetes. <i>Clinical and Experimental Immunology</i> , 2015, 180, 452-457.	2.6	88
619	Immune checkpoint blockade opens an avenue of cancer immunotherapy with a potent clinical efficacy. <i>Cancer Science</i> , 2015, 106, 945-950.	3.9	78
621	Human Cancer Immunotherapy with PD-1/PD-L1 Blockade. <i>Biomarkers in Cancer</i> , 2015, 7s2, BIC.S29325.	3.6	51
622	Self-adjuvanted mRNA vaccination in advanced prostate cancer patients: a first-in-man phase I/IIa study. , 2015, 3, 26.		206
623	Role of Radiation Therapy as Immune Activator in the Era of Modern Immunotherapy for Metastatic Malignant Melanoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2015, 38, 119-125.	1.3	65
624	Programmed death 1 and its ligands do not limit experimental foreign antigen-induced immune complex glomerulonephritis. <i>Nephrology</i> , 2015, 20, 892-898.	1.6	4
625	Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future. <i>Journal of Clinical Investigation</i> , 2015, 125, 3384-3391.	8.2	1,112
626	Nivolumab in the treatment of malignant melanoma: review of the literature. <i>OncoTargets and Therapy</i> , 2015, 8, 2045.	2.0	21
627	Biomarkers of Response to Immune Modulatory Therapies in Cancer. <i>Journal of Clinical & Cellular Immunology</i> , 2015, 06, .	1.5	1
628	Inhibitory Receptors Beyond T Cell Exhaustion. <i>Frontiers in Immunology</i> , 2015, 6, 310.	4.8	188
629	Therapeutic strategy for cancer immunotherapy in head and neck cancer. <i>Advances in Cellular and Molecular Otolaryngology</i> , 2015, 3, 27690.	0.4	5
630	Molecular profiling in the treatment of colorectal cancer: focus on regorafenib. <i>OncoTargets and Therapy</i> , 2015, 8, 2949.	2.0	7

#	ARTICLE	IF	CITATIONS
631	Immunotherapy of Ovarian Cancer: The Role of Checkpoint Inhibitors. <i>Journal of Immunology Research</i> , 2015, 2015, 1-7.	2.2	49
632	Programmed death-1/programmed death-L1 signaling pathway and its blockade in hepatitis C virus immunotherapy. <i>World Journal of Hepatology</i> , 2015, 7, 2449.	2.0	32
633	Cancer and the Cellular Immune Response. , 2015, , 695-708.e2.		0
634	PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. <i>New England Journal of Medicine</i> , 2015, 372, 2509-2520.	27.0	7,696
635	Myeloid-Derived Suppressor Cells Impair Alveolar Macrophages through PD-1 Receptor Ligation during Pneumocystis Pneumonia. <i>Infection and Immunity</i> , 2015, 83, 572-582.	2.2	37
636	Monoclonal antibodies specific to human \hat{P}^{42} PD1: A novel immunoregulator potentially involved in HIV-1 and tumor pathogenesis. <i>MAbs</i> , 2015, 7, 620-629.	5.2	6
637	Costimulation Immunotherapy in Infectious Diseases. , 2015, , 83-129.		10
638	T-Cell Costimulation and Its Applications in Diseases. , 2015, , 255-292.		12
639	Programmed Death-1 Controls T Cell Survival by Regulating Oxidative Metabolism. <i>Journal of Immunology</i> , 2015, 194, 5789-5800.	0.8	104
640	Cardio-Oncology. <i>Circulation</i> , 2015, 132, 2248-2258.	1.6	99
642	Therapeutic Antibodies in Cancer Therapy. , 2015, , 95-120.		1
643	Soluble PD-1 aggravates progression of collagen-induced arthritis through Th1 and Th17 pathways. <i>Arthritis Research and Therapy</i> , 2015, 17, 340.	3.5	80
644	Thymosin alpha1 based immunomodulatory therapy for sepsis: a systematic review and meta-analysis. <i>International Journal of Infectious Diseases</i> , 2015, 33, 90-96.	3.3	34
645	Immunoabsorption therapy in dilated cardiomyopathy. <i>Expert Review of Cardiovascular Therapy</i> , 2015, 13, 145-152.	1.5	33
646	The evolution of checkpoint blockade as a cancer therapy: what's here, what's next?. <i>Current Opinion in Immunology</i> , 2015, 33, 23-35.	5.5	298
647	Immune checkpoint combinations from mouse to man. <i>Cancer Immunology, Immunotherapy</i> , 2015, 64, 885-892.	4.2	40
648	Immune Checkpoint Blockade in Cancer Therapy. <i>Journal of Clinical Oncology</i> , 2015, 33, 1974-1982.	1.6	2,220
649	Anti-programmed death receptor 1 immunotherapy in melanoma: rationale, evidence and clinical potential. <i>Therapeutic Advances in Medical Oncology</i> , 2015, 7, 12-21.	3.2	22

#	ARTICLE	IF	CITATIONS
650	Combination Therapy with Anti-CTLA-4 and Anti-PD-1 Leads to Distinct Immunologic Changes In Vivo. <i>Journal of Immunology</i> , 2015, 194, 950-959.	0.8	362
651	Low immunogenicity in non-small cell lung cancer; do new developments and novel treatments have a role?. <i>Cancer and Metastasis Reviews</i> , 2015, 34, 129-144.	5.9	11
652	Clinical presentation and diagnosis of myocarditis. <i>Heart</i> , 2015, 101, 1332-1344.	2.9	77
653	Cancer Immunotherapy with Vaccines and Checkpoint Blockade. , 2015, , 709-738.e8.		0
654	Nivolumab in renal cell carcinoma. <i>Expert Opinion on Biological Therapy</i> , 2015, 15, 1049-1060.	3.1	4
655	The New Era of Cancer Immunotherapy. <i>Advances in Cancer Research</i> , 2015, 128, 1-68.	5.0	41
656	Checkpoint blockade for cancer therapy: revitalizing a suppressed immune system. <i>Trends in Molecular Medicine</i> , 2015, 21, 482-491.	6.7	146
657	The Role of Anti-PD-1/PD-L1 Agents in Melanoma: Progress to Date. <i>Drugs</i> , 2015, 75, 563-575.	10.9	18
658	Induction of T-cell Immunity Overcomes Complete Resistance to PD-1 and CTLA-4 Blockade and Improves Survival in Pancreatic Carcinoma. <i>Cancer Immunology Research</i> , 2015, 3, 399-411.	3.4	387
659	Immune Checkpoint Protein Inhibition for Cancer: Preclinical Justification for CTLA-4 and PD-1 Blockade and New Combinations. <i>Seminars in Oncology</i> , 2015, 42, 363-377.	2.2	101
660	Acute heart failure due to autoimmune myocarditis under pembrolizumab treatment for metastatic melanoma. , 2015, 3, 11.		274
661	Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. <i>Lancet Oncology</i> , The, 2015, 16, 375-384.	10.7	2,353
662	Immune-checkpoint proteins VISTA and PD-1 nonredundantly regulate murine T-cell responses. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 6682-6687.	7.1	266
663	Toxicity Patterns With Immunomodulating Antibodies and Their Combinations. <i>Seminars in Oncology</i> , 2015, 42, 423-428.	2.2	55
664	Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy. <i>Cancer Cell</i> , 2015, 27, 450-461.	16.8	3,266
665	NF- κ B Regulates PD-1 Expression in Macrophages. <i>Journal of Immunology</i> , 2015, 194, 4545-4554.	0.8	134
666	Clinical significance of soluble programmed death-1 (sPD-1) in rheumatoid arthritis patients: Relation to disease activity and functional status. <i>Egyptian Rheumatologist</i> , 2015, 37, 165-169.	1.0	12
667	<sc>PD</sc>-1 expression on <sc>CD</sc>4+ T cells and myeloid <sc>DC</sc>s correlates with the immune pathogenesis of atrial fibrillation. <i>Journal of Cellular and Molecular Medicine</i> , 2015, 19, 1223-1233.	3.6	23

#	ARTICLE	IF	CITATIONS
668	The role of B-1 cells in inflammation. <i>Immunologic Research</i> , 2015, 63, 153-166.	2.9	91
669	Lung cancer: Biology and treatment options. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2015, 1856, 189-210.	7.4	526
670	Shifting paradigms in the treatment of chronic lymphocytic leukemia. <i>Future Oncology</i> , 2015, 11, 641-657.	2.4	3
671	Pembrolizumab. , 2015, 3, 36.		171
672	Immune Checkpoint Inhibitors. <i>Progress in Tumor Research</i> , 2015, 42, 55-66.	0.1	151
673	Negative immune checkpoints on T lymphocytes and their relevance to cancer immunotherapy. <i>Molecular Oncology</i> , 2015, 9, 1936-1965.	4.6	64
674	Immunotherapy Combinations With Checkpoint Inhibitors in Metastatic Melanoma: Current Approaches and Future Directions. <i>Seminars in Oncology</i> , 2015, 42, S12-S19.	2.2	24
675	B cell epitope spreading: Mechanisms and contribution to autoimmune diseases. <i>Immunology Letters</i> , 2015, 163, 56-68.	2.5	147
676	Clinical blockade of PD1 and LAG3 â€” potential mechanisms of action. <i>Nature Reviews Immunology</i> , 2015, 15, 45-56.	22.7	524
677	Protective effects of Fc-fused PD-L1 on two different animal models of colitis. <i>Gut</i> , 2015, 64, 260-271.	12.1	94
678	Immunotherapy Targeting the PD-1 Signaling Pathway. <i>Japanese Journal of Lung Cancer</i> , 2016, 56, 61-65.	0.1	0
679	New targeted treatments for non-small-cell lung cancer – role of nivolumab. <i>Biologics: Targets and Therapy</i> , 2016, Volume 10, 103-117.	3.2	23
680	Enhanced Anti-tumor Reactivity of Cytotoxic T Lymphocytes Expressing PD-1 Decoy. <i>Immune Network</i> , 2016, 16, 134.	3.6	8
681	Immunotherapy for Glioblastoma. <i>Journal of Clinical & Cellular Immunology</i> , 2016, 7, .	1.5	0
682	The PD1:PD-L1/2 Pathway from Discovery to Clinical Implementation. <i>Frontiers in Immunology</i> , 2016, 7, 550.	4.8	409
683	Combination Approaches with Immune-Checkpoint Blockade in Cancer Therapy. <i>Frontiers in Oncology</i> , 2016, 6, 233.	2.8	148
684	Therapeutic Immune Tolerance Approaches for the Treatment of Allergic Disease. , 2016, , 259-284.		0
685	Immunoregulation in Fungal Diseases. <i>Microorganisms</i> , 2016, 4, 47.	3.6	14

#	ARTICLE	IF	CITATIONS
686	Mechanisms of Immune Escape in Cancer. <i>Journal of the Nihon University Medical Association</i> , 2016, 75, 152-155.	0.0	0
687	Suspected autoimmune myocarditis and cardiac conduction abnormalities with nivolumab therapy for non-small cell lung cancer. <i>BMJ Case Reports</i> , 2016, 2016, bcr2016216228.	0.5	61
688	The dawn of a new era in onco-cardiology: The Kumamoto Classification. <i>International Journal of Cardiology</i> , 2016, 220, 837-841.	1.7	12
689	An Evaluation of the Impact of PD-1 Pathway Blockade on Reproductive Safety of Therapeutic PD-1 Inhibitors. <i>Birth Defects Research Part B: Developmental and Reproductive Toxicology</i> , 2016, 107, 108-119.	1.4	65
690	Exacerbation of myasthenia gravis in a patient with melanoma treated with pembrolizumab. <i>Muscle and Nerve</i> , 2016, 54, 157-161.	2.2	87
691	The promise of immunotherapy in head and neck squamous cell carcinoma: combinatorial immunotherapy approaches. <i>ESMO Open</i> , 2016, 1, e000122.	4.5	55
692	PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer. <i>Breast Care</i> , 2016, 11, 385-390.	1.4	20,872
693	Does extracellular cardiac troponin I play a pathogenic role independently of autoantibodies?. <i>Clinical Science</i> , 2016, 130, 2277-2278.	4.3	0
694	A New VISTA on combination therapy for negative checkpoint regulator blockade. , 2016, 4, 86.		36
695	The PD-1/PD-L1 inhibitory pathway is altered in pre-eclampsia and regulates T cell responses in pre-eclamptic rats. <i>Scientific Reports</i> , 2016, 6, 27683.	3.3	69
696	Checkpoint inhibition in myeloma. <i>Hematology American Society of Hematology Education Program</i> , 2016, 2016, 528-533.	2.5	10
698	Programmed cell death ligand 1 alleviates psoriatic inflammation by suppressing IL-17A production from programmed cell death "high T cells. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 137, 1466-1476.e3.	2.9	65
699	Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy. <i>Journal of Hematology and Oncology</i> , 2016, 9, 47.	17.0	271
700	Therapeutic Antibodies in Cancer Therapy. <i>Advances in Experimental Medicine and Biology</i> , 2016, 917, 95-120.	1.6	36
701	Malignant melanoma "The cradle of anti-neoplastic immunotherapy. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 106, 25-54.	4.4	33
702	Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation. <i>Immunity</i> , 2016, 44, 989-1004.	14.3	1,538
703	Combinatorial Cancer Immunotherapies. <i>Advances in Immunology</i> , 2016, 130, 251-277.	2.2	107
704	Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. <i>Nature Reviews Cancer</i> , 2016, 16, 275-287.	28.4	2,133

#	ARTICLE	IF	CITATIONS
705	Immune checkpoint inhibitors in gynecologic cancers with lessons learned from non-gynecologic cancers. <i>Expert Opinion on Biological Therapy</i> , 2016, 16, 989-1004.	3.1	10
706	TALEN-Mediated Inactivation of PD-1 in Tumor-Reactive Lymphocytes Promotes Intratumoral T-cell Persistence and Rejection of Established Tumors. <i>Cancer Research</i> , 2016, 76, 2087-2093.	0.9	67
707	Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination. <i>Nature Reviews Clinical Oncology</i> , 2016, 13, 473-486.	27.6	831
708	Recent developments in the use of immunotherapy in non-small cell lung cancer. <i>Expert Review of Respiratory Medicine</i> , 2016, 10, 781-798.	2.5	29
709	Validated LC-MS/MS analysis of immune checkpoint inhibitor Nivolumab in human plasma using a Fab peptide-selective quantitation method: nano-surface and molecular-orientation limited (nSMOL) proteolysis. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2016, 1023-1024, 9-16.	2.3	39
710	T cell exhaustion and immune-mediated disease—the potential for therapeutic exhaustion. <i>Current Opinion in Immunology</i> , 2016, 43, 74-80.	5.5	66
711	Cardiovascular Toxic Effects of Targeted Cancer Therapies. <i>New England Journal of Medicine</i> , 2016, 375, 1457-1467.	27.0	470
712	Targeting Immune Checkpoints in Hematologic Malignancies. <i>Pharmacological Reviews</i> , 2016, 68, 1014-1025.	16.0	36
713	Metastatic melanoma and immunotherapy. <i>Clinical Immunology</i> , 2016, 172, 105-110.	3.2	43
714	Assessing Immune-Related Adverse Events of Efficacious Combination Immunotherapies in Preclinical Models of Cancer. <i>Cancer Research</i> , 2016, 76, 5288-5301.	0.9	82
715	Relationship between Overall Survival and Response or Progression-Free Survival in Advanced Non-Small Cell Lung Cancer Patients Treated with Anti-PD-1/PD-L1 Antibodies. <i>Journal of Thoracic Oncology</i> , 2016, 11, 1927-1939.	1.1	63
716	Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy. , 2016, 4, 50.		413
717	T cell exhaustion: understanding the interface of chronic viral and autoinflammatory diseases. <i>Immunology and Cell Biology</i> , 2016, 94, 935-942.	2.3	29
718	Cancer Immunotherapy by Checkpoint Blockade. , 2016, , 561-580.		2
719	Programmed Death-1 Ligand 2-Mediated Regulation of the PD-L1 to PD-1 Axis Is Essential for Establishing CD4 + T Cell Immunity. <i>Immunity</i> , 2016, 45, 333-345.	14.3	92
720	Molecular Pathways: Targeting CD96 and TIGIT for Cancer Immunotherapy. <i>Clinical Cancer Research</i> , 2016, 22, 5183-5188.	7.0	171
721	Varicella-Zoster Virus Downregulates Programmed Death Ligand 1 and Major Histocompatibility Complex Class I in Human Brain Vascular Adventitial Fibroblasts, Perineurial Cells, and Lung Fibroblasts. <i>Journal of Virology</i> , 2016, 90, 10527-10534.	3.4	21
722	PD-1/PD-L and autoimmunity: A growing relationship. <i>Cellular Immunology</i> , 2016, 310, 27-41.	3.0	211

#	ARTICLE	IF	CITATIONS
723	Programmed Death-1 Culls Peripheral Accumulation of High-Affinity Autoreactive CD4 ⁺ T Cells to Protect against Autoimmunity. <i>Cell Reports</i> , 2016, 17, 1783-1794.	6.4	35
724	Immune checkpoint inhibitors for cancer treatment. <i>Archives of Pharmacal Research</i> , 2016, 39, 1577-1587.	6.3	43
725	Fulminant Myocarditis with Combination Immune Checkpoint Blockade. <i>New England Journal of Medicine</i> , 2016, 375, 1749-1755.	27.0	1,668
726	Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway. <i>New England Journal of Medicine</i> , 2016, 375, 1767-1778.	27.0	1,025
727	Immune checkpoint therapy and type 1 diabetes. <i>Diabetology International</i> , 2016, 7, 221-227.	1.4	12
728	Mice lacking Programmed cell death-1 show a role for CD8 ⁺ T cells in long-term immunity against blood-stage malaria. <i>Scientific Reports</i> , 2016, 6, 26210.	3.3	25
729	Current Status of Immunotherapy Treatments for Pancreatic Cancer. <i>Journal of Clinical Gastroenterology</i> , 2016, 50, 836-848.	2.2	11
730	Severe acute interstitial nephritis after combination immune-checkpoint inhibitor therapy for metastatic melanoma. <i>Clinical Kidney Journal</i> , 2016, 9, 411-417.	2.9	98
731	FTY720 (Gilenya) treatment prevents spontaneous autoimmune myocarditis and dilated cardiomyopathy in transgenic HLA-DQ8-BALB/c mice. <i>Cardiovascular Pathology</i> , 2016, 25, 353-361.	1.6	4
732	Immune Checkpoint inhibitors: An introduction to the next generation cancer immunotherapy. <i>Journal of Clinical Pharmacology</i> , 2016, 56, 157-169.	2.0	102
733	Ipilimumab Combined with Nivolumab: A Standard of Care for the Treatment of Advanced Melanoma?. <i>Clinical Cancer Research</i> , 2016, 22, 3992-3998.	7.0	48
734	PD-1 rs2227982 Polymorphism Is Associated With the Decreased Risk of Breast Cancer in Northwest Chinese Women. <i>Medicine (United States)</i> , 2016, 95, e3760.	1.0	42
735	IL-15 temporally reorients IL-10 biased B-1a cells toward IL-12 expression. <i>Cellular and Molecular Immunology</i> , 2016, 13, 229-239.	10.5	7
736	Btn2a2, a T cell immunomodulatory molecule coregulated with MHC class II genes. <i>Journal of Experimental Medicine</i> , 2016, 213, 177-187.	8.5	49
737	Synthetic ROR γ t Agonists Enhance Protective Immunity. <i>ACS Chemical Biology</i> , 2016, 11, 1012-1018.	3.4	48
738	Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders. <i>JAMA Oncology</i> , 2016, 2, 234.	7.1	534
739	Checkpoint Blockade for the Treatment of Advanced Melanoma. <i>Cancer Treatment and Research</i> , 2016, 167, 231-250.	0.5	36
740	A novel regulation of PD-1 ligands on mesenchymal stromal cells through MMP-mediated proteolytic cleavage. <i>Oncimmunology</i> , 2016, 5, e1091146.	4.6	66

#	ARTICLE	IF	CITATIONS
741	Basics of PD-1 in self-tolerance, infection, and cancer immunity. <i>International Journal of Clinical Oncology</i> , 2016, 21, 448-455.	2.2	74
742	Enhancing the safety of antibody-based immunomodulatory cancer therapy without compromising therapeutic benefit: Can we have our cake and eat it too?. <i>Expert Opinion on Biological Therapy</i> , 2016, 16, 655-674.	3.1	21
743	Glycogen Synthase Kinase 3 Inactivation Drives T-bet-Mediated Downregulation of Co-receptor PD-1 to Enhance CD8+ Cytolytic T Cell Responses. <i>Immunity</i> , 2016, 44, 274-286.	14.3	144
744	Facilitating T Cell Infiltration in Tumor Microenvironment Overcomes Resistance to PD-L1 Blockade. <i>Cancer Cell</i> , 2016, 29, 285-296.	16.8	349
745	An increased number of PD-1+ and Tim-3+ CD8+ T cells is involved in immune evasion in gastric cancer. <i>Surgery Today</i> , 2016, 46, 1341-1347.	1.5	34
746	Immunotherapy of Cancer. , 2016, , .		3
747	The future of cancer treatment: immunomodulation, CARs and combination immunotherapy. <i>Nature Reviews Clinical Oncology</i> , 2016, 13, 273-290.	27.6	909
748	Anti-PD-1 and Anti-PD-L1 mAbs. , 2016, , 283-294.		1
749	Genetic and Epigenetic Regulation of PD-1 Expression. <i>Journal of Immunology</i> , 2016, 196, 2431-2437.	0.8	181
750	Predictive Markers for the Efficacy of Anti-“PD-1/PD-L1 Antibodies in Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2016, 11, 976-988.	1.1	197
751	Cytotoxic Cutaneous Adverse Drug Reactions during Anti-PD-1 Therapy. <i>Clinical Cancer Research</i> , 2016, 22, 4023-4029.	7.0	160
752	Immune checkpoint blockade: Releasing the brake towards hematological malignancies. <i>Blood Reviews</i> , 2016, 30, 189-200.	5.7	34
753	PD-1 expression conditions T cell avidity within an antigen-specific repertoire. <i>Oncolmmunology</i> , 2016, 5, e1104448.	4.6	47
754	PD-1 expression on dendritic cells suppresses CD8⁺T cell function and antitumor immunity. <i>Oncolmmunology</i> , 2016, 5, e1085146.	4.6	131
755	Signaling pathway and dysregulation of PD1 and its ligands in lymphoid malignancies. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2016, 1865, 58-71.	7.4	49
756	Immunotherapy and tumor microenvironment. <i>Cancer Letters</i> , 2016, 370, 85-90.	7.2	242
757	Combination Therapy With Reovirus and Anti-PD-1 Blockade Controls Tumor Growth Through Innate and Adaptive Immune Responses. <i>Molecular Therapy</i> , 2016, 24, 166-174.	8.2	161
758	The associations between PD-1, CTLA-4 gene polymorphisms and susceptibility to ankylosing spondylitis: a meta-analysis and systemic review. <i>Rheumatology International</i> , 2016, 36, 33-44.	3.0	17

#	ARTICLE	IF	CITATIONS
759	Mitochondrial activation chemicals synergize with surface receptor PD-1 blockade for T cell-dependent antitumor activity. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, E761-E770.	7.1	295
760	Immunoinhibitory checkpoint deficiency in medium and large vessel vasculitis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, E970-E979.	7.1	172
761	Renal complications of immune checkpoint blockade. <i>Current Problems in Cancer</i> , 2017, 41, 100-110.	2.0	81
762	Novel immune check point inhibiting antibodies in cancer therapy—Opportunities and challenges. <i>Drug Resistance Updates</i> , 2017, 30, 39-47.	14.4	98
763	Cardiovascular Toxicities Associated with Cancer Immunotherapies. <i>Current Cardiology Reports</i> , 2017, 19, 21.	2.9	126
764	Developing Cures: Targeting Ontogenesis in Cancer. <i>Trends in Cancer</i> , 2017, 3, 126-136.	7.4	11
765	In situ and in silico kinetic analyses of programmed cell death-1 (PD-1) receptor, programmed cell death ligands, and B7-1 protein interaction network. <i>Journal of Biological Chemistry</i> , 2017, 292, 6799-6809.	3.4	16
766	Characterization of the Anti-PD-1 Antibody REGN2810 and Its Antitumor Activity in Human PD-1 Knock-In Mice. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 861-870.	4.1	92
767	Structure-guided development of a high-affinity human Programmed Cell Death-1: Implications for tumor immunotherapy. <i>EBioMedicine</i> , 2017, 17, 30-44.	6.1	52
768	Inflammatory cytokines compromise programmed cell death-1 (PD-1)-mediated T cell suppression in inflammatory arthritis through up-regulation of soluble PD-1. <i>Clinical and Experimental Immunology</i> , 2017, 188, 455-466.	2.6	55
769	PD-1 modulates regulatory T-cell homeostasis during low-dose interleukin-2 therapy. <i>Blood</i> , 2017, 129, 2186-2197.	1.4	156
770	Cardiomyopathy—An approach to the autoimmune background. <i>Autoimmunity Reviews</i> , 2017, 16, 269-286.	5.8	33
771	Genetically engineered mouse models in oncology research and cancer medicine. <i>EMBO Molecular Medicine</i> , 2017, 9, 137-153.	6.9	356
772	High programmed death 1 expression on T cells in aplastic anemia. <i>Immunology Letters</i> , 2017, 183, 44-51.	2.5	12
773	Immune checkpoint receptors in cancer: redundant by design?. <i>Current Opinion in Immunology</i> , 2017, 45, 37-42.	5.5	23
774	Advances in targeting inhibitory and stimulatory pathways in transplantation settings: the Yin to the Yang of cancer immunotherapy. <i>Immunological Reviews</i> , 2017, 276, 192-212.	6.0	44
775	The Role of Immune Checkpoint Inhibition in the Treatment of Brain Tumors. <i>Neurotherapeutics</i> , 2017, 14, 1049-1065.	4.4	20
776	Inhibitory blockade while preserving tolerance: checkpoint inhibitors for glioblastoma. <i>Immunological Reviews</i> , 2017, 276, 9-25.	6.0	13

#	ARTICLE	IF	CITATIONS
777	Elevated serum autoantibodies against co-inhibitory PD-1 facilitate T cell proliferation and correlate with disease activity in new-onset systemic lupus erythematosus patients. <i>Arthritis Research and Therapy</i> , 2017, 19, 52.	3.5	25
779	Dysregulated homeostasis of target tissues or autoantigens - A novel principle in autoimmunity. <i>Autoimmunity Reviews</i> , 2017, 16, 602-611.	5.8	27
780	Histopathologic Features of Colitis Due to Immunotherapy With Anti-PD-1 Antibodies. <i>American Journal of Surgical Pathology</i> , 2017, 41, 643-654.	3.7	146
781	Molecular Markers for Colorectal Cancer. <i>Surgical Clinics of North America</i> , 2017, 97, 683-701.	1.5	23
782	Checkpoint inhibitors in hematological malignancies. <i>Journal of Hematology and Oncology</i> , 2017, 10, 103.	17.0	106
783	Immunosuppression in liver tumors: opening the portal to effective immunotherapy. <i>Cancer Gene Therapy</i> , 2017, 24, 114-120.	4.6	15
784	miR-142-5p regulates tumor cell PD-L1 expression and enhances anti-tumor immunity. <i>Biochemical and Biophysical Research Communications</i> , 2017, 488, 425-431.	2.1	133
785	Severe Exacerbation of Myasthenia Gravis Associated with Checkpoint Inhibitor Immunotherapy. <i>Journal of Neuromuscular Diseases</i> , 2017, 4, 169-173.	2.6	33
786	Targeting the programmed cell death-1 pathway in rheumatoid arthritis. <i>Autoimmunity Reviews</i> , 2017, 16, 767-773.	5.8	16
787	Molecular Pathways: Evaluating the Potential for B7-H4 as an Immunoregulatory Target. <i>Clinical Cancer Research</i> , 2017, 23, 2934-2941.	7.0	44
788	Clinical Impact of Single Nucleotide Polymorphism in PD-L1 on Response to Nivolumab for Advanced Non-Small-Cell Lung Cancer Patients. <i>Scientific Reports</i> , 2017, 7, 45124.	3.3	72
789	Cancer immunotherapies targeting the PD-1 signaling pathway. <i>Journal of Biomedical Science</i> , 2017, 24, 26.	7.0	501
790	Isolated ACTH deficiency probably induced by autoimmune-related mechanism evoked with nivolumab. <i>Japanese Journal of Clinical Oncology</i> , 2017, 47, 463-466.	1.3	55
791	Immune checkpoint inhibition and its relationship with hypermutation phenotype as a potential treatment for Glioblastoma. <i>Journal of Neuro-Oncology</i> , 2017, 132, 359-372.	2.9	8
792	Imaging and clinicopathological features of nivolumab-related cholangitis in patients with non-small cell lung cancer. <i>Investigational New Drugs</i> , 2017, 35, 529-536.	2.6	128
793	Troponin Autoantibodies: From Assay Interferent to Mediator of Cardiotoxicity. <i>Clinical Chemistry</i> , 2017, 63, 30-32.	3.2	10
794	MAGT1-mediated disturbance of Mg ²⁺ homeostasis lead to exhausted of HBV-infected NK and CD8+ T cells. <i>Scientific Reports</i> , 2017, 7, 13594.	3.3	11
795	Timing of PD-1 Blockade Is Critical to Effective Combination Immunotherapy with Anti-OX40. <i>Clinical Cancer Research</i> , 2017, 23, 6165-6177.	7.0	249

#	ARTICLE	IF	CITATIONS
796	Tim-3, Lag-3, and TIGIT. Current Topics in Microbiology and Immunology, 2017, 410, 127-156.	1.1	109
797	Role of PD-1 in Immunity and Diseases. Current Topics in Microbiology and Immunology, 2017, 410, 75-97.	1.1	136
798	A canine chimeric monoclonal antibody targeting PD-L1 and its clinical efficacy in canine oral malignant melanoma or undifferentiated sarcoma. Scientific Reports, 2017, 7, 8951.	3.3	111
800	Advances in cancer stem cell targeting: How to strike the evil at its root. Advanced Drug Delivery Reviews, 2017, 120, 89-107.	13.7	58
801	Mechanisms of action and rationale for the use of checkpoint inhibitors in cancer. ESMO Open, 2017, 2, e000213.	4.5	248
802	Lung cancer as a cardiotoxic state: a review. Medical Oncology, 2017, 34, 159.	2.5	12
803	Lichen planus-like drug eruption on anti-PD-1 therapy. JDDG - Journal of the German Society of Dermatology, 2017, 15, 1238-1240.	0.8	7
804	Emerging Concepts Targeting Immune Checkpoints in Cancer and Autoimmunity. Current Topics in Microbiology and Immunology, 2017, , .	1.1	1
805	Cardiac Toxicity of Immune Checkpoint Inhibitors. Circulation, 2017, 136, 1989-1992.	1.6	83
806	Cardiotoxicity of immune checkpoint inhibitors. ESMO Open, 2017, 2, e000247.	4.5	186
807	Live Cell Labeling with Terpyridine Derivative Proligands to Measure Cytotoxicity Mediated by Immune Cells. ChemMedChem, 2017, 12, 2006-2013.	3.2	9
808	The Effect of Inhibitory Signals on the Priming of Drug Hapten-Specific T Cells That Express Distinct V β 2 Receptors. Journal of Immunology, 2017, 199, 1223-1237.	0.8	41
809	Unique B7-H1 expression on masticatory mucosae in the oral cavity and trans-coinhibition by B7-H1-expressing keratinocytes regulating CD4+ T cell-mediated mucosal tissue inflammation. Mucosal Immunology, 2017, 10, 650-660.	6.0	12
810	The safety of anti PD-1 therapeutics for the treatment of melanoma. Expert Opinion on Drug Safety, 2017, 16, 41-53.	2.4	17
811	Cardiac allograft rejection as a complication of PD-1 checkpoint blockade for cancer immunotherapy: a case report. Cancer Immunology, Immunotherapy, 2017, 66, 45-50.	4.2	55
812	Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer. Oncologist, 2017, 22, 81-88.	3.7	128
813	Anti-troponin antibodies following myocardial infarction. Journal of Cardiology, 2017, 69, 38-45.	1.9	15
814	Immune checkpoint inhibitors for nonsmall cell lung cancer treatment. Journal of the Chinese Medical Association, 2017, 80, 7-14.	1.4	39

#	ARTICLE	IF	CITATIONS
815	Immune Checkpoint Blockade in Breast Cancer Therapy. <i>Advances in Experimental Medicine and Biology</i> , 2017, 1026, 383-402.	1.6	24
816	Lichen ruberâ€artiges Arzneimittelexanthem unter Antiâ€PDâ€1â€Therapie. <i>JDDG - Journal of the German Society of Dermatology</i> , 2017, 15, 1237-1239.	0.8	0
817	Control of NK Cell Activation by Immune Checkpoint Molecules. <i>International Journal of Molecular Sciences</i> , 2017, 18, 2129.	4.1	64
818	Newly Emerging Immune Checkpoints: Promises for Future Cancer Therapy. <i>International Journal of Molecular Sciences</i> , 2017, 18, 2642.	4.1	72
819	Programmed Cell Death 1 (PD-1) and Cytotoxic T Lymphocyte-Associated Antigen 4 (CTLA-4) in Viral Hepatitis. <i>International Journal of Molecular Sciences</i> , 2017, 18, 1517.	4.1	69
820	PD-1/PD-L1 Blockade: Have We Found the Key to Unleash the Antitumor Immune Response?. <i>Frontiers in Immunology</i> , 2017, 8, 1597.	4.8	225
821	The Spontaneous Autoimmune Neuromyopathy in ICOSLâ€™/â€™ NOD Mice Is CD4+ T-Cell and Interferon-Î³ Dependent. <i>Frontiers in Immunology</i> , 2017, 8, 287.	4.8	6
822	Recent Successes and Future Directions in Immunotherapy of Cutaneous Melanoma. <i>Frontiers in Immunology</i> , 2017, 8, 1617.	4.8	43
823	Organ-Specific Autoimmune Myocardial Diseases. , 2017, , 25-48.		2
824	Autoimmune Diabetes and Thyroiditis Complicating Treatment with Nivolumab. <i>Case Reports in Oncology</i> , 2017, 10, 230-234.	0.7	35
825	Coinhibitory molecule PD-1 as a therapeutic target in the microenvironment of Multiple Myeloma. <i>Current Cancer Drug Targets</i> , 2017, 17, 839-845.	1.6	11
826	The Mechanism of Checkpoint Inhibitors in Gynecologic Cancer. <i>Journal of Carcinogenesis & Mutagenesis</i> , 2017, 08, .	0.3	0
827	IFN-Î³ versus IL-17: A Battle During Cardiac Autoimmunity Evolution. , 0, , .		2
828	Immune Checkpoint Blockade and Adaptive Immune Resistance in Cancer. , 0, , .		3
829	Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PD-L1 blockade. <i>Oncotarget</i> , 2017, 8, 110693-110707.	1.8	115
830	PD-1 and its ligands are important immune checkpoints in cancer. <i>Oncotarget</i> , 2017, 8, 2171-2186.	1.8	234
831	Tumor immunotherapy: drug-induced neoantigens (xenogenization) and immune checkpoint inhibitors. <i>Oncotarget</i> , 2017, 8, 41641-41669.	1.8	15
832	First Case Report of a Dramatic Radiographic Response to a Checkpoint Inhibitor in a Patient With Proficient Mismatch Repair Gene Expressing Metastatic Colorectal Cancer. <i>JCO Precision Oncology</i> , 2017, 1, 1-4.	3.0	7

#	ARTICLE	IF	CITATIONS
833	Elevated expression of PD-1 on T cells correlates with disease activity in rheumatoid arthritis. <i>Molecular Medicine Reports</i> , 2018, 17, 3297-3305.	2.4	11
834	Uncoupling therapeutic from immunotherapy-related adverse effects for safer and effective anti-CTLA-4 antibodies in CTLA4 humanized mice. <i>Cell Research</i> , 2018, 28, 433-447.	12.0	91
835	PD-1 is required to maintain stem cell properties in human dental pulp stem cells. <i>Cell Death and Differentiation</i> , 2018, 25, 1350-1360.	11.2	31
836	The risk of immune-related endocrine disorders associated with anti-PD-1 inhibitors therapy for solid tumors: A systematic review and meta-analysis. <i>International Immunopharmacology</i> , 2018, 59, 328-338.	3.8	19
837	Emerging Concepts for Immune Checkpoint Blockade-Based Combination Therapies. <i>Cancer Cell</i> , 2018, 33, 581-598.	16.8	393
838	Cardiotoxicity of Immunotherapy: Incidence, Diagnosis, and Management. <i>Current Oncology Reports</i> , 2018, 20, 44.	4.0	53
839	Electrophysiologic Toxicity of Chemoradiation. <i>Current Oncology Reports</i> , 2018, 20, 45.	4.0	18
840	Soluble PD-L1 with PD-1-binding capacity exists in the plasma of patients with non-small cell lung cancer. <i>Immunology Letters</i> , 2018, 196, 155-160.	2.5	55
841	Multifunctional nanoparticles for cancer immunotherapy: A groundbreaking approach for reprogramming malfunctioned tumor environment. <i>Journal of Controlled Release</i> , 2018, 274, 24-34.	9.9	123
842	Inhibition of the checkpoint protein PD-1 by the therapeutic antibody pembrolizumab outlined by quantum chemistry. <i>Scientific Reports</i> , 2018, 8, 1840.	3.3	33
843	Clinical Development of PD-1 in Advanced Melanoma. <i>Cancer Journal (Sudbury, Mass)</i> , 2018, 24, 7-14.	2.0	37
844	Pathophysiological mechanisms of autoimmunity. <i>Annals of the New York Academy of Sciences</i> , 2018, 1413, 59-68.	3.8	20
845	Increased Levels of Soluble Programmed Death Ligand 1 Associate with Malignancy in Patients with Dermatomyositis. <i>Journal of Rheumatology</i> , 2018, 45, 835-840.	2.0	23
846	The innate immune system in chronic cardiomyopathy: a European Society of Cardiology (ESC) scientific statement from the Working Group on Myocardial Function of the ESC. <i>European Journal of Heart Failure</i> , 2018, 20, 445-459.	7.1	118
847	Biomarkers for immune-related toxicities of checkpoint inhibitors: current progress and the road ahead. <i>Expert Review of Molecular Diagnostics</i> , 2018, 18, 297-305.	3.1	23
848	Cancer Immunotherapy: Factors Important for the Evaluation of Safety in Nonclinical Studies. <i>AAPS Journal</i> , 2018, 20, 28.	4.4	13
849	Evaluation of programmed cell death protein 1 (PD-1) expression as a prognostic biomarker in patients with clear cell renal cell carcinoma. <i>Oncolmmunology</i> , 2018, 7, e1413519.	4.6	21
850	Preclinical Data Supporting Antitumor Activity of PD-1 Blockade. <i>Cancer Journal (Sudbury, Mass)</i> , 2018, 24, 2-6.	2.0	5

#	ARTICLE	IF	CITATIONS
851	PD-1/PD-L1 in disease. <i>Immunotherapy</i> , 2018, 10, 149-160.	2.0	90
852	Affinity purification mass spectrometry analysis of PD-1 uncovers SAP as a new checkpoint inhibitor. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E468-E477.	7.1	72
853	Potential cardiac risk of immune checkpoint blockade as anticancer treatment: What we know, what we do not know, and what we can do to prevent adverse effects. <i>Medicinal Research Reviews</i> , 2018, 38, 1447-1468.	10.5	27
854	Monoclonal Antibodies Targeting the Immune System. , 2018, , 141-160.		0
855	Vaccine Therapy and Immunotherapy for Pancreatic Cancer. , 2018, , 1461-1505.		0
856	Immunotherapy for pancreatic cancer: A long and hopeful journey. <i>Cancer Letters</i> , 2018, 425, 143-151.	7.2	35
857	Cardiac Complications Associated With Checkpoint Inhibition: A Systematic Review of the Literature in an Important Emerging Area. <i>Canadian Journal of Cardiology</i> , 2018, 34, 1059-1068.	1.7	95
858	Immune checkpoint blockade therapy. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 142, 1403-1414.	2.9	79
859	Regulation and Function of the PD-L1 Checkpoint. <i>Immunity</i> , 2018, 48, 434-452.	14.3	1,437
860	Cardiac Toxicity in Patients Treated With Immune Checkpoint Inhibitors. <i>Journal of the American College of Cardiology</i> , 2018, 71, 1765-1767.	2.8	49
861	The emerging role of immunotherapy in advanced urothelial cancers. <i>Current Opinion in Oncology</i> , 2018, 30, 172-180.	2.4	23
862	Serial Troponin for Early Detection of Nivolumab Cardiotoxicity in Advanced Non-Small Cell Lung Cancer Patients. <i>Oncologist</i> , 2018, 23, 936-942.	3.7	69
863	Deficiency of host CD96 and PD-1 or TIGIT enhances tumor immunity without significantly compromising immune homeostasis. <i>Oncolmmunology</i> , 2018, 7, e1445949.	4.6	46
864	CD103+ lung dendritic cells (LDCs) induce stronger Th1/Th17 immunity to a bacterial lung infection than CD11bhi LDCs. <i>Cellular and Molecular Immunology</i> , 2018, 15, 377-387.	10.5	33
865	The emerging role of immune checkpoint based approaches in AML and MDS. <i>Leukemia and Lymphoma</i> , 2018, 59, 790-802.	1.3	90
866	Intrinsic and extrinsic causes of malignancies in patients with primary immunodeficiency disorders. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 141, 59-68.e4.	2.9	99
867	Immune checkpoint inhibitor-related myocarditis. <i>Japanese Journal of Clinical Oncology</i> , 2018, 48, 7-12.	1.3	57
868	Checkpoint inhibitor-induced uveitis: a case series. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2018, 256, 187-191.	1.9	59

#	ARTICLE	IF	CITATIONS
869	Mechanistic overview of immune checkpoints to support the rational design of their combinations in cancer immunotherapy. <i>Annals of Oncology</i> , 2018, 29, 71-83.	1.2	253
870	Combination therapy strategies for improving PD-1 blockade efficacy: a new era in cancer immunotherapy. <i>Journal of Internal Medicine</i> , 2018, 283, 110-120.	6.0	162
871	PD-1 pathway and its clinical application: A 20 year journey after discovery of the complete human PD-1 gene. <i>Gene</i> , 2018, 638, 20-25.	2.2	87
872	Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens. <i>JAMA Oncology</i> , 2018, 4, 173.	7.1	753
873	The diverse functions of the PD1 inhibitory pathway. <i>Nature Reviews Immunology</i> , 2018, 18, 153-167.	22.7	1,210
874	Breakthroughs in modern cancer therapy and elusive cardiotoxicity: Critical research-practice gaps, challenges, and insights. <i>Medicinal Research Reviews</i> , 2018, 38, 325-376.	10.5	50
875	Global patent landscape of programmed cell death 1: implications of the rapid expansion. <i>Expert Opinion on Therapeutic Patents</i> , 2018, 28, 69-80.	5.0	5
876	Immunotherapy for Pediatric Malignancies. , 2018, , .		0
877	Investigational PD-1 inhibitors in HL and NHL and biomarkers for predictors of response and outcome. <i>Expert Opinion on Investigational Drugs</i> , 2018, 27, 55-70.	4.1	5
878	PD-L1, inflammation, non-coding RNAs, and neuroblastoma: Immuno-oncology perspective. <i>Seminars in Cancer Biology</i> , 2018, 52, 53-65.	9.6	58
879	PD-L1 Prevents the Development of Autoimmune Heart Disease in Graft-versus-Host Disease. <i>Journal of Immunology</i> , 2018, 200, 834-846.	0.8	23
880	Immune checkpoint inhibitors: new strategies to checkmate cancer. <i>Clinical and Experimental Immunology</i> , 2018, 191, 133-148.	2.6	57
881	Checkpoint inhibitor-associated autoimmunity. <i>Best Practice and Research in Clinical Rheumatology</i> , 2018, 32, 781-802.	3.3	13
882	Gene Expression Profiles of Programmed Death-1 (+) Lymphocytes in Peripheral Blood Reveal their Significance in Tumor Immunity of T Cell Non-Hodgkin Lymphoma. <i>Journal of Blood & Lymph</i> , 2018, 08, .	0.0	0
883	Cardio-toxicity of checkpoint inhibitors. <i>Journal of Thoracic Disease</i> , 2018, 10, S4400-S4404.	1.4	19
884	Heart failure in cancer: role of checkpoint inhibitors. <i>Journal of Thoracic Disease</i> , 2018, 10, S4323-S4334.	1.4	15
885	Biomarkers for the detection of apparent and subclinical cancer therapy-related cardiotoxicity. <i>Journal of Thoracic Disease</i> , 2018, 10, S4282-S4295.	1.4	69
887	Combining immunotherapy with radiation therapy in thoracic oncology. <i>Journal of Thoracic Disease</i> , 2018, 10, S2492-S2507.	1.4	16

#	ARTICLE	IF	CITATIONS
889	Future of anti-PD-1/PD-L1 applications: Combinations with other therapeutic regimens. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2018, 30, 157-172.	2.2	40
890	Cardiovascular oncology: exploring the effects of targeted cancer therapies on atherosclerosis. Current Opinion in Lipidology, 2018, 29, 381-388.	2.7	8
891	The Role of Leukocytes in Diabetic Cardiomyopathy. Frontiers in Physiology, 2018, 9, 1547.	2.8	50
892	Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study. Lancet Oncology, The, 2018, 19, 1579-1589.	10.7	742
893	The Central Role of Inflammation Associated with Checkpoint Inhibitor Treatments. Journal of Immunology Research, 2018, 2018, 1-10.	2.2	26
894	Transforming of the Tumor Microenvironment: Implications for TGF- β Inhibition in the Context of Immune-Checkpoint Therapy. Journal of Oncology, 2018, 2018, 1-9.	1.3	35
895	The suppressive effect of co-inhibiting PD-1 and CTLA-4 expression on H22 hepatomas in mice. Cellular and Molecular Biology Letters, 2018, 23, 58.	7.0	18
896	Immune checkpoint inhibitors in cancer therapy. Journal of Biomedical Research, 2018, 32, 317.	1.6	101
897	Immune checkpoint inhibitors in the onset of myasthenia gravis with hyperkalemia. Annals of Clinical and Translational Neurology, 2018, 5, 1421-1427.	3.7	31
898	The Balancing Act between Cancer Immunity and Autoimmunity in Response to Immunotherapy. Cancer Immunology Research, 2018, 6, 1445-1452.	3.4	132
899	Targeting tumor cells with antibodies enhances anti-tumor immunity. Biophysics Reports, 2018, 4, 243-253.	0.8	17
900	Mechanism and Management of Cancer Chemotherapy-Induced Atherosclerosis. Journal of Atherosclerosis and Thrombosis, 2018, 25, 994-1002.	2.0	29
901	Not All Immune Checkpoints Are Created Equal. Frontiers in Immunology, 2018, 9, 1909.	4.8	114
902	Microbiota as an amplifier of autoimmunity. Current Opinion in Immunology, 2018, 55, 15-21.	5.5	23
903	The application of nanotechnology in immune checkpoint blockade for cancer treatment. Journal of Controlled Release, 2018, 290, 28-45.	9.9	67
904	EF Hand Domain Family Member D2 Is Required for T Cell Cytotoxicity. Journal of Immunology, 2018, 201, 2824-2831.	0.8	13
905	Clinical Significance of Pancreatic Atrophy Induced by Immune-Checkpoint Inhibitors: A Case-Control Study. Cancer Immunology Research, 2018, 6, 1453-1458.	3.4	35
906	T Cell Calcium Signaling Regulation by the Co-Receptor CD5. International Journal of Molecular Sciences, 2018, 19, 1295.	4.1	20

#	ARTICLE	IF	CITATIONS
907	Recent advances in immunotherapies: from infection and autoimmunity, to cancer, and back again. <i>Genome Medicine</i> , 2018, 10, 79.	8.2	36
908	Cardiac morbidity in HIV infection is associated with checkpoint inhibitor LAG-3 on CD4 T cells. <i>PLoS ONE</i> , 2018, 13, e0206256.	2.5	10
909	Inhibitory Receptors and Pathways of Lymphocytes: The Role of PD-1 in Treg Development and Their Involvement in Autoimmunity Onset and Cancer Progression. <i>Frontiers in Immunology</i> , 2018, 9, 2374.	4.8	150
910	Anti-PD-1/PD-L1 immunotherapy in patients with solid organ transplant, HIV or hepatitis B/C infection. <i>European Journal of Cancer</i> , 2018, 104, 137-144.	2.8	97
911	Immune Checkpoints as Therapeutic Targets in Autoimmunity. <i>Frontiers in Immunology</i> , 2018, 9, 2306.	4.8	96
913	Breast Cancer Chemo-immunotherapy through Liposomal Delivery of an Immunogenic Cell Death Stimulus Plus Interference in the IDO-1 Pathway. <i>ACS Nano</i> , 2018, 12, 11041-11061.	14.6	200
914	LAG-3 inhibits the activation of CD4+ T cells that recognize stable pMHCII through its conformation-dependent recognition of pMHCII. <i>Nature Immunology</i> , 2018, 19, 1415-1426.	14.5	178
915	Profile fluctuation of peripheral blood in advanced melanoma patients treated with nivolumab. <i>Journal of Dermatology</i> , 2018, 45, 1452-1455.	1.2	4
916	Immune Checkpoint Inhibition for Pancreatic Ductal Adenocarcinoma: Current Limitations and Future Options. <i>Frontiers in Immunology</i> , 2018, 9, 1878.	4.8	127
917	Immune checkpoint inhibitors and cardiovascular toxicity. <i>Lancet Oncology</i> , The, 2018, 19, e447-e458.	10.7	376
918	Interferon-gamma drives programmed death-ligand 1 expression on islet β cells to limit T cell function during autoimmune diabetes. <i>Scientific Reports</i> , 2018, 8, 8295.	3.3	100
919	T Follicular Regulatory Cells and Antibody Responses in Transplantation. <i>Transplantation</i> , 2018, 102, 1614-1623.	1.0	21
920	Keeping Tumors in Check: A Mechanistic Review of Clinical Response and Resistance to Immune Checkpoint Blockade in Cancer. <i>Journal of Molecular Biology</i> , 2018, 430, 2014-2029.	4.2	42
921	Immune Checkpoint Inhibitor-Associated Myocarditis. <i>Oncologist</i> , 2018, 23, 879-886.	3.7	207
922	Emerging functional markers for cancer stem cell-based therapies: Understanding signaling networks for targeting metastasis. <i>Seminars in Cancer Biology</i> , 2018, 53, 90-109.	9.6	62
923	Proliferative CD8(+) PD-1(+) T-cell infiltration in a pembrolizumab-induced cutaneous adverse reaction. <i>Investigational New Drugs</i> , 2018, 36, 1138-1142.	2.6	13
924	The Immune Response to Glioblastoma: Overview and Focus on Checkpoint Blockade. , 2018, , 653-668.		0
925	Clinicopathological value of programmed cell death 1 (PD-1) and programmed cell death ligand 1 (PD-L1) expression in synovium of patients with rheumatoid arthritis. <i>Clinical and Experimental Medicine</i> , 2018, 18, 487-494.	3.6	15

#	ARTICLE	IF	CITATIONS
926	Targeted deletion of T cell S1P receptor 1 ameliorates cardiac fibrosis in streptozotocin-induced diabetic mice. <i>FASEB Journal</i> , 2018, 32, 5426-5435.	0.5	21
927	Regulatory Role of CD4 ⁺ T Cells in Myocarditis. <i>Journal of Immunology Research</i> , 2018, 2018, 1-11.	2.2	44
928	Identification of IL-10-secreting CD8 ⁺ CD28 ^{hi} PD-1 ⁺ regulatory T cells associated with chronic hepatitis C virus infection. <i>Immunology Letters</i> , 2018, 202, 16-22.	2.5	3
929	Mechanisms of Immune Evasion and Immune Modulation by Lymphoma Cells. <i>Frontiers in Oncology</i> , 2018, 8, 54.	2.8	62
930	Coronary Toxicities of Anti-PD-1 and Anti-PD-L1 Immunotherapies: a Case Report and Review of the Literature and International Registries. <i>Targeted Oncology</i> , 2018, 13, 509-515.	3.6	30
931	Tune Up In Situ Autovaccination against Solid Tumors with Oncolytic Viruses. <i>Cancers</i> , 2018, 10, 171.	3.7	11
932	The Costimulatory Pathways and T Regulatory Cells in Ischemia-Reperfusion Injury: A Strong Arm in the Inflammatory Response?. <i>International Journal of Molecular Sciences</i> , 2018, 19, 1283.	4.1	6
933	Cardiorenal complications of immune checkpoint inhibitors. <i>Nature Reviews Nephrology</i> , 2018, 14, 571-588.	9.6	80
934	Immune-checkpoint inhibitors to treat cancers in specific immunocompromised populations: a critical review. <i>Expert Review of Anticancer Therapy</i> , 2018, 18, 981-989.	2.4	11
935	Cancer immune checkpoint blockade therapy and its associated autoimmune cardiotoxicity. <i>Acta Pharmacologica Sinica</i> , 2018, 39, 1693-1698.	6.1	39
936	Microbial biomarkers for immune checkpoint blockade therapy against cancer. <i>Journal of Gastroenterology</i> , 2018, 53, 999-1005.	5.1	15
937	Cardiotoxicities associated with immune checkpoint inhibitors. <i>Current Problems in Cancer</i> , 2018, 42, 422-432.	2.0	42
938	Immune checkpoint receptors: homeostatic regulators of immunity. <i>Hepatology International</i> , 2018, 12, 223-236.	4.2	43
939	<i>Trichinella spiralis</i> Infection Mitigates Collagen-Induced Arthritis via Programmed Death 1-Mediated Immunomodulation. <i>Frontiers in Immunology</i> , 2018, 9, 1566.	4.8	29
940	Fundamental Mechanisms of Immune Checkpoint Blockade Therapy. <i>Cancer Discovery</i> , 2018, 8, 1069-1086.	9.4	2,128
941	T cell exhaustion implications during transplantation. <i>Immunology Letters</i> , 2018, 202, 52-58.	2.5	8
942	Safety of combining radiotherapy with immune-checkpoint inhibition. <i>Nature Reviews Clinical Oncology</i> , 2018, 15, 477-494.	27.6	208
943	Immune checkpoint inhibitor PD-1 pathway is down-regulated in synovium at various stages of rheumatoid arthritis disease progression. <i>PLoS ONE</i> , 2018, 13, e0192704.	2.5	82

#	ARTICLE	IF	CITATIONS
944	Principles of Protein Recognition by Small T-Cell Adhesion Proteins and Costimulatory Receptors. , 2018, , 39-80.		0
945	Cardiac Immune-Related Adverse Events in Immune Checkpoint Inhibition Therapy. <i>Cardiology in Review</i> , 2019, 27, 97-107.	1.4	19
946	Update on cardio-oncology: Novel cancer therapeutics and associated cardiotoxicities. <i>Trends in Cardiovascular Medicine</i> , 2019, 29, 29-39.	4.9	43
947	Genetic alterations of 9p24 in lymphomas and their impact for cancer (immuno-)therapy. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2019, 474, 497-509.	2.8	8
948	Balancing cancer immunotherapy and immune-related adverse events: The emerging role of regulatory T cells. <i>Journal of Autoimmunity</i> , 2019, 104, 102310.	6.5	57
949	Immune inhibitory proteins and their pathogenic and therapeutic implications in autoimmunity and autoimmune hepatitis. <i>Autoimmunity</i> , 2019, 52, 144-160.	2.6	10
950	Side Effects of Systemic Therapy and Their Clinical Management. , 2019, , 773-789.		0
951	The Immune Landscape of Thyroid Cancer in the Context of Immune Checkpoint Inhibition. <i>International Journal of Molecular Sciences</i> , 2019, 20, 3934.	4.1	69
952	Fundamental Mechanisms of Regulated Cell Death and Implications for Heart Disease. <i>Physiological Reviews</i> , 2019, 99, 1765-1817.	28.8	550
953	Programmed Death-1 Restrains the Germinal Center in Type 1 Diabetes. <i>Journal of Immunology</i> , 2019, 203, 844-852.	0.8	15
954	Management of Adverse Events in Cancer Patients Treated With PD-1/PD-L1 Blockade: Focus on Asian Populations. <i>Frontiers in Pharmacology</i> , 2019, 10, 726.	3.5	20
955	Lymphocytic subsets play distinct roles in heart diseases. <i>Theranostics</i> , 2019, 9, 4030-4046.	10.0	17
956	Immune-Related Adverse Events: A Case-Based Approach. <i>Frontiers in Oncology</i> , 2019, 9, 530.	2.8	31
957	PD-1 aborts the activation trajectory of autoreactive CD8+ T cells to prohibit their acquisition of effector functions. <i>Journal of Autoimmunity</i> , 2019, 105, 102296.	6.5	12
958	<p>Combination pembrolizumab plus chemotherapy: a new standard of care for patients with advanced non-small-cell lung cancer</p>. <i>Lung Cancer: Targets and Therapy</i> , 2019, Volume 10, 47-56.	2.7	12
959	The PD-1/PD-L1 Axis and Virus Infections: A Delicate Balance. <i>Frontiers in Cellular and Infection Microbiology</i> , 2019, 9, 207.	3.9	194
960	Role of immune checkpoint inhibitors in the treatment of colorectal cancer: focus on nivolumab. <i>Expert Opinion on Biological Therapy</i> , 2019, 19, 1247-1263.	3.1	29
961	Myasthenia gravis induced by avelumab. <i>Immunotherapy</i> , 2019, 11, 1181-1185.	2.0	9

#	ARTICLE	IF	CITATIONS
962	Glycogen synthase 3 (GSK-3) regulation of PD-1 expression and its therapeutic implications. <i>Seminars in Immunology</i> , 2019, 42, 101295.	5.6	16
963	Drug Discovery in Japan. , 2019, , .		5
964	A Comprehensive Analysis of Key Immune Checkpoint Receptors on Tumor-Infiltrating T Cells From Multiple Types of Cancer. <i>Frontiers in Oncology</i> , 2019, 9, 1066.	2.8	43
965	Increased circulating IgG levels, myocardial immune cells and IgG deposits support a role for an immune response in pre- and end-stage heart failure. <i>Journal of Cellular and Molecular Medicine</i> , 2019, 23, 7505-7516.	3.6	26
966	Engineered Dendritic Cell-Directed Concurrent Activation of Multiple T cell Inhibitory Pathways Induces Robust Immune Tolerance. <i>Scientific Reports</i> , 2019, 9, 12065.	3.3	11
967	Immune Checkpoints of the B7 Family. Part 1. General Characteristics and First Representatives: B7-1, B7-2, B7-H1, B7-H2, and B7-DC. <i>Russian Journal of Bioorganic Chemistry</i> , 2019, 45, 225-240.	1.0	6
968	Cardiac troponin I autoantibody induces myocardial dysfunction by PTEN signaling activation. <i>EBioMedicine</i> , 2019, 47, 329-340.	6.1	12
969	Viral Infections and Autoimmune Disease: Roles of LCMV in Delineating Mechanisms of Immune Tolerance. <i>Viruses</i> , 2019, 11, 885.	3.3	5
970	Autoimmune complications of cancer immunotherapy. <i>Current Opinion in Immunology</i> , 2019, 61, 54-59.	5.5	9
971	Design and application of oral colon administration system. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2019, 34, 1590-1596.	5.2	18
972	T-Cell Costimulation and Coinhibition in Graft-Versus-Host Disease and Graft-Versus-Leukemia Effect. , 2019, , 167-194.		2
973	Immunotherapy Toxicity. <i>Hematology/Oncology Clinics of North America</i> , 2019, 33, 275-290.	2.2	23
974	Cardiovascular toxicities associated with immune checkpoint inhibitors. <i>Cardiovascular Research</i> , 2019, 115, 854-868.	3.8	311
975	Success of immune checkpoint blockade therapies – mechanisms and implications for hepatology. <i>Zeitschrift Fur Gastroenterologie</i> , 2019, 57, 74-86.	0.5	2
976	<p>Cardiac toxicity of immune-checkpoint inhibitors: a clinical case of nivolumab-induced myocarditis and review of the evidence and new challenges</p>. <i>Cancer Management and Research</i> , 2019, Volume 11, 4541-4548.	1.9	23
977	<p>Incidence risk of PD-1/PD-L1 related diarrhea in non-small cell lung cancer (NSCLC) patients: a systematic review and meta-analysis</p>. <i>Cancer Management and Research</i> , 2019, Volume 11, 3957-3969.	1.9	5
978	Cardiotoxicity of Immune Checkpoint Inhibitors. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2019, 21, 32.	0.9	42
979	Heart Failure and Cancer: Mechanisms of Old and New Cardiotoxic Drugs in Cancer Patients. <i>Cardiac Failure Review</i> , 2019, 5, 112-118.	3.0	39

#	ARTICLE	IF	CITATIONS
980	Application of PD-1 Blockade in Cancer Immunotherapy. Computational and Structural Biotechnology Journal, 2019, 17, 661-674.	4.1	333
981	Blood Levels of Co-inhibitory-Receptors: A Biomarker of Disease Prognosis in Multiple Sclerosis. Frontiers in Immunology, 2019, 10, 835.	4.8	25
982	Combination of CTLA-4 and PD-1 blockers for treatment of cancer. Journal of Experimental and Clinical Cancer Research, 2019, 38, 255.	8.6	577
983	Development of immune checkpoint therapy for cancer. Journal of Experimental Medicine, 2019, 216, 1244-1254.	8.5	125
984	Dilated cardiomyopathy. Nature Reviews Disease Primers, 2019, 5, 32.	30.5	347
985	Myocarditis in Cynomolgus Monkeys Following Treatment with Immune Checkpoint Inhibitors. Clinical Cancer Research, 2019, 25, 4735-4748.	7.0	80
986	Myocarditis in Humans and in Experimental Animal Models. Frontiers in Cardiovascular Medicine, 2019, 6, 64.	2.4	99
987	Adaptive immune cells in calcific aortic valve disease. American Journal of Physiology - Heart and Circulatory Physiology, 2019, 317, H141-H155.	3.2	47
988	Immune Checkpoint Ligand Reverse Signaling: Looking Back to Go Forward in Cancer Therapy. Cancers, 2019, 11, 624.	3.7	32
989	Strain-Specific Manifestation of Lupus-like Systemic Autoimmunity Caused by <i>Zap70</i> Mutation. Journal of Immunology, 2019, 202, 3161-3172.	0.8	15
990	Managing cardiotoxicity associated with immune checkpoint inhibitors. Chronic Diseases and Translational Medicine, 2019, 5, 6-14.	1.2	52
991	Incidence of thyroid dysfunctions during treatment with nivolumab for non-small cell lung cancer: Retrospective study of 105 patients. Presse Medicale, 2019, 48, e199-e207.	1.9	26
992	Exacerbation of Previously Undiagnosed Bird Fancier's Lung by Pembrolizumab Therapy. Chest, 2019, 155, e79-e82.	0.8	4
993	Expression analysis of PD-1 and Tim-3 immune checkpoint receptors in patients with vitiligo; positive association with disease activity. Experimental Dermatology, 2019, 28, 674-681.	2.9	17
994	Nivolumab-induced myocardial necrosis in a patient with lung cancer: A case report. Respiratory Medicine Case Reports, 2019, 27, 100839.	0.4	8
995	Sequential Blockade of PD-1 and PD-L1 Causes Fulminant Cardiotoxicity—From Case Report to Mouse Model Validation. Cancers, 2019, 11, 580.	3.7	28
996	Ubiquitin Ligases in Cancer Immunotherapy — Balancing Antitumor and Autoimmunity. Trends in Molecular Medicine, 2019, 25, 428-443.	6.7	35
997	Cat and Mouse: HIV Transcription in Latency, Immune Evasion and Cure/Remission Strategies. Viruses, 2019, 11, 269.	3.3	26

#	ARTICLE	IF	CITATIONS
998	Immune Cell-Derived Extracellular Vesicles – Functions and Therapeutic Applications. Trends in Molecular Medicine, 2019, 25, 382-394.	6.7	188
999	Negative Co-stimulation Constrains T Cell Differentiation by Imposing Boundaries on Possible Cell States. Immunity, 2019, 50, 1084-1098.e10.	14.3	75
1000	PD-1 Primarily Targets TCR Signal in the Inhibition of Functional T Cell Activation. Frontiers in Immunology, 2019, 10, 630.	4.8	112
1001	Teriflunomide induces a tolerogenic bias in blood immune cells of MS patients. Annals of Clinical and Translational Neurology, 2019, 6, 355-363.	3.7	21
1002	Cardiac phenotype in mouse models of systemic autoimmunity. DMM Disease Models and Mechanisms, 2019, 12, .	2.4	19
1003	Diabetes Mellitus Secondary to Treatment with Immune Checkpoint Inhibitors. Current Oncology, 2019, 26, 111-114.	2.2	23
1004	<p>Risk and incidence of fatal adverse events associated with immune checkpoint inhibitors: a systematic review and meta-analysis</p>. Therapeutics and Clinical Risk Management, 2019, Volume 15, 293-302.	2.0	27
1005	CD8+CD122+PD-1+ Tregs Synergize With Costimulatory Blockade of CD40/CD154, but Not B7/CD28, to Prolong Murine Allograft Survival. Frontiers in Immunology, 2019, 10, 306.	4.8	15
1006	Cardiac Toxicity Associated with Immune Checkpoint Inhibitors: Case Series and Review of the Literature. Case Reports in Oncology, 2019, 12, 260-276.	0.7	63
1007	Development of Cancer Immunotherapy Targeting the PD-1 Pathway. Journal of Nippon Medical School, 2019, 86, 10-14.	0.9	15
1008	T Cells Play a Causal Role in Diastolic Dysfunction during Uremic Cardiomyopathy. Journal of the American Society of Nephrology: JASN, 2019, 30, 407-420.	6.1	20
1009	T cell checkpoint regulators in the heart. Cardiovascular Research, 2019, 115, 869-877.	3.8	70
1010	Cardiac Complications in Immune Checkpoint Inhibition Therapy. Frontiers in Cardiovascular Medicine, 2019, 6, 3.	2.4	65
1011	The co-inhibitory molecule PD-L1 contributes to regulatory T cell-mediated protection in murine crescentic glomerulonephritis. Scientific Reports, 2019, 9, 2038.	3.3	25
1012	T cell co-stimulation and co-inhibition in cardiovascular disease: a double-edged sword. Nature Reviews Cardiology, 2019, 16, 325-343.	13.7	65
1013	Inter-tumor heterogeneity of PD-L1 expression in non-small cell lung cancer. Journal of Thoracic Disease, 2019, 11, 4982-4991.	1.4	33
1014	Cardiotoxicity of Immune Therapy. Cardiology Clinics, 2019, 37, 385-397.	2.2	54
1015	Recent advances in cardio-oncology: a report from the –Heart Failure Association 2019 and World Congress on Acute Heart Failure 2019–™. ESC Heart Failure, 2019, 6, 1140-1148.	3.1	34

#	ARTICLE	IF	CITATIONS
1016	Odds ratio of programmed cell death-1 or ligand 1 inhibitor-related endocrine dysfunction in patients with lung cancer. <i>Medicine (United States)</i> , 2019, 98, e18310.	1.0	2
1017	Co-signal Molecules in T Cell Activation. <i>Advances in Experimental Medicine and Biology</i> , 2019, , .	1.6	6
1018	Phosphorylation of PD-1-Y248 is a marker of PD-1-mediated inhibitory function in human T cells. <i>Scientific Reports</i> , 2019, 9, 17252.	3.3	20
1019	Development and clinical applications of cancer immunotherapy against PD-1 signaling pathway. <i>Journal of Biomedical Science</i> , 2019, 26, 96.	7.0	26
1020	Immune Checkpoint Inhibitor-Associated Cardiotoxicity: Current Understanding on Its Mechanism, Diagnosis and Management. <i>Frontiers in Pharmacology</i> , 2019, 10, 1350.	3.5	75
1021	Hypophysitis induced by immune checkpoint inhibitors: a 10-year assessment. <i>Expert Review of Endocrinology and Metabolism</i> , 2019, 14, 381-398.	2.4	54
1022	Cardiac toxicities of anticancer treatments. <i>Current Opinion in Cardiology</i> , 2019, 34, 441-450.	1.8	16
1023	Mechanisms of immune-related adverse events during the treatment of cancer with immune checkpoint inhibitors. <i>Rheumatology</i> , 2019, 58, vii59-vii67.	1.9	137
1024	Toxicities associated with checkpoint inhibitorsâ€”an overview. <i>Rheumatology</i> , 2019, 58, vii7-vii16.	1.9	80
1025	The roles ofPDâ€1/PDâ€L1 and its signalling pathway in gastrointestinal tract cancers. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2019, 46, 3-10.	1.9	12
1026	Immunomodulators targeting the PDâ€1/PDâ€L1 proteinâ€protein interaction: From antibodies to small molecules. <i>Medicinal Research Reviews</i> , 2019, 39, 265-301.	10.5	128
1027	Immunotherapy for Prostate Cancer. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2019, 9, a030627.	6.2	41
1028	Immune Checkpoint Inhibitors. , 2019, , 1-17.		2
1029	PD-1 blockade augments humoral immunity through ICOS-mediated CD4+ T cell instruction. <i>International Immunopharmacology</i> , 2019, 66, 127-138.	3.8	18
1030	Fibrotic Signaling in Cardiomyopathies. <i>Molecular and Translational Medicine</i> , 2019, , 273-317.	0.4	1
1031	Roles, function and relevance of LAG3 in HIV infection. <i>PLoS Pathogens</i> , 2019, 15, e1007429.	4.7	27
1032	Synthesis and Immunomodulatory Activity of Fluorineâ€Containing Bisphosphonates. <i>ChemMedChem</i> , 2019, 14, 462-468.	3.2	7
1033	A novel humanized anti-PD-1 monoclonal antibody potentiates therapy in oral squamous cell carcinoma. <i>Investigational New Drugs</i> , 2019, 37, 799-809.	2.6	4

#	ARTICLE	IF	CITATIONS
1034	Endocrine Toxicity of Cancer Immunotherapy Targeting Immune Checkpoints. <i>Endocrine Reviews</i> , 2019, 40, 17-65.	20.1	349
1035	Monoclonal Antibodies for the Treatment of Melanoma: Present and Future Strategies. <i>Methods in Molecular Biology</i> , 2019, 1904, 83-108.	0.9	47
1036	Tipping the balance: inhibitory checkpoints in intestinal homeostasis. <i>Mucosal Immunology</i> , 2019, 12, 21-35.	6.0	13
1037	The role and clinical significance of programmed cell death- ligand 1 expressed on CD19+B-cells and subsets in systemic lupus erythematosus. <i>Clinical Immunology</i> , 2019, 198, 89-99.	3.2	12
1038	Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 1715-1730.	6.4	92
1039	Targeting Programmed Cell Death -1 (PD-1) and Ligand (PD-L1): A new era in cancer active immunotherapy. , 2019, 194, 84-106.		248
1040	Rheumatic diseases associated with immune checkpoint inhibitors in cancer immunotherapy. <i>Modern Rheumatology</i> , 2019, 29, 721-732.	1.8	10
1041	From Molecular Mechanisms to Clinical Management of Antineoplastic Drug-Induced Cardiovascular Toxicity: A Translational Overview. <i>Antioxidants and Redox Signaling</i> , 2019, 30, 2110-2153.	5.4	96
1042	A flow cytometry-based method to screen for modulators of tumor-specific T cell cytotoxicity. <i>Methods in Enzymology</i> , 2020, 631, 467-482.	1.0	1
1043	Type 1 diabetes pathogenesis and the role of inhibitory receptors in islet tolerance. <i>Annals of the New York Academy of Sciences</i> , 2020, 1461, 73-103.	3.8	15
1044	<i>Cancer Immunology</i> . , 2020, , 84-96.e5.		0
1045	TIM3 comes of age as an inhibitory receptor. <i>Nature Reviews Immunology</i> , 2020, 20, 173-185.	22.7	535
1046	Current issues and perspectives in PD-1 blockade cancer immunotherapy. <i>International Journal of Clinical Oncology</i> , 2020, 25, 790-800.	2.2	120
1047	<i>Animal Models: Systemic Autoimmune Diseases</i> . , 2020, , 533-551.		1
1048	Progress in PD-1/PD-L1 pathway inhibitors: From biomacromolecules to small molecules. <i>European Journal of Medicinal Chemistry</i> , 2020, 186, 111876.	5.5	98
1049	TIGIT as an emerging immune checkpoint. <i>Clinical and Experimental Immunology</i> , 2020, 200, 108-119.	2.6	310
1050	Immune Checkpoint Inhibitorsâ€œRelated Cardiotoxicity. <i>American Journal of Therapeutics</i> , 2020, 27, e591-e598.	0.9	14
1051	<sc>PTPN</sc> 2 phosphatase deletion in T cells promotes antiâ€œtumour immunity and <sc>CAR</sc> Tâ€œcell efficacy in solid tumours. <i>EMBO Journal</i> , 2020, 39, e103637.	7.8	79

#	ARTICLE	IF	CITATIONS
1052	Structure and Optimization of Checkpoint Inhibitors. <i>Cancers</i> , 2020, 12, 38.	3.7	37
1053	Antibody and antibody fragments for cancer immunotherapy. <i>Journal of Controlled Release</i> , 2020, 328, 395-406.	9.9	63
1054	Uncoupling Therapeutic Efficacy from Immune-Related Adverse Events in Immune Checkpoint Blockade. <i>IScience</i> , 2020, 23, 101580.	4.1	22
1055	Human T Cells Expressing a CD19 CAR-T Receptor Provide Insights into Mechanisms of Human CD19-Positive \hat{I}^2 Cell Destruction. <i>Cell Reports Medicine</i> , 2020, 1, 100097.	6.5	16
1056	Cardiac dysfunction in cancer patients: beyond direct cardiomyocyte damage of anticancer drugs: novel cardio-oncology insights from the joint 2019 meeting of the ESC Working Groups of Myocardial Function and Cellular Biology of the Heart. <i>Cardiovascular Research</i> , 2020, 116, 1820-1834.	3.8	51
1057	Regulation of PD-L1 Expression by NF- \hat{I}^B in Cancer. <i>Frontiers in Immunology</i> , 2020, 11, 584626.	4.8	179
1058	Overcoming Immune Evasion in Melanoma. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8984.	4.1	88
1059	Cardiotoxicity of Contemporary Anticancer Immunotherapy. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2020, 22, 62.	0.9	34
1060	Comparison of a Novel Bisphosphonate Prodrug and Zoledronic Acid in the Induction of Cytotoxicity in Human $\hat{V}^3\hat{V}^2$ T Cells. <i>Frontiers in Immunology</i> , 2020, 11, 1405.	4.8	16
1061	Mechanisms of Immune-Related Complications in Cancer Patients Treated with Immune Checkpoint Inhibitors. <i>Pharmacology</i> , 2021, 106, 123-136.	2.2	24
1062	Adverse cardiac events in the treatment of non-small cell lung cancer with programmed death-1 and programmed death-ligand 1 inhibitors. <i>Medicine (United States)</i> , 2020, 99, e21613.	1.0	0
1063	Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of immune-mediated cardiovascular, rheumatic, and renal toxicities from checkpoint inhibitors. <i>Supportive Care in Cancer</i> , 2020, 28, 6159-6173.	2.2	11
1064	Cancer immunotherapy harnessing $\hat{I}^3\hat{I}^1$ T cells and programmed death-1. <i>Immunological Reviews</i> , 2020, 298, 237-253.	6.0	16
1065	Review of the Combination Strategies Used in Anti-PD1/PD-L1 Monoclonal Antibody Treatment. <i>E3S Web of Conferences</i> , 2020, 185, 03009.	0.5	1
1066	PD-L1 on dendritic cells attenuates T cell activation and regulates response to immune checkpoint blockade. <i>Nature Communications</i> , 2020, 11, 4835.	12.8	290
1067	Revisiting the PD-1 pathway. <i>Science Advances</i> , 2020, 6, .	10.3	277
1068	Concomitant development of neurologic and cardiac immune-related adverse effects in patients treated with immune checkpoint inhibitors for melanoma. <i>Melanoma Research</i> , 2020, 30, 484-491.	1.2	10
1069	Role of the PD-1/PD-L1 Dyad in the Maintenance of Pancreatic Immune Tolerance for Prevention of Type 1 Diabetes. <i>Frontiers in Endocrinology</i> , 2020, 11, 569.	3.5	39

#	ARTICLE	IF	CITATIONS
1070	Cardiotoxicity of immune checkpoint inhibitors: An updated review. <i>Biotechnology and Applied Biochemistry</i> , 2022, 69, 61-69.	3.1	6
1071	Co-inhibitory Receptor Signaling in T-Cell-Mediated Autoimmune Glomerulonephritis. <i>Frontiers in Medicine</i> , 2020, 7, 584382.	2.6	3
1072	Delicate Role of PD-L1/PD-1 Axis in Blood Vessel Inflammatory Diseases: Current Insight and Future Significance. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8159.	4.1	23
1074	A guide to cancer immunotherapy: from T cell basic science to clinical practice. <i>Nature Reviews Immunology</i> , 2020, 20, 651-668.	22.7	2,160
1075	Targeted anti-inflammatory therapy is a new insight for reducing cardiovascular events: A review from physiology to the clinic. <i>Life Sciences</i> , 2020, 253, 117720.	4.3	4
1076	Adjuvant Effect of Toll-Like Receptor 9 Activation on Cancer Immunotherapy Using Checkpoint Blockade. <i>Frontiers in Immunology</i> , 2020, 11, 1075.	4.8	36
1077	Metastatic melanoma: therapeutic agents in preclinical and early clinical development. <i>Expert Opinion on Investigational Drugs</i> , 2020, 29, 739-753.	4.1	2
1079	Emerging role of immune checkpoint inhibitors and their relevance for the cardiovascular system. <i>Herz</i> , 2020, 45, 645-651.	1.1	16
1080	Development of Severe Heart Failure in a Patient with Squamous Non-small-cell Lung Cancer During Nivolumab Treatment. <i>Internal Medicine</i> , 2020, 59, 2003-2008.	0.7	10
1081	Regulation of PD-1 in T cells for cancer immunotherapy. <i>European Journal of Pharmacology</i> , 2020, 881, 173240.	3.5	27
1082	PD-1: Its Discovery, Involvement in Cancer Immunotherapy, and Beyond. <i>Cells</i> , 2020, 9, 1376.	4.1	31
1083	PD-1/PD-L1 axis regulation in cancer therapy: The role of long non-coding RNAs and microRNAs. <i>Life Sciences</i> , 2020, 256, 117899.	4.3	45
1084	Evolving insights into the mechanisms of toxicity associated with immune checkpoint inhibitor therapy. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 1778-1789.	2.4	34
1085	Left ventricular dysfunction associated with axitinib and nivolumab experience in an advanced renal cell carcinoma. <i>Journal of Oncology Pharmacy Practice</i> , 2020, 26, 1765-1768.	0.9	6
1086	Lymphocyte Activation Gene (LAG)-3 Is Associated With Mucosal Inflammation and Disease Activity in Ulcerative Colitis. <i>Journal of Crohn's and Colitis</i> , 2020, 14, 1446-1461.	1.3	25
1088	Immune-related adverse events of checkpoint inhibitors: Insights into immunological dysregulation. <i>Clinical Immunology</i> , 2020, 213, 108377.	3.2	44
1089	MicroRNAs in Cancer Treatment-Induced Cardiotoxicity. <i>Cancers</i> , 2020, 12, 704.	3.7	26
1090	State-of-the-art Review: Interventional Onco-Cardiology. Current Treatment Options in Cardiovascular Medicine, 2020, 22, 1.	0.9	3

#	ARTICLE	IF	CITATIONS
1091	Suppression of age-related salivary gland autoimmunity by glycosylation-dependent galectin-1-driven immune inhibitory circuits. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 6630-6639.	7.1	37
1092	Adverse cardiac effects of cancer therapies: cardiotoxicity and arrhythmia. <i>Nature Reviews Cardiology</i> , 2020, 17, 474-502.	13.7	332
1093	Clinical Characteristics and Treatment of Immune-Related Adverse Events of Immune Checkpoint Inhibitors. <i>Immune Network</i> , 2020, 20, e9.	3.6	143
1094	Heart-Specific Immune Responses in an Animal Model of Autoimmune-Related Myocarditis Mitigated by an Immunoproteasome Inhibitor and Genetic Ablation. <i>Circulation</i> , 2020, 141, 1885-1902.	1.6	53
1095	Unanticipated Myocarditis in a Surgical Patient Treated With Pembrolizumab: A Case Report. <i>A&A Practice</i> , 2020, 14, e01177.	0.4	8
1096	Personalized Approach to Cancer Treatment-Related Cardiomyopathy. <i>Current Heart Failure Reports</i> , 2020, 17, 43-55.	3.3	3
1097	Pharmacogenomics for immunotherapy and immune-related cardiotoxicity. <i>Human Molecular Genetics</i> , 2020, 29, R186-R196.	2.9	7
1098	Cancer-induced immunosuppression can enable effectiveness of immunotherapy through bistability generation: A mathematical and computational examination. <i>Journal of Theoretical Biology</i> , 2020, 492, 110185.	1.7	10
1099	The emerging role of precision medicine in the treatment of endometrial cancer. <i>Expert Review of Precision Medicine and Drug Development</i> , 2020, 5, 87-93.	0.7	1
1100	Critical role of PD-L1 expression on non-tumor cells rather than on tumor cells for effective anti-PD-L1 immunotherapy in a transplantable mouse hematopoietic tumor model. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 1001-1014.	4.2	7
1101	Immunomodulatory treatment of immune checkpoint inhibitor-induced myocarditis: Pathway toward precision-based therapy. <i>Cardiovascular Pathology</i> , 2020, 47, 107211.	1.6	31
1102	HX008: a humanized PD-1 blocking antibody with potent antitumor activity and superior pharmacologic properties. <i>MAbs</i> , 2020, 12, 1724751.	5.2	25
1103	Myocardial and Pericardial Toxicity Associated With Immune Checkpoint Inhibitors in Cancer Patients. <i>JACC: Case Reports</i> , 2020, 2, 191-199.	0.6	15
1104	Pembrolizumab-Induced Mobitz Type 2 Second-Degree Atrioventricular Block. <i>Case Reports in Cardiology</i> , 2020, 2020, 1-5.	0.2	6
1105	Immune checkpoint inhibitor-induced inflammatory arthritis as a model of autoimmune arthritis. <i>Immunological Reviews</i> , 2020, 294, 106-123.	6.0	24
1106	The yin and yang of co-inhibitory receptors: toward anti-tumor immunity without autoimmunity. <i>Cell Research</i> , 2020, 30, 285-299.	12.0	129
1107	Toxicity of Immune Checkpoint Inhibitors: Considerations for the Surgeon. <i>Annals of Surgical Oncology</i> , 2020, 27, 1533-1545.	1.5	6
1108	Immunosurveillance and Immunoediting of Lung Cancer: Current Perspectives and Challenges. <i>International Journal of Molecular Sciences</i> , 2020, 21, 597.	4.1	58

#	ARTICLE	IF	CITATIONS
1109	Immune Checkpoint Inhibitor Myocarditis: Pathophysiological Characteristics, Diagnosis, and Treatment. <i>Journal of the American Heart Association</i> , 2020, 9, e013757.	3.7	240
1110	Neoadjuvant checkpoint blockade for cancer immunotherapy. <i>Science</i> , 2020, 367, .	12.6	553
1111	Precision Cardio-Oncology: a Systems-Based Perspective on Cardiotoxicity of Tyrosine Kinase Inhibitors and Immune Checkpoint Inhibitors. <i>Journal of Cardiovascular Translational Research</i> , 2020, 13, 402-416.	2.4	16
1112	PD-L1 is induced on the hepatocyte surface via CKLF-like MARVEL transmembrane domain-containing protein 6 up-regulation by the anti-HBV drug Entecavir. <i>International Immunology</i> , 2020, 32, 519-531.	4.0	8
1113	Combination Strategies for Immune-Checkpoint Blockade and Response Prediction by Artificial Intelligence. <i>International Journal of Molecular Sciences</i> , 2020, 21, 2856.	4.1	31
1114	Late cardiac adverse events in patients with cancer treated with immune checkpoint inhibitors. , 2020, 8, e000261.		53
1116	A retrospective study of immune checkpoint inhibitor-associated myocarditis in a single center in China. <i>Chinese Clinical Oncology</i> , 2020, 9, 16-16.	1.2	23
1117	The Role of PD-1 in Acute and Chronic Infection. <i>Frontiers in Immunology</i> , 2020, 11, 487.	4.8	167
1118	Programmed Cell Death-1: Programmed Cell Death-Ligand 1 Interaction Protects Human Cardiomyocytes Against T-Cell Mediated Inflammation and Apoptosis Response In Vitro. <i>International Journal of Molecular Sciences</i> , 2020, 21, 2399.	4.1	29
1119	Localized Immunomodulation with PD-L1 Results in Sustained Survival and Function of Allogeneic Islets without Chronic Immunosuppression. <i>Journal of Immunology</i> , 2020, 204, 2840-2851.	0.8	26
1120	Safety profile of immune checkpoint inhibitors: An analysis of the Italian spontaneous reporting system database. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 527-541.	2.4	5
1121	Immune Checkpoint Inhibitor Cardiotoxicity: Understanding Basic Mechanisms and Clinical Characteristics and Finding a Cure. <i>Annual Review of Pharmacology and Toxicology</i> , 2021, 61, 113-134.	9.4	40
1122	Distinct Expression of Coinhibitory Molecules on Alveolar T Cells in Patients With Rheumatoid Arthritisâ€“Associated and Idiopathic Inflammatory Myopathyâ€“Associated Interstitial Lung Disease. <i>Arthritis and Rheumatology</i> , 2021, 73, 576-586.	5.6	11
1123	Myocarditis and inflammatory cardiomyopathy: current evidence and future directions. <i>Nature Reviews Cardiology</i> , 2021, 18, 169-193.	13.7	589
1124	PD-1/PDL-1 Inhibitors and Cardiotoxicity; Molecular, Etiological and Management Outlines. <i>Journal of Advanced Research</i> , 2021, 29, 45-54.	9.5	31
1125	Novel human immunomodulatory T cell receptors and their double-edged potential in autoimmunity, cardiovascular disease and cancer. <i>Cellular and Molecular Immunology</i> , 2021, 18, 919-935.	10.5	11
1126	A Genetic Mouse Model Recapitulates Immune Checkpoint Inhibitorâ€“Associated Myocarditis and Supports a Mechanism-Based Therapeutic Intervention. <i>Cancer Discovery</i> , 2021, 11, 614-625.	9.4	145
1127	Toxicities Associated with Immunotherapy and Approach to Cardiotoxicity with Novel Cancer Therapies. <i>Critical Care Clinics</i> , 2021, 37, 47-67.	2.6	5

#	ARTICLE	IF	CITATIONS
1128	Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance. <i>Annual Review of Pathology: Mechanisms of Disease</i> , 2021, 16, 223-249.	22.4	956
1129	The application of nano-medicine to overcome the challenges related to immune checkpoint blockades in cancer immunotherapy: Recent advances and opportunities. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 157, 103160.	4.4	26
1130	The risk of cardiac events in patients receiving immune checkpoint inhibitors: a nationwide Danish study. <i>European Heart Journal</i> , 2021, 42, 1621-1631.	2.2	102
1131	The tumor microenvironment of lymphomas: Insights into the potential role and modes of actions of checkpoint inhibitors. <i>Hematological Oncology</i> , 2021, 39, 3-10.	1.7	15
1132	Autoimmune Endocrinopathies: An Emerging Complication of Immune Checkpoint Inhibitors. <i>Annual Review of Medicine</i> , 2021, 72, 313-330.	12.2	24
1133	Programmed Death-Ligand 2 Deficiency Exacerbates Experimental Autoimmune Myocarditis in Mice. <i>International Journal of Molecular Sciences</i> , 2021, 22, 1426.	4.1	10
1134	A snapshot of the PD-1/PD-L1 pathway. <i>Journal of Cancer</i> , 2021, 12, 2735-2746.	2.5	105
1135	Dynamic Regulation of T Cell Activation by Coupled Feedforward Loops. <i>Mathematics of Planet Earth</i> , 2021, , 241-255.	0.1	1
1137	Cardiac Toxicities Associated with Immune Checkpoints Inhibitors: Mechanisms, Manifestations and Management. <i>Korean Circulation Journal</i> , 2021, 51, 579.	1.9	3
1138	Immunotherapy-Associated Cardiotoxicity of Immune Checkpoint Inhibitors and Chimeric Antigen Receptor T Cell Therapy: Diagnostic and Management Challenges and Strategies. <i>Current Cardiology Reports</i> , 2021, 23, 11.	2.9	35
1139	T-cell-intrinsic and -extrinsic regulation of PD-1 function. <i>International Immunology</i> , 2021, 33, 693-698.	4.0	8
1140	Immune Checkpoint Inhibitors in Special Populations. <i>Technology in Cancer Research and Treatment</i> , 2021, 20, 153303382110365.	1.9	4
1141	YY1 expression and PD-1 regulation in CD8 T lymphocytes. , 2021, , 289-309.		1
1142	Transcriptomic and Network Analysis of Minor Salivary Glands of Patients With Primary Sjögren's Syndrome. <i>Frontiers in Immunology</i> , 2020, 11, 606268.	4.8	21
1143	Are activated B cells involved in the process of myocardial fibrosis after acute myocardial infarction? An in vivo experiment. <i>BMC Cardiovascular Disorders</i> , 2021, 21, 5.	1.7	26
1144	Mechanisms and Management of Immune Checkpoint Inhibitor-Related Cardiac Adverse Events. <i>JMA Journal</i> , 2021, 4, 91-98.	0.8	13
1145	Generation of triacyl lipopeptide-modified glycoproteins by metabolic glycoengineering as the neoantigen to boost anti-tumor immune response. <i>Theranostics</i> , 2021, 11, 7425-7438.	10.0	7
1146	Cardiovascular Toxicity of Immune Checkpoint Inhibitors: Clinical Risk Factors. <i>Current Oncology Reports</i> , 2021, 23, 13.	4.0	38

#	ARTICLE	IF	CITATIONS
1147	Spatial Regulation of T-Cell Signaling by Programmed Death-Ligand 1 on Wireframe DNA Origami Flat Sheets. <i>ACS Nano</i> , 2021, 15, 3441-3452.	14.6	42
1148	Immune Profile Analysis in Peripheral Blood and Tumor in Patients with Malignant Melanoma. <i>International Journal of Molecular Sciences</i> , 2021, 22, 1957.	4.1	4
1149	Cardiotoxicity Induced by Immune Checkpoint Inhibitors: A Pharmacovigilance Study From 2014 to 2019 Based on FAERS. <i>Frontiers in Pharmacology</i> , 2021, 12, 616505.	3.5	23
1150	Current and Future Perspectives of PD-1/PDL-1 Blockade in Cancer Immunotherapy. <i>Journal of Immunology Research</i> , 2021, 2021, 1-15.	2.2	77
1151	Building Multi-Dimensional Induced Pluripotent Stem Cells-Based Model Platforms to Assess Cardiotoxicity in Cancer Therapies. <i>Frontiers in Pharmacology</i> , 2021, 12, 607364.	3.5	20
1152	PD-1/PDL1 Blockade Exacerbates Pancreatic Damage and Immune Response in a Mouse Model of Acute Pancreatitis. <i>Inflammation</i> , 2021, 44, 1441-1451.	3.8	2
1153	Low-Dose Decitabine Inhibits Cytotoxic T Lymphocytes-Mediated Platelet Destruction via Modulating PD-1 Methylation in Immune Thrombocytopenia. <i>Frontiers in Immunology</i> , 2021, 12, 630693.	4.8	19
1154	Combined anti-PD-1 and anti-CTLA-4 checkpoint blockade: Treatment of melanoma and immune mechanisms of action. <i>European Journal of Immunology</i> , 2021, 51, 544-556.	2.9	71
1155	Decoding Melanoma Development and Progression: Identification of Therapeutic Vulnerabilities. <i>Frontiers in Oncology</i> , 2020, 10, 626129.	2.8	48
1156	High numbers of programmed cell death-1-positive tumor infiltrating lymphocytes correlate with early onset of post-transplant lymphoproliferative disorder. <i>International Journal of Hematology</i> , 2021, 114, 53-64.	1.6	1
1157	An in vivo method for diversifying the functions of therapeutic antibodies. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	7.1	3
1158	Is There a Place for PD-1-PD-L Blockade in Acute Myeloid Leukemia?. <i>Pharmaceuticals</i> , 2021, 14, 288.	3.8	21
1159	Strategies to overcome drug resistance using SHP2 inhibitors. <i>Acta Pharmaceutica Sinica B</i> , 2021, 11, 3908-3924.	12.0	18
1160	Thyroid Dysfunction in Lung Cancer Patients Treated with Immune Checkpoint Inhibitors (ICIs): Outcomes in a Multiethnic Urban Cohort. <i>Cancers</i> , 2021, 13, 1464.	3.7	7
1161	Advanced Nanotechnology for Enhancing Immune Checkpoint Blockade Therapy. <i>Nanomaterials</i> , 2021, 11, 661.	4.1	23
1162	The Multifaceted Role of Th1, Th9, and Th17 Cells in Immune Checkpoint Inhibition Therapy. <i>Frontiers in Immunology</i> , 2021, 12, 625667.	4.8	32
1163	Immune checkpoint inhibitor-associated myocarditis: manifestations and mechanisms. <i>Journal of Clinical Investigation</i> , 2021, 131, .	8.2	84
1164	Mechanisms and clinical manifestations of cardiovascular toxicities associated with immune checkpoint inhibitors. <i>Clinical Science</i> , 2021, 135, 703-724.	4.3	18

#	ARTICLE	IF	CITATIONS
1165	Cardiac adverse events associated with anti-PD-1 therapy in patients treated for advanced melanoma: relevance of dosing troponin T levels. <i>European Journal of Dermatology</i> , 2021, 31, 205-212.	0.6	3
1166	Checkpoint Inhibitor-Induced Colitis—A Clinical Overview of Incidence, Prognostic Implications and Extension of Current Treatment Options. <i>Pharmaceuticals</i> , 2021, 14, 367.	3.8	13
1167	How can we manage the cardiac toxicity of immune checkpoint inhibitors?. <i>Expert Opinion on Drug Safety</i> , 2021, 20, 1-10.	2.4	8
1168	Function and Role of Regulatory T Cells in Rheumatoid Arthritis. <i>Frontiers in Immunology</i> , 2021, 12, 626193.	4.8	73
1169	Emerging Role of PD-1 in the Central Nervous System and Brain Diseases. <i>Neuroscience Bulletin</i> , 2021, 37, 1188-1202.	2.9	30
1170	Gastrointestinal disorders as immune-related adverse events. <i>Exploration of Targeted Anti-tumor Therapy</i> , 0, , .	0.8	2
1171	Downregulation of the PD-1/PD-Ls pathway in peripheral cells correlates with asbestosis severity. <i>BMC Pulmonary Medicine</i> , 2021, 21, 175.	2.0	1
1172	Cardiotoxicity of Immune Checkpoint Inhibitors. <i>Current Oncology Reports</i> , 2021, 23, 79.	4.0	85
1173	Coping with sterile inflammation: between risk and necessity. <i>Cardiovascular Research</i> , 2021, 117, e84-e87.	3.8	5
1174	The Role of Programmed Death-1 in Type 1 Diabetes. <i>Current Diabetes Reports</i> , 2021, 21, 20.	4.2	11
1175	Molecular Mechanisms of PD-1 and PD-L1 Activity on a Pan-Cancer Basis: A Bioinformatic Exploratory Study. <i>International Journal of Molecular Sciences</i> , 2021, 22, 5478.	4.1	6
1176	Comparative Transcriptomics of Immune Checkpoint Inhibitor Myocarditis Identifies Guanylate Binding Protein 5 and 6 Dysregulation. <i>Cancers</i> , 2021, 13, 2498.	3.7	23
1177	Modulating T Follicular Cells In Vivo Enhances Antigen-Specific Humoral Immunity. <i>Journal of Immunology</i> , 2021, 206, 2583-2595.	0.8	0
1178	Preclinical Models of Cancer Therapy—Associated Cardiovascular Toxicity: A Scientific Statement From the American Heart Association. <i>Circulation Research</i> , 2021, 129, e21-e34.	4.5	37
1179	Immune Cells and Immunotherapy for Cardiac Injury and Repair. <i>Circulation Research</i> , 2021, 128, 1766-1779.	4.5	93
1180	Risk of Cardiac Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 645245.	2.8	9
1182	Programmed Cell Death-1 Pathway Deficiency Enhances Autoimmunity Leading to Dacryoadenitis of Mice. <i>American Journal of Pathology</i> , 2021, 191, 1077-1093.	3.8	6
1183	Immune Checkpoint Inhibitors and Cardiotoxicity: An Analysis of Spontaneous Reports in Eudravigilance. <i>Drug Safety</i> , 2021, 44, 957-971.	3.2	38

#	ARTICLE	IF	CITATIONS
1184	Our current understanding of checkpoint inhibitor therapy in cancer immunotherapy. <i>Annals of Allergy, Asthma and Immunology</i> , 2021, 126, 630-638.	1.0	23
1185	A phase I study of IMC-001, a PD-L1 blocker, in patients with metastatic or locally advanced solid tumors. <i>Investigational New Drugs</i> , 2021, 39, 1624-1632.	2.6	0
1186	Cardiovascular toxicity of angiogenesis inhibitors and immune checkpoint inhibitors: synergistic anti-tumour effects at the cost of increased cardiovascular risk?. <i>Clinical Science</i> , 2021, 135, 1649-1668.	4.3	10
1187	Targeting the spectrum of immune checkpoints in prostate cancer. <i>Expert Review of Clinical Pharmacology</i> , 2021, 14, 1253-1266.	3.1	13
1188	Immunotherapy-Related Cystitis: Case Report and Review of the Literature. <i>OncoTargets and Therapy</i> , 2021, Volume 14, 4321-4328.	2.0	12
1190	Myocarditis Induced by Immune Checkpoint Inhibitors: Mechanisms and Therapeutic Prospects. <i>Journal of Inflammation Research</i> , 2021, Volume 14, 3077-3088.	3.5	5
1191	Immune Myocarditis Overlapping With Myasthenia Gravis Due to Anti-PD-1 Treatment for a Chordoma Patient: A Case Report and Literature Review. <i>Frontiers in Immunology</i> , 2021, 12, 682262.	4.8	13
1192	Cells to Surgery Quiz: July 2021. <i>Journal of Investigative Dermatology</i> , 2021, 141, e83-e86.	0.7	0
1193	Mechanisms Driving Immune-Related Adverse Events in Cancer Patients Treated with Immune Checkpoint Inhibitors. <i>Current Cardiology Reports</i> , 2021, 23, 98.	2.9	34
1194	Computational design of a synthetic PD-1 agonist. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	7.1	28
1195	Immunoadsorption treatment for dilated cardiomyopathy. <i>Medicine (United States)</i> , 2021, 100, e26475.	1.0	10
1196	Serum Troponin T Concentrations Are Frequently Elevated in Advanced Skin Cancer Patients Prior to Immune Checkpoint Inhibitor Therapy: Experience From a Single Tertiary Referral Center. <i>Frontiers in Medicine</i> , 2021, 8, 691618.	2.6	4
1198	Inhibitors of immune checkpoints—PD-1, PD-L1, CTLA-4—new opportunities for cancer patients and a new challenge for internists and general practitioners. <i>Cancer and Metastasis Reviews</i> , 2021, 40, 949-982.	5.9	72
1199	STAT5 interferes with PD-1 transcriptional activation and affects CD8+ T-cell sensitivity to PD-1-dependent immunoregulation. <i>International Immunology</i> , 2021, 33, 563-572.	4.0	6
1201	PD-1 preferentially inhibits the activation of low-affinity T cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	7.1	9
1202	Faecal microbiota transplantation enhances efficacy of immune checkpoint inhibitors therapy against cancer. <i>World Journal of Gastroenterology</i> , 2021, 27, 5362-5375.	3.3	17
1203	Epitranscriptomic Approach: To Improve the Efficacy of ICB Therapy by Co-Targeting Intracellular Checkpoint CISH. <i>Cells</i> , 2021, 10, 2250.	4.1	6
1204	Immune Checkpoint Inhibitors Mediated Lymphocytic and Giant Cell Myocarditis: Uncovering Etiological Mechanisms. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 721333.	2.4	14

#	ARTICLE	IF	CITATIONS
1205	Clinical and molecular parameters associated to pneumonitis development in non-small-cell lung cancer patients receiving chemoimmunotherapy from NADIM trial. , 2021, 9, e002804.		5
1206	Cancer immunotherapy: Classification, therapeutic mechanisms, and nanomaterial-based synergistic therapy. <i>Applied Materials Today</i> , 2021, 24, 101149.	4.3	7
1207	Immune checkpoint inhibitors and cardiotoxicity: possible mechanisms, manifestations, diagnosis and management. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 1211-1228.	2.4	1
1208	Immunopathological basis of immune-related adverse events induced by immune checkpoint blockade therapy. <i>Immunological Medicine</i> , 2022, 45, 108-118.	2.6	10
1209	Cardiotoxicity of Cancer Treatments: Focus on Anthracycline Cardiomyopathy. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2021, 41, 2648-2660.	2.4	20
1210	Immune Checkpoint Inhibitors and the Heart. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 726426.	2.4	8
1211	Targeting TIGIT for Immunotherapy of Cancer: Update on Clinical Development. <i>Biomedicines</i> , 2021, 9, 1277.	3.2	38
1212	Regulation of the immune tolerance system determines the susceptibility to HLA-mediated abacavir-induced skin toxicity. <i>Communications Biology</i> , 2021, 4, 1137.	4.4	8
1213	Role of the PD-1/PD-L1 Signaling in Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis: Recent Insights and Future Directions. <i>Molecular Neurobiology</i> , 2021, 58, 6249-6271.	4.0	15
1214	Cardiotoxicity in cancer immune-checkpoint therapy: Mechanisms, clinical evidence, and management strategies. <i>International Journal of Cardiology</i> , 2021, 344, 170-178.	1.7	13
1215	The Role of Oncogenes and Redox Signaling in the Regulation of PD-L1 in Cancer. <i>Cancers</i> , 2021, 13, 4426.	3.7	15
1216	Cellular and molecular regulation of the programmed death-1/programmed death ligand system and its role in multiple sclerosis and other autoimmune diseases. <i>Journal of Autoimmunity</i> , 2021, 123, 102702.	6.5	16
1217	Glucocorticoid and PD-1 Cross-Talk: Does the Immune System Become Confused?. <i>Cells</i> , 2021, 10, 2333.	4.1	13
1218	Mechanisms and Insights for the Development of Heart Failure Associated with Cancer Therapy. <i>Children</i> , 2021, 8, 829.	1.5	2
1219	Successful Treatment of Steroid-Refractory Checkpoint Inhibitor Myocarditis with Globulin Derived-Therapy: A Case Report and Literature Review. <i>American Journal of the Medical Sciences</i> , 2021, 362, 424-432.	1.1	5
1220	The PD1 inhibitory pathway and mature dendritic cells contribute to abacavir hypersensitivity in human leukocyte antigen transgenic PD1 knockout mice. <i>Toxicology</i> , 2021, 463, 152971.	4.2	0
1221	Pathophysiology, diagnosis and management of cardiac toxicity induced by immune checkpoint inhibitors and BRAF and MEK inhibitors. <i>Cancer Treatment Reviews</i> , 2021, 100, 102282.	7.7	25
1222	Cardiotoxicity associated with immune checkpoint inhibitors and CAR T-cell therapy. <i>American Journal of Emergency Medicine</i> , 2021, 50, 51-58.	1.6	6

#	ARTICLE	IF	CITATIONS
1223	Immunoediting and cancer priming. , 2022, , 111-136.		1
1224	Cancer Immunotherapy. Advances in Medical Diagnosis, Treatment, and Care, 2021, , 1-41.	0.1	0
1225	Relationship between T cell receptor clonotype and PD-1 expression of tumor-infiltrating lymphocytes in colorectal cancer. European Journal of Immunology, 2020, 50, 1580-1590.	2.9	3
1226	Frontiers in Viral Diagnostics. , 2006, , 39-54.		2
1227	Organ Transplantation: Modulation of T-Cell Activation Pathways Initiated by Cell Surface Receptors to Suppress Graft Rejection. Methods in Molecular Biology, 2010, 677, 419-430.	0.9	2
1229	Immune Checkpoint Inhibitors (ICIs)-Related Cardiotoxicity. Advances in Experimental Medicine and Biology, 2020, 1244, 277-285.	1.6	9
1232	Roles of PD-1/PD-L1 Pathway: Signaling, Cancer, and Beyond. Advances in Experimental Medicine and Biology, 2020, 1248, 33-59.	1.6	232
1233	Co-signal Molecules in T-Cell Activation. Advances in Experimental Medicine and Biology, 2019, 1189, 3-23.	1.6	45
1234	Cancer Immunotherapy Targeting Co-signal Molecules. Advances in Experimental Medicine and Biology, 2019, 1189, 313-326.	1.6	4
1235	Molecular Dynamics of Co-signal Molecules in T-Cell Activation. Advances in Experimental Medicine and Biology, 2019, 1189, 135-152.	1.6	12
1236	Control of Regulatory T Cells by Co-signal Molecules. Advances in Experimental Medicine and Biology, 2019, 1189, 179-210.	1.6	25
1237	Stimulatory and Inhibitory Co-signals in Autoimmunity. Advances in Experimental Medicine and Biology, 2019, 1189, 213-232.	1.6	10
1238	Incidence of Pericardial Effusion in Patients with Advanced Non-Small Cell Lung Cancer Receiving Immunotherapy. Advances in Therapy, 2020, 37, 3178-3184.	2.9	27
1239	Cancer Immunology. , 2014, , 78-97.e5.		3
1240	Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion. , 0, .		1
1241	PD-1 and BTLA regulate T cell signaling differentially and only partially through SHP1 and SHP2. Journal of Cell Biology, 2020, 219, .	5.2	65
1242	A different type of acute myocarditis: a case report of acute autoimmune myocarditis mediated by anti-PD-1 T lymphocyte receptor (pembrolizumab). European Heart Journal - Case Reports, 2020, 4, 1-6.	0.6	9
1243	PD-1+ Monocytes Mediate Cerebral Vasospasm Following Subarachnoid Hemorrhage. Neurosurgery, 2021, 88, 855-863.	1.1	11

#	ARTICLE	IF	CITATIONS
1246	SHP-1 phosphatase activity counteracts increased T cell receptor affinity. <i>Journal of Clinical Investigation</i> , 2013, 123, 1044-1056.	8.2	109
1247	Inhibition of SHP2 ameliorates the pathogenesis of systemic lupus erythematosus. <i>Journal of Clinical Investigation</i> , 2016, 126, 2077-2092.	8.2	56
1248	A Case of Acute Exacerbation of Chronic Adrenal Insufficiency Due to Ipilimumab Treatment for Advanced Melanoma. <i>American Journal of Case Reports</i> , 2019, 20, 106-110.	0.8	7
1249	Signaling in T cells “ is anything the m(a)TOR with the picture(s)”. <i>F1000Research</i> , 2016, 5, 191.	1.6	6
1250	PD-L1 expression in equine malignant melanoma and functional effects of PD-L1 blockade. <i>PLoS ONE</i> , 2020, 15, e0234218.	2.5	10
1251	TIM3 Mediates T Cell Exhaustion during Mycobacterium tuberculosis Infection. <i>PLoS Pathogens</i> , 2016, 12, e1005490.	4.7	147
1252	A Case of Acute Heart Failure due to Immune Checkpoint Blocker Nivolumab. <i>Cardiology Research</i> , 2019, 10, 120-123.	1.1	11
1253	Immune Checkpoint Inhibitors in the Treatment of Melanoma: From Basic Science to Clinical Application. , 0, , 121-142.		31
1254	The anticancer immune response of anti-PD-1/PD-L1 and the genetic determinants of response to anti-PD-1/PD-L1 antibodies in cancer patients. <i>Oncotarget</i> , 2015, 6, 19393-19404.	1.8	61
1255	Costimulation and Pancreatic Autoimmunity: The PD-1/PD-L Conundrum. <i>Review of Diabetic Studies</i> , 2006, 3, 6-6.	1.3	10
1256	Mouse Models of Autoimmune Diseases - Autoimmune Myocarditis. <i>Current Pharmaceutical Design</i> , 2015, 21, 2498-2512.	1.9	28
1257	Immunomodulatory Drugs: Immune Checkpoint Agents in Acute Leukemia. <i>Current Drug Targets</i> , 2017, 18, 315-331.	2.1	39
1258	Molecular Mechanisms and Targeted Therapies Including Immunotherapy for Non-Small Cell Lung Cancer. <i>Current Cancer Drug Targets</i> , 2019, 19, 595-630.	1.6	61
1259	PD-L1 Expression Is a Prognostic Factor in Patients with Thoracic Esophageal Cancer Treated Without Adjuvant Chemotherapy. <i>Anticancer Research</i> , 2017, 37, 1433-1442.	1.1	30
1260	The role of B cells in animal models of rheumatoid arthritis. <i>Frontiers in Bioscience - Landmark</i> , 2007, 12, 1722.	3.0	19
1261	Molecular immunology of the maternal“fetal interface. <i>Reproductive Medicine and Assisted Reproductive Techniques Series</i> , 2008, , 524-545.	0.1	2
1262	Cardiovascular Complications of Prostate Cancer Treatment. <i>Frontiers in Pharmacology</i> , 2020, 11, 555475.	3.5	14
1263	Genomics of Vasculitis: Lessons from Mouse Models. <i>Annals of Vascular Diseases</i> , 2013, 6, 16-21.	0.5	10

#	ARTICLE	IF	CITATIONS
1264	Costimulatory molecule programmed death-1 in the cytotoxic response during chronic hepatitis C. World Journal of Gastroenterology, 2009, 15, 5129.	3.3	18
1265	Combining protein arginine methyltransferase inhibitor and anti-programmed death-ligand-1 inhibits pancreatic cancer progression. World Journal of Gastroenterology, 2020, 26, 3737-3749.	3.3	23
1267	The mRNA expression of <i>IL6</i> and <i>Pdcd1</i> are predictive and protective factors for doxorubicin-induced cardiotoxicity. Molecular Medicine Reports, 2020, 23, .	2.4	6
1268	HLA-mediated tumor escape mechanisms that may impair immunotherapy clinical outcomes via T-cell activation. Oncology Letters, 2017, 14, 4415-4427.	1.8	60
1269	Immunotherapy a New Hope for Cancer Treatment: A Review. Pakistan Journal of Biological Sciences, 2018, 21, 135-150.	0.5	21
1270	Level of circulating PD-L1 expression in patients with advanced gastric cancer and its clinical implications. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2014, 26, 104-11.	2.2	90
1271	Geografía histórica de los espacios reales: Aláridiga, Aceca y Barciles, despoblados del rey en la vega del Tajo. Estudios Geograficos, 2018, 79, 209.	0.3	3
1272	Cardiovascular Complications of Novel Anti-Cancer Immunotherapy: Old Problems from New Agents?. Korean Circulation Journal, 2020, 50, 743.	1.9	6
1273	The Promise of PD-1 Signaling Pathway for Cancer Immunotherapy. Journal of Clinical & Cellular Immunology, 2012, 03, .	1.5	2
1274	Present and future of immune checkpoint blockade: Monotherapy to adjuvant approaches. World Journal of Immunology, 2015, 5, 1.	0.5	4
1275	The Upregulation of Molecules Related to Tumor Immune Escape in Human Pituitary Adenomas. Frontiers in Endocrinology, 2021, 12, 726448.	3.5	11
1276	Bradyarrhythmias in Cardio-Oncology. South Asian Journal of Cancer, 2021, 10, 195-210.	0.6	0
1277	The regulation of PD-1/PD-L1 pathway and autoimmune diseases. , 2001, , 211-214.		0
1278	B cell signal transduction and autoimmunity. Japanese Journal of Clinical Immunology, 2002, 25, 244-254.	0.0	0
1279	Mechanistic Features of Cell-Surface Adhesion Receptors. , 2003, , 71-77.		0
1280	Costimulatory Molecules in T Cell Activation and Transplantation. , 2004, , 291-312.		0
1282	Co-stimulation Regulation of Immune Tolerance and Autoimmunity. , 2007, , 121-138.		0
1283	Are Autoimmune Manifestations in Human Dilated Cardiomyopathy Primary or Secondary Events?. , 2008, , 373-378.		0

#	ARTICLE	IF	CITATIONS
1284	New Approaches for Optimizing Melanoma Vaccines. Translational Medicine Series, 2008, , 143-160.	0.0	1
1285	Targeting Immunological Synapse: New Horizons in Immunotherapy for Cancer. , 2009, , 575-590.		0
1286	Transplantation Immunobiology. , 2009, , 1835-1866.		1
1287	Vaccine Therapy and Immunotherapy for Pancreatic Cancer. , 2010, , 1269-1318.		0
1288	Immunoabsorption in dilated cardiomyopathy patients. , 2010, , 279-289.		0
1289	Pathogenic relevance of autoantibodies in dilated cardiomyopathy. , 2010, , 157-170.		0
1293	Anti-PD-1 and Anti-B7-H1/PD-L1 Monoclonal Antibodies. , 2012, , 291-306.		0
1294	Developing Cancer Immunotherapies by the manipulation of Immune Checkpoints. IOSR Journal of Pharmacy, 2012, 2, 01-08.	0.1	0
1295	Targeted Therapies and Vaccination. , 2012, , 261-275.		0
1296	The Role of Polymorphisms in Co-Signalling Moleculesâ€™ Genes in Susceptibility to B-Cell Chronic Lymphocytic Leukaemia. , 0, , .		1
1297	Progress of Immunotherapy for Hepatocellular Carcinoma. Immuno-gastroenterology, 2013, 2, 167.	0.4	1
1298	Overcoming Immune Suppression: Therapeutic Strategies Targeting T-Cell Function in Cancer. , 2014, , 435-462.		0
1299	Immuno-tolerance in infectious disease: a chronic hepatitis model. International Journal of Infectious and Tropical Diseases, 2014, 1, 3-12.	0.1	0
1300	Overcoming Cancer Tolerance with Immune Checkpoint Blockade. , 2015, , 87-129.		0
1301	Immunology of Pediatric Renal Transplantation. , 2015, , 1-51.		0
1302	PD-1,CTLA-4. Okayama Igakkai Zasshi, 2015, 127, 63-65.	0.0	0
1303	T Cell Modulation: Anti-PD-1 Antibodies for the Treatment of Cancer. Cancer Drug Discovery and Development, 2015, , 231-244.	0.4	0
1304	Immunology of Pediatric Renal Transplantation. , 2016, , 2457-2500.		0

#	ARTICLE	IF	CITATIONS
1305	PD-1/PD-L1. The Japanese Journal of SURGICAL METABOLISM and NUTRITION, 2019, 53, 267-270.	0.1	0
1306	The Multifaceted Role of PD-1 in Health and Disease. , 2016, , 441-457.		0
1307	Surgical Considerations and Emergencies in the Cancer Patient Receiving Immunotherapy. , 2017, , 31-44.		0
1308	Responses and response evaluation of immune checkpoint inhibitors in lymphoma. Annals of Lymphoma, 0, 1, 1-1.	4.5	0
1309	Vaccine Therapy and Immunotherapy for Pancreatic Cancer. , 2017, , 1-45.		0
1310	Co-inhibitory receptor programmed cell death protein 1 targets co-stimulatory CD28. Translational Cancer Research, 2017, 6, S1080-S1083.	1.0	2
1311	Side Effects of Systemic Therapy and Their Clinical Management. , 2018, , 1-17.		0
1312	Front line of cancer immunotherapy development. The Journal of the Japanese Society of Internal Medicine, 2017, 106, 2645-2658.	0.0	0
1313	New Development of Cancer Immunotherapy : History of Immunity Check Inhibitors Focusing on Programmed Death-1 (PD-1). Japanese Journal of Neurosurgery, 2018, 27, 712-722.	0.0	0
1314	Construction and Identification of Eukaryotic Expression Vector of Human Programmed Death Receptor 1. Bioprocess, 2018, 08, 55-60.	0.0	0
1315	Implications of the HDAC6-ERK1 feed forward loop in immunotherapy. Journal of Immunological Sciences, 2018, 2, 59-68.	1.1	2
1317	PD-1/PD-L1. The Japanese Journal of SURGICAL METABOLISM and NUTRITION, 2019, 53, 267-270.	0.1	0
1318	Nivolumab (Opdivo). , 2019, , 255-283.		1
1319	A new strategy for fighting cancer, or how the "brake" of the immune system works. Visnik Nacional Noi Akademii Nauk Ukraini, 2019, , 44-57.	0.3	0
1320	Development of PD-1 Inhibition in Cancer Therapy: Dramatic Advances for Medical Oncology. Trends in the Sciences, 2019, 24, 2_25-2_29.	0.0	0
1321	PD-1 Research: History and Future Perspectives. Trends in the Sciences, 2019, 24, 2_8-2_14.	0.0	0
1323	Nivolumab-. The Journal of the Japanese Society of Internal Medicine, 2019, 108, 1766-1771.	0.0	0
1325	T cell Immune Pathways Current and Future Implementation in Cancer Immunotherapy. Novel Approaches in Cancer Study, 2019, 3, .	0.2	0

#	ARTICLE	IF	CITATIONS
1326	Cardiovascular Toxicities of Immunotherapy. , 2020, , 259-276.		0
1328	Immune-Related Myocarditis Presenting as Shortness of Breath and Complete Heart Block in an Urothelial Cancer Patient Receiving Pembrolizumab: A Case Report. Journal of Clinical Review & Case Reports, 2020, 5, .	0.0	0
1329	Cardiovascular effects of innovative therapies in lung cancer. , 2020, , 154-166.		0
1330	Retrospective Study of Intercalated Disk Defects Associated with Dilated Cardiomyopathy, Atrial Thrombosis, and Heart Failure in BALB/c Mice Deficient in IL4 Receptor $\hat{\pm}$. Comparative Medicine, 2020, 70, 266-276.	1.0	2
1331	Overcoming Cancer Tolerance with Immune Checkpoint Blockade. , 2021, , 85-128.		0
1333	Biological Bases of Immune-Related Adverse Events and Potential Crosslinks With Immunogenic Effects of Radiation. Frontiers in Pharmacology, 2021, 12, 746853.	3.5	14
1334	The Mechanism and Management of Adverse Cardiac Reactions Induced by Immune Checkpoint Inhibitors Therapy. Cardiology Research and Practice, 2020, 2020, 1-5.	1.1	0
1336	Pulmonary Toxicities of Immunotherapy. , 2020, , 243-252.		0
1337	Clinical Presentation of Myocarditis. , 2020, , 19-36.		2
1338	Organ-Specific Autoimmune Myocarditis. , 2020, , 173-194.		0
1339	Checkpoint Inhibitors in Melanoma Patients with Underlying Autoimmune Disease. Cancer Management and Research, 2021, Volume 13, 8199-8208.	1.9	9
1340	Unravelling Checkpoint Inhibitor Associated Autoimmune Diabetes: From Bench to Bedside. Frontiers in Endocrinology, 2021, 12, 764138.	3.5	22
1341	The double-edged sword: Harnessing PD-1 blockade in tumor and autoimmunity. Science Immunology, 2021, 6, eabf4034.	11.9	22
1342	Cardio-Oncology Preclinical Models: A Comprehensive Review. Anticancer Research, 2021, 41, 5355-5364.	1.1	3
1344	Immunoabsorption in Dilated Cardiomyopathy. , 2006, , 353-361.		0
1346	Contribution of B7-H1/PD-1 Co-inhibitory Pathway to T-Cell Dysfunction in Cancer. , 2008, , 29-40.		0
1348	Immunoregulatory role of B7-H1 in chronicity of inflammatory responses. Cellular and Molecular Immunology, 2006, 3, 179-87.	10.5	65
1350	Divide and conquer: Blocking graft versus host but not graft versus leukemia T cells with agonist BTLA co-inhibitory signals. Chimerism, 2011, 2, 29-32.	0.7	1

#	ARTICLE	IF	CITATIONS
1351	Blockade of the B7-H1/PD-1 pathway for cancer immunotherapy. <i>Yale Journal of Biology and Medicine</i> , 2011, 84, 409-21.	0.2	97
1352	Genomics of vasculitis: lessons from mouse models. <i>Annals of Vascular Diseases</i> , 2013, 6, 16-21.	0.5	5
1353	Targeting immune checkpoints: releasing the restraints on anti-tumor immunity for patients with melanoma. <i>Cancer Journal (Sudbury, Mass)</i> , 2012, 18, 153-9.	2.0	25
1355	Clinical significance of programmed death ligand-1 (PD-L1) in colorectal serrated adenocarcinoma. <i>International Journal of Clinical and Experimental Pathology</i> , 2015, 8, 9351-9.	0.5	22
1356	PD-L1 is required for human endometrial regenerative cells-associated attenuation of experimental colitis in mice. <i>American Journal of Translational Research (discontinued)</i> , 2019, 11, 4696-4712.	0.0	8
1357	Combined induction with anti-PD-1 and anti-CTLA-4 antibodies provides synergistic antitumor effects in DC-CIK cells in renal carcinoma cell lines. <i>International Journal of Clinical and Experimental Pathology</i> , 2019, 12, 123-132.	0.5	4
1358	Prevalence of programmed death-1 ligand-1 (PD-L1) and infiltrating lymphocytes in human gastric carcinogenesis. <i>International Journal of Clinical and Experimental Pathology</i> , 2017, 10, 11754-11759.	0.5	1
1360	Microglial PD-1 stimulation by astrocytic PD-L1 suppresses neuroinflammation and Alzheimer's disease pathology. <i>EMBO Journal</i> , 2021, 40, e108662.	7.8	41
1361	Sudden and severe cardiotoxicity induced with pembrolizumab, its clinical course, therapeutic intervention, and outcome. <i>International Cancer Conference Journal</i> , 2022, 11, 81-86.	0.5	2
1362	Immune Checkpoints and Innate Lymphoid Cells—New Avenues for Cancer Immunotherapy. <i>Cancers</i> , 2021, 13, 5967.	3.7	11
1363	Platelet PD-L1 reflects collective intratumoral PD-L1 expression and predicts immunotherapy response in non-small cell lung cancer. <i>Nature Communications</i> , 2021, 12, 7005.	12.8	66
1364	Immunotherapy of Ovarian Cancer with Particular Emphasis on the PD-1/PDL-1 as Target Points. <i>Cancers</i> , 2021, 13, 6063.	3.7	8
1365	Immune Checkpoint Inhibitor (ICI)-Related Cardiotoxicity. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1342, 377-387.	1.6	2
1366	Endocrine Complications of Biological Cancer Therapies. , 2022, , 1775-1778.		0
1367	Evaluation of PD1 and PDL1 Expressions in Squamous Cell Carcinoma and Lichen Planus. <i>SdÄœ SaÄžlik BÄ°lÄ°m DergÄ°sÄ°</i> , 2021, 12, 147-157.	0.2	0
1368	A Review on the Application of PD-1 Blockade in EBV-Associated Nasopharyngeal Carcinoma Immunotherapy. <i>Applied Bionics and Biomechanics</i> , 2022, 2022, 1-6.	1.1	5
1369	Vitamin D can reduce severity in COVID-19 through regulation of PD-L1. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2022, 395, 487-494.	3.0	9
1370	Targeting Protein Tyrosine Phosphatase 22 Does Not Enhance the Efficacy of Chimeric Antigen Receptor T Cells in Solid Tumors. <i>Molecular and Cellular Biology</i> , 2022, 42, MCB0044921.	2.3	8

#	ARTICLE	IF	CITATIONS
1371	Methods of screening, monitoring and management of cardiac toxicity induced by chemotherapeutics. Chinese Chemical Letters, 2022, , .	9.0	3
1372	Blocking the inhibitory receptor programmed cell death 1 prevents allergic immune response and anaphylaxis in mice. Journal of Allergy and Clinical Immunology, 2022, 150, 178-191.e9.	2.9	5
1373	Myocardial Inflammation and Sudden Death in the Inherited Cardiomyopathies. Canadian Journal of Cardiology, 2022, 38, 427-438.	1.7	6
1374	Immune-related adverse events in various organs caused by immune checkpoint inhibitors. Allergology International, 2022, 71, 169-178.	3.3	34
1375	Immune-checkpoint inhibitors: long-term implications of toxicity. Nature Reviews Clinical Oncology, 2022, 19, 254-267.	27.6	360
1376	B7 immune checkpoint family members as putative therapeutics in autoimmune disease: An updated overview. International Journal of Rheumatic Diseases, 2022, 25, 259-271.	1.9	4
1377	Metabolic Implications of Immune Checkpoint Proteins in Cancer. Cells, 2022, 11, 179.	4.1	15
1378	Inborn Errors of Immunity and Their Phenocopies: CTLA4 and PD-1. Frontiers in Immunology, 2021, 12, 806043.	4.8	7
1379	PD-1 inhibitor causes pathological injury to multiple organs in a Lewis lung cancer mouse model. International Immunopharmacology, 2022, 105, 108551.	3.8	4
1380	PD-1 agonism by anti-CD80 inhibits T cell activation and alleviates autoimmunity. Nature Immunology, 2022, 23, 399-410.	14.5	36
1381	The Potential Cardiotoxicity of Immune Checkpoint Inhibitors. Journal of Clinical Medicine, 2022, 11, 865.	2.4	8
1382	Checkpoint: Inspecting the barriers in glioblastoma immunotherapies. Seminars in Cancer Biology, 2022, 86, 473-481.	9.6	9
1383	Immune Checkpoint Therapies and Atherosclerosis: Mechanisms and Clinical Implications. Journal of the American College of Cardiology, 2022, 79, 577-593.	2.8	34
1384	Cardiotoxicity and Chemotherapy The Role of Precision Medicine. Diseases (Basel, Switzerland), 2021, 9, 90.	2.5	3
1385	Role of PD-L1 in licensing immunoregulatory function of dental pulp mesenchymal stem cells. Stem Cell Research and Therapy, 2021, 12, 598.	5.5	21
1386	Immune Checkpoint Inhibitors in 10 Years: Contribution of Basic Research and Clinical Application in Cancer Immunotherapy. Immune Network, 2022, 22, e2.	3.6	53
1387	Effects of PD-1 Signaling on Immunometabolic Reprogramming. Immunometabolism, 2022, 4, .	1.6	10
1388	The Diagnosis and Management of Immune Checkpoint Inhibitor Cardiovascular Toxicity: Myocarditis and Beyond. Vaccines, 2022, 10, 304.	4.4	2

#	ARTICLE	IF	CITATIONS
1389	Overexpression of Programmed Cell Death 1 Prevents Doxorubicin-Induced Apoptosis Through Autophagy Induction in H9c2 Cardiomyocytes. <i>Cardiovascular Toxicology</i> , 2022, 22, 462-476.	2.7	7
1390	Combining Radiotherapy and Immunotherapy in Metastatic Breast Cancer: Current Status and Future Directions. <i>Biomedicines</i> , 2022, 10, 821.	3.2	5
1391	Holistic Approach to Immune Checkpoint Inhibitor-Related Adverse Events. <i>Frontiers in Immunology</i> , 2022, 13, 804597.	4.8	27
1392	A Systematic Review of the Mechanisms Involved in Immune Checkpoint Inhibitors Cardiotoxicity and Challenges to Improve Clinical Safety. <i>Frontiers in Cell and Developmental Biology</i> , 2022, 10, 851032.	3.7	14
1393	CMTM6 as a master regulator of PD-L1. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 2325-2340.	4.2	7
1394	Cardiotoxicity risk factors with immune checkpoint inhibitors. <i>Cardio-Oncology</i> , 2022, 8, 3.	1.7	12
1395	In Vivo Murine Models of Cardiotoxicity Due to Anticancer Drugs: Challenges and Opportunities for Clinical Translation. <i>Journal of Cardiovascular Translational Research</i> , 2022, , 1.	2.4	2
1396	Exploring the Mechanisms Underlying the Cardiotoxic Effects of Immune Checkpoint Inhibitor Therapies. <i>Vaccines</i> , 2022, 10, 540.	4.4	8
1397	Checkpoint Inhibitors and Induction of Celiac Disease-like Condition. <i>Biomedicines</i> , 2022, 10, 609.	3.2	5
1398	Resistance to immune checkpoint blockade: Mechanisms, counter-acting approaches, and future directions. <i>Seminars in Cancer Biology</i> , 2022, 86, 532-541.	9.6	14
1399	Targeting HIF-1 α abrogates PD-L1-mediated immune evasion in tumor microenvironment but promotes tolerance in normal tissues. <i>Journal of Clinical Investigation</i> , 2022, 132, .	8.2	42
1400	PD-1/L1 inhibitors may increase the risk of pericardial disease in non-small-cell lung cancer patients: a meta-analysis and systematic review. <i>Immunotherapy</i> , 2022, , .	2.0	2
1401	Genetics of cancer therapy-associated cardiotoxicity. <i>Journal of Molecular and Cellular Cardiology</i> , 2022, 167, 85-91.	1.9	10
1402	Case Report: Cardiac Toxicity Associated With Immune Checkpoint Inhibitors. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 727445.	2.4	7
1403	The foundations of immune checkpoint blockade and the ipilimumab approval decennial. <i>Nature Reviews Drug Discovery</i> , 2022, 21, 509-528.	46.4	201
1404	pH Low Insertion Peptide-Modified Programmed Cell Death-Ligand 1 Potently Suppresses T-Cell Activation Under Acidic Condition. <i>Frontiers in Immunology</i> , 2021, 12, 794226.	4.8	2
1405	Blockade of B7-H1 and PD-1 by Monoclonal Antibodies Potentiates Cancer Therapeutic Immunity. <i>Cancer Research</i> , 2005, 65, 1089-1096.	0.9	819
1406	Cross talks between autoimmunity and cancer. , 2022, , 15-49.		0

#	ARTICLE	IF	CITATIONS
1407	Activation of T cell checkpoint pathways during $\hat{I}^2\hat{A}$ cell antigen presentation by engineered dendritic cells promotes protection from type 1 diabetes. <i>Immunology</i> , 2022, 166, 341-356.	4.4	2
1408	PD-1 cooperates with AIRE-mediated tolerance to prevent lethal autoimmune disease. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, e2120149119.	7.1	8
1428	Novel PD-L1 mAb HC16 reveals upregulation of PD-L1 in BAC subtype. <i>Histology and Histopathology</i> , 2021, 36, 77-89.	0.7	0
1432	Melanoma: An immunotherapy \hat{A} journey from bench to bedside. <i>Cancer Treatment and Research</i> , 2022, 183, 49-89.	0.5	0
1433	Autoimmunity and Cancer \hat{E} Two Sides of the Same Coin. <i>Frontiers in Immunology</i> , 2022, 13, .	4.8	16
1434	The study of immune checkpoint inhibitors in chronic hepatitis B virus infection. <i>International Immunopharmacology</i> , 2022, 109, 108842.	3.8	3
1435	Mechanism and Management of Checkpoint Inhibitor-Related Toxicities in Genitourinary Cancers. <i>Cancers</i> , 2022, 14, 2460.	3.7	2
1436	PD-1 Suppresses the Osteogenic and Odontogenic Differentiation of Stem Cells from Dental Apical Papilla via Targeting SHP2/NF- \hat{I}^{β} Axis. <i>Stem Cells</i> , 2022, 40, 763-777.	3.2	3
1437	Nivolumab-induced pneumonitis and cardiopathy in a patient with relapsed Hodgkin's lymphoma. <i>Journal of Oncology Pharmacy Practice</i> , 0, , 107815522211055.	0.9	3
1439	PD-1/PD-L Axis in Neuroinflammation: New Insights. <i>Frontiers in Neurology</i> , 0, 13, .	2.4	16
1440	Differential Engraftment of Parental A20 PD-L1 WT and PD-L1 KO Leukemia Cells in Semiallogeneic Recipients in the Context of PD-L1/PD-1 Interaction and NK Cell-Mediated Hybrid Resistance. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	1
1441	Integrated multi-omic characterization of congenital heart disease. <i>Nature</i> , 2022, 608, 181-191.	27.8	37
1442	Insights Into the Host Contribution of Endocrine Associated Immune-Related Adverse Events to Immune Checkpoint Inhibition Therapy. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	9
1443	The Neonatal Innate Immune Response to Sepsis: Checkpoint Proteins as Novel Mediators of This Response and as Possible Therapeutic/Diagnostic Levers. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	1
1444	Preparation and Evaluation of Animal Models of Cardiotoxicity in Antineoplastic Therapy. <i>Oxidative Medicine and Cellular Longevity</i> , 2022, 2022, 1-16.	4.0	4
1445	TNF- \hat{I}^{\pm} Inhibitors and Other Biologic Agents for the Treatment of Immune Checkpoint Inhibitor-Induced Myocarditis. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	11
1446	The expression pattern of Immune checkpoints after chemo/radiotherapy in the tumor microenvironment. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	2
1447	Cutting-Edge: Preclinical and Clinical Development of the First Approved Lag-3 Inhibitor. <i>Cells</i> , 2022, 11, 2351.	4.1	29

#	ARTICLE	IF	CITATIONS
1448	Targeting PD-1/PD-L1 in cancer immunotherapy: An effective strategy for treatment of triple-negative breast cancer (TNBC) patients. <i>Genes and Diseases</i> , 2023, 10, 1318-1350.	3.4	11
1449	Progress in programmed cell death-1/programmed cell death-ligand 1 pathway inhibitors and binding mode analysis. <i>Molecular Diversity</i> , 0, , .	3.9	1
1450	Activation Markers on B and T Cells and Immune Checkpoints in Autoimmune Rheumatic Diseases. <i>International Journal of Molecular Sciences</i> , 2022, 23, 8656.	4.1	4
1452	Conjugation of human serum albumin and flucloxacillin provokes specific immune response in HLA-B*57:01 transgenic mice. <i>Immunology Letters</i> , 2022, 249, 5-11.	2.5	3
1453	Pathophysiology of Immune Checkpoint Inhibitor-Induced Myocarditis. <i>Cancers</i> , 2022, 14, 4494.	3.7	16
1454	Management of Patients with Cardiac Toxicity: The Point of View of the Oncologist. <i>Current Clinical Pathology</i> , 2022, , 91-111.	0.0	0
1455	Intracellular Cardiac Signaling Pathways Altered by Cancer Therapies. , 2022, , 111-173.		0
1456	Cardiovascular complications of immune checkpoint inhibitors for cancer. <i>European Heart Journal</i> , 2022, 43, 4458-4468.	2.2	30
1457	Overcoming the cardiac toxicities of cancer therapy immune checkpoint inhibitors. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	5
1458	Immune checkpoint inhibitor-induced myocarditis. , 2022, 2, 35-43.		1
1459	Advanced Research on Immune Checkpoint Inhibitor Therapy. <i>Journal of Clinical Medicine</i> , 2022, 11, 5392.	2.4	0
1460	The role of non-coding RNAs in myocarditis: a narrative review. <i>Annals of Translational Medicine</i> , 2022, 10, 1022-1022.	1.7	0
1461	miR-acious new avenues for cancer immunotherapy. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	0
1464	PD-1 inhibitor therapy causes multisystem immune adverse reactions: a case report and literature review. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	4
1465	Myocarditis Induced by Immunotherapy in Metastatic Melanomaâ€”Review of Literature and Current Guidelines. <i>Journal of Clinical Medicine</i> , 2022, 11, 5182.	2.4	2
1466	Cardiotoxicity induced by immune checkpoint inhibitor: The complete insight into mechanisms, monitoring, diagnosis, and treatment. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	2.4	4
1467	Sphingosine kinase 1 promotes tumor immune evasion by regulating the MTA3-PD-L1 axis. , 2022, 19, 1153-1167.		6
1468	Diagnosis and management of immune checkpoint inhibitor-associated acute kidney injury. <i>Nature Reviews Nephrology</i> , 2022, 18, 794-805.	9.6	20

#	ARTICLE	IF	CITATIONS
1469	Signaling pathways and targeted therapies in lung squamous cell carcinoma: mechanisms and clinical trials. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, .	17.1	33
1470	The role of immune checkpoints in cardiovascular disease. <i>Frontiers in Pharmacology</i> , 0, 13, .	3.5	10
1471	The Programmed Death-1 Signaling Axis Modulates Inflammation and LV Structure/Function in a Stress-Induced Cardiomyopathy Model. <i>JACC Basic To Translational Science</i> , 2022, 7, 1120-1139.	4.1	8
1472	Fueling immune checkpoint blockade with oncolytic viruses: Current paradigms and challenges ahead. <i>Cancer Letters</i> , 2022, 550, 215937.	7.2	6
1473	Association between Histological Changes and Clinical Manifestations of Fulminant Myocarditis. , 2022, , 127-148.		0
1474	Targeting Inflammation in the Diagnosis, Management, and Prevention of Cardiovascular Diseases. <i>Global Heart</i> , 2022, 17, .	2.3	5
1475	PD-L1 evaluation in the gastrointestinal tract: from biological rationale to its clinical application. <i>Pathologica</i> , 2022, 114, 352-364.	3.4	13
1477	The intracellular cation channel TMEM176B as a dual immunoregulator. <i>Frontiers in Cell and Developmental Biology</i> , 0, 10, .	3.7	2
1478	The PD-1/PD-L1 Pathway: A Perspective on Comparative Immuno-Oncology. <i>Animals</i> , 2022, 12, 2661.	2.3	2
1479	Immune Checkpoint Inhibitors Related to Cardiotoxicity. <i>Journal of Cardiovascular Development and Disease</i> , 2022, 9, 378.	1.6	3
1480	Cardiotoxicity Induced by Immune Checkpoint Inhibitors: What a Cardio-Oncology Team Should Know and Do. <i>Cancers</i> , 2022, 14, 5403.	3.7	7
1481	Immune checkpoint inhibitor monotherapy is associated with less cardiac toxicity than combination therapy. <i>PLoS ONE</i> , 2022, 17, e0272022.	2.5	4
1482	The impact of microbiota on PD-1/PD-L1 inhibitor therapy outcomes: A focus on solid tumors. <i>Life Sciences</i> , 2022, 310, 121138.	4.3	14
1483	Characterization of immune checkpoint inhibitor-induced cardiotoxicity reveals interleukin-17A as a driver of cardiac dysfunction after anti-PD-1 treatment. <i>British Journal of Pharmacology</i> , 2023, 180, 740-761.	5.4	17
1484	Cardiac myosin-specific autoimmune T cells contribute to immune-checkpoint-inhibitor-associated myocarditis. <i>Cell Reports</i> , 2022, 41, 111611.	6.4	28
1485	Current studies and future promises of PD-1 signal inhibitors in cervical cancer therapy. <i>Biomedicine and Pharmacotherapy</i> , 2023, 157, 114057.	5.6	5
1486	The spectrum of cardiovascular complications related to immune-checkpoint inhibitor treatment. <i>Cardio-Oncology</i> , 2022, 8, .	1.7	8
1487	The Flip of the Coin of Personalized Cancer Immunotherapy: A Focused Review on Rare Immune Checkpoint Related Adverse Effects. , 0, , .		0

#	ARTICLE	IF	CITATIONS
1488	Reprogramming immune cells activity by furin-like enzymes as emerging strategy for enhanced immunotherapy in cancer. <i>British Journal of Cancer</i> , 0, , .	6.4	0
1489	Reproducible and opposing gut microbiome signatures distinguish autoimmune diseases and cancers: a systematic review and meta-analysis. <i>Microbiome</i> , 2022, 10, .	11.1	8
1490	Assessing the risk of cardiovascular events in patients receiving immune checkpoint inhibitors. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	2.4	2
1491	Atezolizumab Plus Bevacizumab as First-line Treatment for Patients With Metastatic Nonsquamous Nonâ€“Small Cell Lung Cancer With High Tumor Mutation Burden. <i>JAMA Oncology</i> , 2023, 9, 344.	7.1	13
1492	The protective effect of total glucosides of white paeony capsules on experimental autoimmune encephalomyelitis. <i>Immunobiology</i> , 2023, 228, 152313.	1.9	2
1493	In or out of control: Modulating regulatory T cell homeostasis and function with immune checkpoint pathways. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	6
1494	Immune checkpoint inhibitor-induced myocarditis and myositis in liver cancer patients: A case report and literature review. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	1
1495	Immunopathogenesis of Immune Checkpoint Inhibitor Induced Myocarditis: Insights from Experimental Models and Treatment Implications. <i>Biomedicines</i> , 2023, 11, 107.	3.2	4
1496	Dermatologic autoimmunity associated with immune checkpoint inhibitors. , 2023, , 311-327.		0
1497	[18F]FDG PET/CT Imaging in Cancer Treatment with Checkpoint Inhibitors. , 2023, , 1-40.		0
1498	Fulminant Myocarditis Complicated with Immune Checkpoint Inhibitor in Patients with Thymoma: Report of Three Cases. <i>International Journal of Cardiovascular Practice</i> , 2023, 7, .	0.2	0
1499	DNA methylation and transcriptome signatures of the PDCD1 gene in ankylosing spondylitis. <i>Genes and Immunity</i> , 2023, 24, 46-51.	4.1	2
1500	Peripheral blood lymphocytes differentiation patterns in responses / outcomes to immune checkpoint blockade therapies in non-small cell lung cancer: a retrospective study. <i>BMC Cancer</i> , 2023, 23, .	2.6	3
1501	Checkpoint Blockade in Cancer Immunotherapy: Squaring the Circle. <i>European Medical Journal Oncology</i> , 0, , 70-76.	0.0	1
1502	Long-term persistence and functionality of adoptively transferred antigen-specific T cells with genetically ablated PD-1 expression. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2023, 120, .	7.1	9
1503	Cardiovascular Effects of Immune Checkpoint Inhibitors: More Than Just Myocarditis. <i>Current Oncology Reports</i> , 2023, 25, 743-751.	4.0	2
1504	Blockade of trans PD-L1 interaction with CD80 augments antitumor immunity. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2023, 120, .	7.1	5
1505	Nivolumab plus ipilimumab combination therapy in cancer: Current evidence to date. <i>International Immunopharmacology</i> , 2023, 117, 109881.	3.8	8

#	ARTICLE	IF	CITATIONS
1506	Autoantibodies Drive Heart Damage Caused by Concomitant Radiation and PD-1 Blockade. <i>Cancer Immunology Research</i> , 2023, 11, 546-555.	3.4	2
1507	Acquired radioresistance in EMT6 mouse mammary carcinoma cell line is mediated by CTLA-4 and PD-1 through JAK/STAT/PI3K pathway. <i>Scientific Reports</i> , 2023, 13, .	3.3	1
1508	Advances in immune checkpoint inhibitors induced-cardiotoxicity. <i>Frontiers in Immunology</i> , 0, 14, .	4.8	2
1509	The Role of BCL-2 and PD-1/PD-L1 Pathway in Pathogenesis of Myelodysplastic Syndromes. <i>International Journal of Molecular Sciences</i> , 2023, 24, 4708.	4.1	2
1510	Effect of SARS-CoV-2 mRNA-Vaccine on the Induction of Myocarditis in Different Murine Animal Models. <i>International Journal of Molecular Sciences</i> , 2023, 24, 5011.	4.1	1
1511	Tumor-infiltrating regulatory T cells as targets of cancer immunotherapy. <i>Cancer Cell</i> , 2023, 41, 450-465.	16.8	60
1512	Rheumatic Immune-Related Adverse Events due to Immune Checkpoint Inhibitors—A 2023 Update. <i>International Journal of Molecular Sciences</i> , 2023, 24, 5643.	4.1	7
1513	<i>In Situ</i> Separable Nanovaccines with Stealthy Bioadhesive Capability for Durable Cancer Immunotherapy. <i>Journal of the American Chemical Society</i> , 0, , .	13.7	4
1514	Immune Checkpoint Inhibitor Associated Myocarditis and Cardiomyopathy: A Translational Review. <i>Biology</i> , 2023, 12, 472.	2.8	2
1515	Refractory right ventricular myocarditis induced by immune checkpoint inhibitor despite therapy cessation and immune suppression. <i>Cardio-Oncology</i> , 2023, 9, .	1.7	1
1516	Myocarditis and myasthenia gravis induced by immune checkpoint inhibitor in a patient with relapsed thymoma: A case report. <i>Clinical Case Reports (discontinued)</i> , 2023, 11, .	0.5	1
1517	Immune checkpoint inhibitors break whose heart? Perspectives from cardio-immuno-oncology. <i>Genes and Diseases</i> , 2024, 11, 807-818.	3.4	4
1518	Immunotherapeutic and their immunological aspects: Current treatment strategies and agents. <i>National Journal of Maxillofacial Surgery</i> , 2022, 13, 322.	0.5	1
1519	Immune checkpoint therapy—current perspectives and future directions. <i>Cell</i> , 2023, 186, 1652-1669.	28.9	114
1520	Cardiotoxicity of lung cancer-related immunotherapy versus chemotherapy: a systematic review and network meta-analysis of randomized controlled trials. <i>Frontiers in Oncology</i> , 0, 13, .	2.8	0
1521	A strategy for tumor immune microenvironment remodeling based on complementary immune checkpoint blockade. <i>Chemical Engineering Journal</i> , 2023, 466, 142956.	12.7	1
1522	SOHO State of the Art Updates and Next Questions New Pathways and New Targets in PTCL: Staying on Target. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2023, 23, 561-574.	0.4	2
1523	Evaluating the effect of PD-1 inhibitors on left ventricular function in lung cancer with noninvasive myocardial work. <i>Quantitative Imaging in Medicine and Surgery</i> , 2023, .	2.0	1

#	ARTICLE	IF	CITATIONS
1524	Insights from a 30-year journey: function, regulation and therapeutic modulation of PD1. <i>Nature Reviews Immunology</i> , 2023, 23, 682-695.	22.7	24
1525	Nivolumabâ€induced fatal myocarditis: A case report. <i>Clinical Case Reports (discontinued)</i> , 2023, 11, .	0.5	1
1526	Peripheral immune mapping and multi-omics analysis in PD-1 inhibitor-induced myocarditis. <i>Journal of Leukocyte Biology</i> , 0, , .	3.3	0
1527	Transcriptomic Comparison of Human Peripartum and Dilated Cardiomyopathy Identifies Differences in Key Disease Pathways. <i>Journal of Cardiovascular Development and Disease</i> , 2023, 10, 188.	1.6	0
1528	[99mTc]-labelled anti-Programmed Death-Ligand 1 single-domain antibody SPECT/CT: a novel imaging biomarker for myocardial PD-L1 expression. <i>EJNMMI Research</i> , 2023, 13, .	2.5	0
1529	Microsatellite Instability and Immune Response: From Microenvironment Features to Therapeutic Actionabilityâ€Lessons from Colorectal Cancer. <i>Genes</i> , 2023, 14, 1169.	2.4	3
1530	Myocarditis and autoimmunity. <i>Expert Review of Cardiovascular Therapy</i> , 2023, 21, 437-451.	1.5	0
1531	Immune-related adverse effects of checkpoint immunotherapy and implications for the treatment of patients with cancer and autoimmune diseases. <i>Frontiers in Immunology</i> , 0, 14, .	4.8	6
1532	Nuclear Factor-Î²B is a Prime Candidate for the Diagnosis and Control of Inflammatory Cardiovascular Disease. <i>European Cardiology Review</i> , 0, 18, .	2.2	7
1533	PD-L1â€™s Role in Preventing Alloreactive T Cell Responses Following Hematopoietic and Organ Transplant. <i>Cells</i> , 2023, 12, 1609.	4.1	1
1534	Cardiomuscular Biomarkers in the Diagnosis and Prognostication of Immune Checkpoint Inhibitor Myocarditis. <i>Circulation</i> , 2023, 148, 473-486.	1.6	18
1535	Research progression of PD-1/PD-L1 in non-small cell lung cancer. , 2017, 3, 111-115.		0
1537	Neurological adverse events associated with PD-1/PD-L1 immune checkpoint inhibitors. <i>Frontiers in Neuroscience</i> , 0, 17, .	2.8	1
1538	Combining radiation and systemic therapy. , 2024, , 99-126.		0
1539	Potential Immunotherapy Targets for Liver-Directed Therapies, and the Current Scope of Immunotherapeutics for Liver-Related Malignancies. <i>Cancers</i> , 2023, 15, 2624.	3.7	1
1540	Immune checkpoint inhibitorâ€™related myocarditis in thymic epithelial tumors: Recent progress and perspectives. , 2023, 2, .		0
1541	Cumulative effects of weakly repressive regulatory regions in the 3â€™ UTR maintain PD-1 expression homeostasis in mammals. <i>Communications Biology</i> , 2023, 6, .	4.4	1
1542	A case of spontaneous regression of advanced maxillary gingival cancer. <i>Nihon Koku Geka Gakkai Zasshi</i> , 2023, 69, 150-157.	0.0	0

#	ARTICLE	IF	CITATIONS
1543	Negative intracellular regulators of T-cell receptor (TCR) signaling as potential antitumor immunotherapy targets. , 2023, 11, e005845.		2
1544	Cardiotoxicity of Targeted Therapies in Children with Haematological Malignancies and Solid Tumors. Anti-Cancer Agents in Medicinal Chemistry, 2023, 23, 1702-1709.	1.7	0
1545	Role of B cells in immune-related adverse events following checkpoint blockade. Immunological Reviews, 0, , .	6.0	2
1546	Worldwide productivity and research trend of publications concerning tumor immune microenvironment (TIME): a bibliometric study. European Journal of Medical Research, 2023, 28, .	2.2	3
1547	Single-cell profiling reveals unique features of diabetogenic T cells in anti-PD-1-induced type 1 diabetes mice. Journal of Experimental Medicine, 2023, 220, .	8.5	4
1548	Gastrointestinal mucosal toxicities from immune checkpoint inhibitors: Current understanding and future directions. Immunological Reviews, 0, , .	6.0	1
1549	Immunological mechanisms underlying clinical phenotypes and noninvasive diagnosis of immune checkpoint inhibitor-induced kidney disease. Immunological Reviews, 2023, 318, 61-69.	6.0	1
1550	Efficacy of Immune Checkpoint Inhibitors in Treating Patients with Melanoma. Advances in Clinical Medicine, 2023, 13, 11691-11698.	0.0	0
1551	Fractalkine Signalling (CX3CL1/CX3CR1 Axis) as an Emerging Target in Coronary Artery Disease. Journal of Clinical Medicine, 2023, 12, 4821.	2.4	1
1552	A small molecule inhibitor of PTP1B and PTPN2 enhances T cell anti-tumor immunity. Nature Communications, 2023, 14, .	12.8	11
1553	Mechanisms underlying response and resistance to immune checkpoint blockade in cancer immunotherapy. Frontiers in Oncology, 0, 13, .	2.8	1
1554	Deciphering the complexities of cancer cell immune evasion: Mechanisms and therapeutic implications. Advances in Cancer Biology Metastasis, 2023, 8, 100107.	2.0	1
1555	Disease in the <i>Pld4</i>/thss/thss Model of Murine Lupus Requires TLR9. ImmunoHorizons, 2023, 7, 577-586.	1.8	1
1556	Novel Cellular and Immunotherapy: Toxicities and Perioperative Implications. Current Oncology, 2023, 30, 7638-7653.	2.2	0
1557	Immune interactions in pembrolizumab (PD-1 inhibitor) cancer therapy and cardiovascular complications. American Journal of Physiology - Heart and Circulatory Physiology, 2023, 325, H751-H767.	3.2	1
1559	Anti-breast cancer-induced cardiomyopathy: Mechanisms and future directions. Biomedicine and Pharmacotherapy, 2023, 166, 115373.	5.6	3
1560	Immune checkpoint inhibitor-related myocarditis: current understanding and potential diagnostic and therapeutic strategies. Expert Opinion on Drug Safety, 2023, 22, 909-919.	2.4	1
1561	Cardiotoxicity of anti-cancer drugs: cellular mechanisms and clinical implications. Frontiers in Cardiovascular Medicine, 0, 10, .	2.4	1

#	ARTICLE	IF	CITATIONS
1562	Immune-Checkpoint Inhibitor-Related Myocarditis: Where We Are and Where We Will Go. <i>Angiology</i> , 0, , .	1.8	0
1563	Stocking the toolboxâ€”Using preclinical models to understand the development and treatment of immune checkpoint inhibitorâ€induced immuneâ€related adverse events. <i>Immunological Reviews</i> , 2023, 318, 110-137.	6.0	1
1564	Homeostatic PD-1 signaling restrains EOMES-dependent oligoclonal expansion of liver-resident CD8 Tâ€cells. <i>Cell Reports</i> , 2023, 42, 112876.	6.4	0
1565	Cardiac Autoantibodies Against Cardiac Troponin I in Post-Myocardial Infarction Heart Failure: Evaluation in a Novel Murine Model and Applications in Therapeutics. <i>Circulation: Heart Failure</i> , 2023, 16, .	3.9	2
1566	Successful treatment with carboplatin and paclitaxel in melanoma progression after immune-related adverse events. <i>Immunotherapy</i> , 2023, 15, 993-999.	2.0	2
1567	Cancer Immunotherapy. , 2023, , 121-154.		0
1571	NUTMEG: A randomized phase II study of nivolumab and temozolomide versus temozolomide alone in newly diagnosed older patients with glioblastoma. <i>Neuro-Oncology Advances</i> , 2023, 5, .	0.7	0
1572	ATP protects anti-PD-1/radiation-induced cardiac dysfunction by inhibiting anti-PD-1 exacerbated cardiomyocyte apoptosis, and improving autophagic flux. <i>Heliyon</i> , 2023, 9, e20660.	3.2	0
1573	Cancer cell-intrinsic mechanisms driving acquired immune tolerance. <i>Immunity</i> , 2023, 56, 2270-2295.	14.3	4
1574	Immune Checkpoints in Solid Organ Transplantation. <i>Biology</i> , 2023, 12, 1358.	2.8	0
1575	Research Progress on Cardiotoxicity Associated with Immune Checkpoint Inhibitors. <i>Advances in Clinical Medicine</i> , 2023, 13, 16772-16778.	0.0	0
1576	Reflecting on the cardiac toxicity in non-small cell lung cancer in the era of immune checkpoint inhibitors therapy combined with thoracic radiotherapy. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2023, 1878, 189008.	7.4	0
1577	A comprehensive review on immune checkpoint inhibitors induced cardiotoxicity characteristics and associated factors. <i>European Journal of Medical Research</i> , 2023, 28, .	2.2	0
1578	Synergistic effects of immune checkpoints and checkpoint inhibitors in inflammatory neuropathies: Implications and mechanisms. <i>Journal of the Peripheral Nervous System</i> , 2024, 29, 6-16.	3.1	0
1579	Research Progress of Immuno-Inhibitory Receptors in Gynecological Cervical Cancer. <i>Technology in Cancer Research and Treatment</i> , 2023, 22, .	1.9	0
1580	Risk and Incidence of Endocrine Immune-Related Adverse Effects Under Checkpoint Inhibitor Mono- or Combination Therapy in Solid Tumors: A Meta-Analysis of Randomized Controlled Trials. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2024, 109, 1132-1144.	3.6	0
1581	Previous cardiovascular injury is a prerequisite for immune checkpoint inhibitorâ€associated lethal myocarditis in mice. <i>ESC Heart Failure</i> , 0, , .	3.1	0
1582	The Heart of the Matter: Immune Checkpoint Inhibitors and Immune-Related Adverse Events on the Cardiovascular System. <i>Cancers</i> , 2023, 15, 5707.	3.7	0

#	ARTICLE	IF	CITATIONS
1583	Programmed death receptor 1 (PD-1) ligand Fc fusion proteins reduce T cell proliferation <i>in vitro</i> independently of PD-1. <i>Immunology and Cell Biology</i> , 2024, 102, 117-130.	2.3	0
1584	Editorial: Gene expression: epigenetic and transcriptional regulation in neurodegenerative diseases and ageing. <i>Frontiers in Neuroscience</i> , 0, 17, .	2.8	0
1585	The implication of targeting PD-1:PD-L1 pathway in treating sepsis through immunostimulatory and anti-inflammatory pathways. <i>Frontiers in Immunology</i> , 0, 14, .	4.8	0
1586	PD-1 receptor outside the main paradigm: tumour-intrinsic role and clinical implications for checkpoint blockade. <i>British Journal of Cancer</i> , 2023, 129, 1409-1416.	6.4	4
1587	Optimal strategy in managing advanced melanoma. <i>Journal of Dermatology</i> , 2024, 51, 324-334.	1.2	0
1588	Colorectal Cancer Liver Metastasis: State-of-the-Art and Future Perspectives. <i>Gastrointestinal Disorders</i> , 2023, 5, 580-608.	0.8	0
1589	Ex vivo gene therapy in organ transplantation: considerations and clinical translation. <i>Human Gene Therapy</i> , 0, , .	2.7	0
1590	Cardiovascular events after cancer immunotherapy as oncologic emergencies: Analyses of 610 head and neck cancer patients treated with immune checkpoint inhibitors. <i>Head and Neck</i> , 2024, 46, 627-635.	2.0	1
1591	Associations between HIFs and tumor immune checkpoints: mechanism and therapy. <i>Discover Oncology</i> , 2024, 15, .	2.1	1
1592	Progress in mechanism-based diagnosis and treatment of tuberculosis comorbid with tumor. <i>Frontiers in Immunology</i> , 0, 15, .	4.8	0
1593	Predictive and prognostic biomarkers in gastrointestinal tract tumours. <i>Pathology</i> , 2024, 56, 205-213.	0.6	1
1594	The development and characterization of a CRISPR/Cas9-mediated PD-1 functional knockout rat as a tool to study idiosyncratic drug reactions. <i>Toxicological Sciences</i> , 2024, 198, 233-245.	3.1	0
1595	Unraveling the complex interplay between anti-tumor immune response and autoimmunity mediated by B cells and autoantibodies in the era of anti-checkpoint monoclonal antibody therapies. <i>Frontiers in Immunology</i> , 0, 15, .	4.8	0
1596	Clinical characteristics, diagnosis and management of nivolumab-induced myocarditis. <i>Investigational New Drugs</i> , 2024, 42, 116-126.	2.6	0
1597	Immune checkpoints in cardiac physiology and pathology: therapeutic targets for heart failure. <i>Nature Reviews Cardiology</i> , 0, , .	13.7	0
1598	Applications of CRISPR Epigenome Editors in Tumor Immunology and Autoimmunity. <i>ACS Synthetic Biology</i> , 2024, 13, 413-427.	3.8	0
1599	Immune checkpoint inhibitors associated cardiovascular immune-related adverse events. <i>Frontiers in Immunology</i> , 0, 15, .	4.8	0
1600	The role of programmed death receptor (PD-1)/PD-ligand (L)1 in periodontitis and cancer. <i>Periodontology</i> 2000, 0, , .	13.4	0

#	ARTICLE	IF	CITATIONS
1601	Clinical and translational attributes of immune-related adverse events. <i>Nature Cancer</i> , 2024, 5, 557-571.	13.2	0
1602	A bispecific anti-PD-1 and PD-L1 antibody induces PD-1 cleavage and provides enhanced anti-tumor activity. <i>Oncimmunology</i> , 2024, 13, .	4.6	0
1605	PD-1 regulation in immune homeostasis and immunotherapy. <i>Cancer Letters</i> , 2024, 588, 216726.	7.2	0
1606	Immunotherapy-associated cardiovascular toxicities: insights from preclinical and clinical studies. <i>Frontiers in Oncology</i> , 0, 14, .	2.8	0
1607	The PD-1/PD-L1 pathway maintains an immunosuppressive environment essential for neonatal heart regeneration. , 2024, 3, 389-402.		0
1608	Perspectives on Psoriasisiform Adverse Events from Immune Checkpoint Inhibitors: Lessons Learned from Our Practice. <i>Medicina (Lithuania)</i> , 2024, 60, 373.	2.0	0
1609	Cellular Alterations in Immune Checkpoint Inhibitor Therapy-Related Cardiac Dysfunction. <i>Current Heart Failure Reports</i> , 0, , .	3.3	0
1610	Immune-oncological drug pembrolizumab. , 2024, , 123-141.		0
1611	Pathogenesis, Diagnosis and Treatment of Immune-Related Cardiotoxicity. <i>Advances in Clinical Medicine</i> , 2024, 14, 284-290.	0.0	0
1612	Programmed cell death-1-modified pig developed using electroporation-mediated gene editing for in vitro fertilized zygotes. <i>In Vitro Cellular and Developmental Biology - Animal</i> , 0, , .	1.5	0
1613	Mapping the intellectual structure and landscape of colorectal cancer immunotherapy: A bibliometric analysis. <i>Human Vaccines and Immunotherapeutics</i> , 2024, 20, .	3.3	0